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Abstract 
Oral squamous cell carcinoma (OSCC) is a major global healthcare problem. 
OSCC has devastating consequences for many patients diagnosed with the 
disease. Outcomes may be improved if the disease is identified in its precursor 
stages, termed oral potentially malignant disorders (OPMD). Unfortunately, 
histological assessment of OPMD does not reliably predict which cases will 
progress to OSCC. Several candidate biomarkers have emerged in recent 
decades. To date, however, none have been validated for use in clinical 
practice. This study sought to address the continuing need for biomarkers that 
stratify OPMD according to their risk of malignant transformation. 
Our data show that EGFR gene copy number abnormalities correlate with 
malignant transformation in OPMD. EGFR genomic gain was also present in a 
quarter of early-stage OSCC. SOX2 had a heterogeneous expression profile in 
both OPMD and OSCC, limiting its clinical utility. Nevertheless, the pattern of 
SOX2 expression suggests it may be a marker of OSCC stem cells and 
consequently represent a potential chemotherapeutic target. PAX9 is down-
regulated in OPMD and early-stage OSCC. Following a course of chemical 
induction, Pax9-deficient mice were more likely to develop OPMD and OSCC 
than controls. These findings support the hypothesis that PAX9 has a tumour-
suppressor function. In addition to enhanced local sensitivity to chemical 
induction, Pax9-deficient mice were more susceptible to the toxic systemic 
effects of treatment. A modified protocol for chemical induction in Pax9-deficient 
mice is recommended. Paradoxically, our analysis of human tissues showed 
increased PAX9 expression in OPMD that underwent malignant transformation, 
suggesting that, in some circumstances, PAX9 may have a tumour-promoting 
effect. Finally, we summarise the generation of stably transfected cell lines in 
which PAX9 and SOX2 expression may be manipulated by tetracycline 
administration. These cell lines will facilitate future studies of the functional role 
of PAX9 and SOX2 in oral carcinogenesis.  
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Chapter 1. General Introduction 
1.1 Cancer 
The term ‘cancer’ encompasses a group of over 200 diseases characterised by 
the uncontrolled proliferation of abnormal cells (Cancer Research UK, 2010). 
Each year, there are approximately 13 million new cancer cases and 8 million 
cancer-related deaths worldwide (Jemal et al., 2011). In the UK, cancer affects 
more than one-third of the population and accounts for over a quarter of all 
deaths. Excluding non-melanocytic skin cancers, the four commonest cancers 
are those involving the lung, breast, gastrointestinal tract, and prostate gland. 
Lung cancer has the highest mortality rate in the UK (Cancer Research UK, 
2010). Metastatic dissemination of tumour cells to distant sites is the principal 
cause of cancer mortality (Meyer and Hart, 1998). 
Cancers vary in their pathogenesis. However, it is now accepted that most 
cancers develop through a multistep accumulation of genetic alterations 
(Hanahan and Weinberg, 2011). Observations of the ‘adenoma-carcinoma 
sequence’ identified in colorectal cancer informed the first step-wise molecular 
progression model of cancer (Fearon and Vogelstein, 1990). This model has 
been applied to other cancers, including oral cancer (Califano et al., 1996). 
Recent advances in cancer research support the view that key genetic events 
are common to the development of many cancers. These hallmarks include 
altered expression of oncogenes, suppression of tumour-suppressor genes, and 
induction of angiogenesis (Hanahan and Weinberg, 2011). 
1.2 Oral cancer 
1.2.1 Epidemiology 
Oral cancer (OC) is the 13th commonest cancer globally. OC has an annual 
incidence of around 264,000 cases. Each year, OC accounts for up to 130,000 
deaths (Jemal et al., 2011). However, the distribution of OC varies markedly 
around the world. OC is rare in countries such as Japan, Finland, and Greece, 
but is prevalent in Hungary and parts of northern France (Barnes et al., 2005; 
Warnakulasuriya, 2009). The highest incidence of OC is in south-east Asia: it is 
the commonest cancer in Sri Lanka, India, and regions of Pakistan (Indian 
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Council of Medical Research, 2010; International Agency for Research on 
Cancer, 2010). Recently, the incidence of OC has been increasing in the 
developed world. Over the past decade, the incidence in the UK has increased 
by one-third to ~6500 new cases in 2010 (Cancer Research UK, 2010). Similar 
increases have been documented in the USA and parts of Europe, particularly 
among young adults (Schantz and Yu, 2002; Garavello et al., 2010). 
1.2.2 Histological classification of oral cancer 
A diverse spectrum of epithelial, mesenchymal, and haematolymphoid 
neoplasms may present in the oral cavity. However, oral squamous cell 
carcinoma (OSCC) accounts for more than 90% of OC cases. OSCC is a 
malignant neoplasm of the mucosal squamous epithelium. Histologically, OSCC 
is characterised by the formation of keratin and/or the presence of intercellular 
bridges (Barnes et al., 2005). This project will focus specifically on OSCC and 
its precursor lesions. 
OSCC is classified according to its histological differentiation, i.e. the proportion 
of the OSCC that resembles normal squamous epithelium. This classification 
was first described by Broders more than 90 years ago (cited by Gnepp (2009)). 
However, the evidence to date suggests that differentiation does not accurately 
predict the clinical outcome of OSCC (Roland et al., 1992). Many OSCC 
comprise a heterogeneous population of malignant cells that show variable 
differentiation. The majority of OSCC are therefore classified as moderately 
differentiated (Kearsley and Thomas, 1993). 
A multifactorial system for grading OSCC has been described by Jakobsson et 
al (1973). This system assesses differentiation alongside a range of tumour-
host factors, including invasive pattern and peri-tumoral lymphoplasmacytic 
infiltrate. Of these tumour-host factors, invasive pattern has the greatest 
prognostic significance. OSCC with a non-cohesive invasive pattern (comprising 
malignant cells arranged singly or in small nests) behave more aggressively 
than OSCC with a cohesive invasive pattern (Odell et al., 1994). The adverse 
prognostic significance of neural invasion, vascular invasion, and positive 
surgical resection margins is also well documented (Close et al., 1989; 
Slootweg et al., 2002; Rahima et al., 2004). 
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1.2.3 Tobacco and alcohol: major environmental risk factors for OSCC 
OSCC has a multifactorial aetiology. A range of environmental factors may 
precipitate the genetic alterations and subsequent aberrations - in cell growth, 
survival, and migration – that characterise OSCC (Leemans et al., 2011). 
However, tobacco smoking remains one of the most significant risk factors, 
accounting for ~70% of OSCC-related deaths in the developed world. The 
carcinogenic potential of tobacco and alcohol is enhanced through synergistic 
interactions between constituent molecules and metabolites when the two are 
consumed together (Danaei et al., 2005; Hashibe et al., 2009). Recently, it has 
been suggested that all patients diagnosed with either lung cancer or liver 
cirrhosis – attributable to tobacco and alcohol consumption respectively - should 
be screened for OSCC and its precursors as an integral part of their care 
pathway (Salaric et al., 2015). 
Tobacco contains more than 60 distinct carcinogens. These include 
nitrosamines, polycyclic aromatic hydrocarbons, aromatic amines, aldehydes, 
and phenols. Nitrosamines such as NNK (4-methylnitrosamino-1-(-3-pyridyl)-1-
butanone) are among the most significant carcinogens (Hecht, 2003). NNK is 
metabolised via hydroxylation to methyldiazo-hydroxide, which binds to the 
guanine residues of DNA. Guanine residues are also bound by aromatic 
hydrocarbons such as benzopyrene (Hoffman and Wynder, 1986). Chemical 
modification of guanine residues induces nucleotide transversions in critical 
genes such as the tumour-suppressor p53 (Brennan et al., 1995). 
In addition to inhalation via smoking, tobacco may be chewed. Tobacco 
chewing is responsible for the high incidence of OSCC in south-east Asia 
(Jayalekshmi et al., 2009). Chewed tobacco is often combined with other 
substances – areca nut/leaf, catechu, and lime - to form ‘paan’. These 
substances contain molecules that interact to generate further distinct 
carcinogens, such as arecaidine. Arecaidine is formed by hydrolysis of 
arecoline - an alkaloid constituent of the areca nut - by calcium hydroxide in 
lime (Khan et al., 2012). 
Alcohol (ethanol) in its pure form is not currently regarded as a carcinogen. 
Alcoholic drinks, however, may contain carcinogenic by-products, such as 
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nitrosamines and urethane compounds. Ethanol facilitates the absorption of 
these molecules in the oral cavity (Hashibe et al., 2009). Ethanol is metabolised 
to acetaldehyde by dehydrogenases and the cytochrome p450 system. 
Acetaldehyde induces direct DNA damage. Acetaldehyde also promotes further 
indirect damage by blocking glutathione, hampering the detoxification of other 
carcinogens. Induction of the cytochrome p450 enzyme has the potential to 
activate other pro-carcinogens in both alcohol and tobacco (Hunter et al., 2005). 
1.2.4 High-risk human papillomavirus infection in oral cancer and oro-
pharyngeal cancer 
There is now an established body of evidence to support the role of high-risk 
human papillomavirus (HR-HPV), notably subtypes 16/18, in the aetiology of 
oropharyngeal squamous cell carcinoma (OPSCC) (Thariat et al., 2010; 
Schache et al., 2011; Thavaraj et al., 2011; Robinson et al., 2012). However, 
convincing evidence that HR-HPV infection is significant in the aetiology of 
OSCC has yet to emerge (Lopes et al., 2011; Lingen et al., 2013; McCord et al., 
2014; Nankivell et al., 2014). HR-HPV infection has been detected in a subset 
of OSCC precursor lesions and specific histopathological features have been 
described in these cases (Angiero et al., 2010; Lerman and Woo, 2014). 
However, the proportion of HPV-positive OSCC remains low (~3%), which 
suggests that HR-HPV infection is not a major aetiological agent in OSCC 
formation (Salazar et al., 2014). The role of HR-HPV infection in OSCC 
formation remains unclear. HR-HPV is not a validated prognostic factor for 
either OSCC or its precursors (McCord et al., 2014; Nankivell et al., 2014). 
However, there is emerging evidence that HPV positivity may be a useful 
prognostic indicator in the small proportion of HPV-positive squamous cell 
carcinomas presenting at non-oropharyngeal sites, including the oral cavity 
(Chung et al., 2014). 
Given the contrasting aetiological and prognostic significance of HR-HPV in 
OPSCC and OSCC reported in the literature to date, this project will focus 
specifically on cases of squamous cell carcinoma and its precursor lesions that 
are confined to the oral cavity.  
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1.2.5 The contribution of other infective conditions to OSCC formation 
Although HR-HPV infection has yet to be convincingly implicated in the 
aetiology of OSCC, there are two infective conditions that have a well-
documented association. Chronic hyperplastic candidosis is characterised by 
epithelial hyperplasia and inflammatory changes in both the squamous 
epithelium and lamina propria. These changes enhance the susceptibility of the 
epithelium to carcinogenic nitrosamine compounds that are generated by 
Candida organisms. Tertiary syphilis causes epithelial atrophy, increasing the 
vulnerability of the epithelium to carcinogens; moreover, medicaments 
historically used to treat syphilis, notably arsenic compounds, are now known 
carcinogens (Neville et al., 2009). 
1.2.6 Histopathological staging of OSCC 
Once a histopathological diagnosis of OSCC has been established, the disease 
is staged using the ‘Tumour, Node, Metastasis’ (TNM) classification developed 
by the International Union Against Cancer (Sobin et al., 2009). A numerical 
value is assigned for each of the three domains (Table 1-1). These are 
combined to provide the overall clinical stage (Table 1-2). The clinical stage 
informs treatment decisions. It may be modified following histopathological 
examination of the surgical resection specimen. 
This project will focus specifically on patients with early-stage OSCC. Early-
stage OCCC encompasses patients at both pStage I (pT1 N0 M0) and pStage II 
(pT2 N0 M0). Tumours in this group may therefore measure up to 4 cm in 
maximum dimension; however, they have not metastasised either to cervical 
lymph nodes or to distant sites.  
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Table 1-1 The ‘Tumour, Node, Metastasis’ classification of oral squamous 
cell carcinoma, International Union Against Cancer 
 
Code Description 
T0 
T1 
T2 
T3 
T4a 
 
T4b 
No evidence of tumour 
Tumour 2 cm or less in greatest dimension 
Tumour more than 2 cm but not more 4 cm in greatest dimension 
Tumour more than 4 cm in greatest dimension 
Tumour invades through cortical bone, deep/extrinsic muscles of 
tongue, maxillary sinus or skin 
Tumour invades masticator space, pterygoid plates, skull base, or 
encases internal carotid artery 
N0 
N1 
 
N2a 
 
N2b 
 
N2c 
 
N3 
No regional lymph node metastasis 
Metastasis in a single ipsilateral lymph node, 3 cm or less in 
greatest dimension 
Metastasis in a single ipsilateral lymph nodes, more than 3 cm but 
not more than 6 cm in greatest dimension 
Metastases in multiple ipsilateral lymph nodes, none more than 6 
cm in greatest dimension 
Metastasis in bilateral/contralateral lymph nodes, none more than 
6 cm in greatest dimension 
Metastasis in a lymph node more than 6 cm in greatest dimension 
M0 
M1 
No distant metastasis 
Distant metastasis 
 
Table 1-2 Summary of the component TNM categories of each stage of OSCC 
 
Stage  Tumour Node Metastasis 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 
T1, T2, T3 
N0 
N1 
M0 
M0 
Stage IVA 
 
Stage IVB 
 
StageIVC 
T4a 
T1, T2, T3, T4a 
Any T 
T4b 
Any T 
N0, N1 
N2 
N3 
Any N 
Any N 
M0 
M0 
M0 
M0 
M1 
 
Adapted from the ‘TNM Classification of Malignant Tumours’, 7th Edition (Sobin et al., 2009). 
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1.2.7 Treatment modalities 
Surgical resection is currently the preferred treatment modality for early-stage 
OSCC. Adjuvant radiotherapy may be used for selected cases (Shah and Gil, 
2009). Surgical removal of OSCC may be debilitating, leaving patients with 
dysfunctions in speech, mastication, and swallowing (dysphagia). Radiotherapy 
is also associated with a range of complications, including mucositis and 
dysphagia (Campos et al., 2014; Szczesniak et al., 2014). Long-term, 
radiotherapy may also result in vasculopathy of the carotid artery, thus 
increasing the risk of cerebrovascular events (Wilbers et al., 2014). These 
functional impairments may impact negatively on social interactions, and thus 
contribute to the development of psychological problems (Zwahlen et al., 2008). 
Whilst both of the current treatment modalities may cause significant aesthetic 
and functional impairments, neither guarantees a complete cure. There is, 
therefore, a pressing need to develop chemotherapeutic agents that either halt 
or reverse the progress of OSCC and its precursor lesions with minimal long-
term impact on patients’ function and aesthetics (Braakhuis et al., 2010). 
1.2.8 Clinical outcomes for patients with OSCC 
Outcomes for patients with OSCC may be improved if the disease is identified 
in its earliest or precursor stages (Goodson and Thomson, 2010). Due to its 
anatomical location, OSCC is amenable to early detection and management 
(Sankaranarayanan et al., 2013). Evidence from high-incidence areas suggests 
that screening programmes may facilitate early detection of OSCC and 
improved patient outcomes (Amit et al., 2013). However, despite the increasing 
standardisation of its management, OSCC is consistently associated with poor 
survival rates in the developed world (Warnakulasuriya, 2009). Alarmingly, 
OSCC mortality rates are actually increasing in parts of Europe (Garavello et 
al., 2010). 
Several factors contribute to poor patient outcomes. Despite efforts to raise the 
profile of OSCC (Mouth Cancer Foundation, 2013), there is generally low public 
awareness of the disease relative to other cancers (Warnakulasuriya et al., 
1999). Lack of awareness is compounded by the clinical course of OSCC. The 
early stages are often painless. An asymptomatic OSCC may therefore achieve 
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a significant size and have already seeded metastases prior to the patient 
seeking help (McGurk et al., 2005). The consequent late-stage presentation 
may preclude complete surgical clearance. This increases the risk of local 
recurrence, which is the major cause of death in advanced cases of OSCC 
(Woolgar et al., 1999). 
1.2.9 Second primary tumours and the phenomenon of ‘field 
cancerisation’ 
Clinical outcomes are further confounded by the high propensity of OSCC to 
form second primary tumours (SPT). SPT develop in up to 36% of patients with 
OSCC (Chuang et al., 2008; Atienza and Dasanu, 2012). SPT thus have a 
higher incidence than primary OSCC, a trend that is consistent across all age 
groups (Bosetti et al., 2011). SPT portend a poor prognosis. In early-stage 
(pStage I and pStage II) OSCC, SPT are the commonest cause of treatment 
failure and death from disease (Day and Blot, 1992; Tsou et al., 2007). 
The development of SPT reflects the phenomenon of ‘field cancerisation’, which 
was first described by Slaughter et al (1953) more than 60 years ago. Field 
cancerisation postulates that potentially malignant changes extend into 
squamous epithelium adjacent to OSCC that appears normal, both clinically and 
histologically. The concept stemmed from the recognition that common 
carcinogens, such as alcohol and tobacco smoke, contact multiple epithelial 
surfaces of the upper aero-digestive tract (Slaughter et al., 1953). 
The concept of field cancerisation is supported by recent insights into the 
genetic and molecular hallmarks of OSCC formation (Braakhuis et al., 2003; 
Braakhuis et al., 2004; Braakhuis et al., 2010; Leemans et al., 2011). Most 
synchronous/metachronous primary OSCC are believed to evolve from a single 
clone of progenitor cells and to have undergone similar genetic alterations 
(Figure 1-1) (Bedi et al., 1996; Scholes et al., 1998; Braakhuis et al., 2004). The 
recognition that pre-cancerous genetic changes extend into apparently normal 
epithelium provides an explanation for the high incidence of SPT (Partridge et 
al., 2000).  
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Figure 1-1 Summary of the genetic progression model of field cancerisation 
A) Initial Phase: Mutation in basal stem cell. B) “Patch” Phase: Clonal expansion of mutant 
daughter cells. C) Expanding Field: Lateral expansion of stem cells and descendants having 
acquired a growth advantage. D) “Second Hit”: Precursor lesion develops within field due to 
secondary mutations and increasing genomic instability. E) Carcinoma Formation: Precursor 
lesion becomes invasive carcinoma. F) Novel “Second Hit”: New precursor lesion independently 
develops at another site within field. G) Carcinoma Excision: Premalignant field and new 
precursor lesion remain. H) Tumour recurrence: Second Field Tumour develop from new 
precursor lesion. 
Adapted from Braakhuis et al (2004).  
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1.2.10 Oral potentially malignant disorders 
A range of precancerous lesions and conditions are recognised in the oral 
cavity. Together, these are termed oral potentially malignant disorders (OPMD) 
(van der Waal, 2009). Clinically, the majority of OPMD present either as white 
(‘leukoplakic’), red (‘erythroplakic’) or mixed red and white (‘speckled 
leukoplakic’) patches (Barnes et al., 2005). Histopathological examination of the 
affected squamous epithelium may reveal a spectrum of changes, ranging from 
squamous cell hyperplasia, through mild, moderate, and severe epithelial 
dysplasia to carcinoma in-situ (Table 1-3). 
Although the 2005 WHO classification is widely recognised and applied by both 
clinicians and histopathologists, there is continuing debate as to how 
precancerous epithelial changes should be conceptualised and classified. Two 
alternative classification systems are currently recognised by the WHO (Barnes 
et al., 2005). In addition to these, a binary classification system has also been 
proposed (Kujan et al., 2006 ). The binary grading system complements the 
WHO Classification by excluding the intermediate category of ‘moderate 
epithelial dysplasia’, which confounds inter-observer agreement. The 
histopathologist assigns a grade according to the overall perceived ‘risk’ of the 
squamous epithelium. The binary system may therefore guide clinicians and 
facilitate critical management decisions (Kujan et al., 2006 ). 
The debate surrounding the classification of epithelial dysplasia highlights the 
subjective nature of interpreting the histological features of precancerous 
lesions and assigning them to precise diagnostic categories. It is recognised 
that this interpretative process is liable to both intra- and inter-observer variation 
(Kujan et al., 2007). So far, no histological features have been identified that 
accurately predict which OPMD will progress to OSCC (Lodi et al., 2006). There 
is therefore a need to develop biomarkers that enhance prognostication and 
direct treatment (Mishra, 2012).  
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Table 1-3 Summary of the current classification systems for epithelial 
dysplasia 
 
2005 WHO 
Classification 
Squamous 
Intra-epithelial 
Neoplasia 
Classification 
Ljubljana 
Classification of 
squamous Intra-
epithelial lesions  
Binary 
Classification 
Squamous cell 
hyperplasia 
- Squamous cell 
(simple) hyperplasia 
- 
Mild dysplasia SIN 1 Basal/parabasal cell 
hyperplasia 
Low-grade 
dysplasia 
Moderate dysplasia SIN 2 Atypical hyperplasia Low-grade OR 
high-grade 
dysplasia 
Severe dysplasia SIN 3 Atypical hyperplasia High-grade 
dysplasia 
Carcinoma in-situ SIN 3 Carcinoma in-situ High-grade 
dysplasia 
Adapted from Barnes et al (2005) and Kujan et al (2006 ). 
 
1.2.11 Genetic and molecular alterations in oral cancer 
Analogous to the progression model that is now accepted for colorectal 
carcinoma (Fearon and Vogelstein, 1990), the genetic alterations characteristic 
of OSCC are understood to occur in a multistep, sequential pattern (Califano et 
al., 1996; Leemans et al., 2011). The spectrum of potentially malignant 
disorders contains common chromosomal, genetic, and molecular aberrations 
that are also present in OSCC (Mithani et al., 2007). A working model for the 
formation of OSCC has been widely accepted. First proposed by Califano et al 
(1996) nearly 20 years ago, this model describes sequential loss of 
heterozygosity (LOH) in chromosomal regions that contain key cancer-
associated genes, and maps these genomic changes to clinical and histological 
precursor lesions. The model draws attention to alterations in the genes 
governing growth promotion (proto-oncogenes) and growth inhibition (tumour-
suppressor genes) (Califano et al., 1996; Forastiere et al., 2001). 
Mutations of proto-oncogenes result in abnormally activated ‘oncogenes’ that 
confer growth self-sufficiency to cells, thus enabling them to escape normal 
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growth control mechanisms (Kumar et al., 2005). Early research into proto-
oncogenes in OSCC focused largely on c-myc (Eversole and Sapp, 1993), K-
ras (Caulin et al., 2004; Vitale-Cross et al., 2004a) and ErbB-1 genes (Wong, 
1987). Ki67 is marker of cell proliferation that has been used in the diagnosis 
and prognostication of breast and prostate cancers, in which the fraction of Ki67 
positive cells correlates with the clinical progression of the disease (Scholzen 
and Gerdes, 2000). Ki67 alterations have also been documented in OPMD. 
However, Ki67 has yet to be validated as a prognostic marker for detecting the 
subset of OPMD that are destined to undergo malignant transformation (Kovesi 
and Szende, 2003). More recent work on OSCC oncogenes has focused on the 
complex protein-kinase B (Akt) pathway (Amornphimoltham et al., 2004; 
Amornphimoltham et al., 2005). There is an increasing body of evidence that 
supports the potential therapeutic significance of this pathway (Czerninski et al., 
2009; Wang et al., 2014). 
The tumour-suppressor genes of greatest significance in OSCC formation are 
p53 and CDKN2A (Hunter et al., 2005; Kumar et al., 2005). CDKN2A encodes 
p16INK4a, which controls the cell cycle through inhibition of cyclin-dependent 
kinases. CDKN2A may be inactivated by promoter hyper-methylation in 
combination with deletions in chromosomal regions 3p and 9p21 (Califano et 
al., 1996; Forastiere et al., 2001). 
p53 encodes a critical tumour-suppressor protein and is mutated in more than 
50% of human cancers (Yuen et al., 2001). p53 mutations are a consistent 
feature of OSCC (Gasco and Crook, 2003). p53 is located on chromosome 17p 
and encodes a transcription factor (p53) that detects DNA damage and other 
stress signals. p53 acts as a ‘gatekeeper’ at the G1 phase of the cell cycle, 
permitting repair of damaged DNA prior to DNA synthesis and triggering 
apoptosis if irreparable DNA damage is detected (Liu and Gelmann, 2002). p53 
mutations therefore result in loss of this critical tumour-suppressor function. This 
confers a significant survival advantage and is frequently an early step in oral 
carcinogenesis (Leemans et al., 2011). p53 is upregulated in human OPMD and 
expression of p53 in suprabasal keratinocytes has been associated with 
malignant transformation (Nylander et al., 2000; Kovesi and Szende, 2003; 
Varun et al., 2014). The carcinogens present in tobacco smoke, one of the 
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major risk factors for OSCC, are associated with an increase in both the number 
and type of p53 mutations (Brennan et al., 1995). 
While Califano’s (1996) genetic progression model continues to frame the 
current molecular understanding of OSCC formation, it remains incomplete. For 
example, the model does not account for the over-expression of epidermal 
growth factor receptor (EGFR) that has been identified in a high proportion of 
OSCC (Grandis and Tweardy, 1993a). The most reliable factors for predicting 
patients’ risk of developing OSCC continue to be their cancer history and the 
presence/grade of epithelial dysplasia. Markers for LOH, chromosomal 
aneuploidy, and aberrant p16INK4a/p53 expression remain adjuncts to these 
clinical and histopathological parameters (Leemans et al., 2011). Advances in 
the field of ploidy analysis are compromised by the questionable probity of 
some studies; initial hopes that the detection of aneuploidy might identify 
epithelium at high-risk of developing OSCC have yet to be widely accepted 
(Klanrit et al., 2007; Torres-Rendon et al., 2009). Doubts have also emerged as 
to the reliability of p53 as a standalone prognostic biomarker (Nylander et al., 
2000; Takeda et al., 2006). Although it remains the mainstay of diagnosis and 
prognostication, the reliability of histopathological examination is itself 
compromised by well-documented intra- and inter-observer variation (Kujan et 
al., 2007). 
There is a continuing need to delineate the genetic alterations and molecular 
events of OSCC formation in order to inform the development of reliable 
diagnostic and prognostic biomarkers. An ideal biomarker should be objectively 
measurable in small biopsy samples, and altered in high-risk tissue in the 
earliest stages of oral carcinogenesis (Wu et al., 2010).  
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1.3 Epidermal growth factor receptor 
1.3.1 Structure and biological function 
Epidermal growth factor receptor (EGFR) is a cell surface tyrosine kinase 
receptor that binds to members of the epidermal growth factor family of 
extracellular protein ligands. These ligands include epidermal growth factor and 
transforming growth factor-α (Herbst, 2004). EGFR is one of four proteins in the 
ErbB family and is expressed in most epithelial tissues, including the oral 
squamous epithelium (Citri and Yarden, 2006). 
Binding of growth factor ligands to the EGFR extracellular domain induces a 
conformational change in the EGFR molecule. The conformational change 
usually involves formation of an active homodimer from two inactive monomers. 
Alternatively, a heterodimer may also be formed through pairing EGFR with 
another member of the ErbB receptor family, such as ErbB2/Her2/neu (Yarden 
and Schlessinger, 1987). Dimerization induces phosphorylation of the tyrosine 
residues located on the internal domain of EGFR. Phosphotyrosines bind to 
downstream signalling in proteins that contain the SH2 (Src Homology 2) 
domain (Molinolo et al., 2009). The activated proteins initiate a range of signal-
transduction cascades, including the mitogen-activated protein kinase (MAPK) 
and protein-kinase B (Akt) pathways. Activation of these pathways stimulate 
DNA synthesis and contribute to a range of cellular processes, including cell 
proliferation (Oda et al., 2005). 
1.3.2 EGFR as a cancer biomarker 
EGFR protein expression and gene copy number are currently used in the 
prognostication of non-small cell lung carcinoma (Nicholson et al., 2001; Hirsch 
et al., 2003). They are also used to predict the response of non-small cell 
carcinoma to EGFR-targeting chemotherapeutic agents (Takano et al., 2005 ). 
EGFR was first heralded as a potential biomarker in OSCC in the early 1990s 
(Grandis and Tweardy, 1993b). EGFR protein is over-expressed in up to 90% of 
OSCC. Furthermore, over-expression of EGFR protein in OSCC is associated 
with poor clinical outcomes (Grandis and Tweardy, 1993a; Grandis, 1998; 
Kumar et al., 2008). Similarly, EGFR genomic gain is also associated with poor 
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clinical outcomes (Chung et al., 2006; Temam et al., 2007). To date, the 
prevalence of EGFR genomic gain that has been reported in OSCC ranges 
from 9% (in pStage I and pStage II OSCC) to 56% (in mixed pStage I – pStage 
IV OSCC) (Freier et al., 2003; Rössle et al., 2013; Ryott et al., 2009). These 
data suggest that EGFR genomic gain is more common in late-stage OSCC 
and may be a relatively late event in oral carcinogenesis. 
In vitro studies have demonstrated that ectopic expression of EGFR is 
implicated in the transformation of normal oral keratinocytes to a malignant, 
immortalised phenotype (Goessel et al., 2005). EGFR is critical to many of the 
cellular processes - such as adhesion, proliferation, and migration – which, 
when disturbed, encode hallmarks of cancer, including invasion and metastasis 
(Normanno et al., 2006; Hanahan and Weinberg, 2011). However, the clinical 
significance of this finding must be interpreted cautiously given the complexity 
of the EGFR pathway (Forastiere, 2007; Gusterson and Hunter, 2009). 
1.3.3 EGFR in oral potentially malignant disorders 
The prevalence of EGFR protein over-expression may limit its clinical utility as a 
biomarker in OSCC. However, it has recently been reported that in OPMD over-
expression of EGFR protein correlates with an increased risk of malignant 
transformation (Ries et al., 2013). There are also data which suggest that 
OPMD with an abnormal EGFR gene copy number are more likely to progress 
to OSCC relative to cases with normal EGFR gene copy number (Benchekroun 
et al., 2010; Poh et al., 2012). These data need to interpreted cautiously: 
abnormal EGFR gene copy number is not regarded as evidence of genomic 
gain in the criteria that are currently validated for the interpretation of non-small 
cell lung carcinoma (Hirsch et al., 2003). However, it is unclear whether criteria 
validated for the interpretation of EGFR gene copy number in a solid tumour, 
and involving a different organ, should be applied to OPMD. The evidence from 
these studies support the contention that EGFR gene copy number 
abnormalities accumulate in the early stages of oral carcinogenesis. Although 
EGFR copy number abnormalities do not amount to genomic gain, it is 
conceivable that they precede genomic gain. Abnormal EGFR gene copy 
number may therefore be a useful diagnostic adjunct for detecting OPMD at an 
elevated risk of malignant transformation. 
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1.4 The SOX gene family 
The SOX (SRY-Box) gene family encode transcription factors that play 
important roles in regulating the development of both vertebrates and 
invertebrates (Bowles et al., 2000). To date, ~30 member genes have been 
identified, each encoding transcription factors which share a 79 amino-acid 
high-mobility group (HMG) DNA-binding domain that was first identified in SRY, 
the mammalian testis-determining factor (Chew and Gallo, 2009). The 30 SOX 
transcription factors are sub-classified into ten different groups according to 
their functional properties, structural motifs, and homology within the HMG 
domain. Outside of their conserved domain, SOX transcription factors include 
variable domains that permit binding to a range of co-regulatory proteins. The 
resulting ‘SOX-partner codes’ are stable transcription factor complexes that 
enable SOX proteins to differentially regulate gene transcription by modulating 
promoter activity (Chew and Gallo, 2009). 
SOX genes have multiple cellular functions, including induction/suppression of 
proliferation and multipotency, and specifying the terminal differentiation of 
progenitor cells from a variety of lineages. During embryonic development, SOX 
genes are among the earliest groups to be expressed (Chew and Gallo, 2009). 
Abnormal SOX gene expression and function has been identified in a spectrum 
of neurological disorders, including tumours. SOX proteins have now been 
validated as diagnostic markers for paediatric medulloblastoma and 
ependymoma (de Bont et al., 2008). 
1.4.1 SOX2 in development 
SOX2 belongs to the SOX B1 subgroup, along with SOX1 and SOX3. Members 
of this subgroup are consistently expressed by central nervous system (CNS) 
progenitor cells but not by mature neuronal cells, indicating their role in 
maintenance of the progenitor state (Chew and Gallo, 2009). This role has been 
further specified as the direction of basal cell ‘fate’ choices, i.e. balancing the 
rates of renewal and differentiation of progenitor cells. SOXB1 subgroup genes 
are therefore important during both tissue morphogenesis and homeostasis. 
SOX2 is known to maintain pluripotency of embryonic stem cells (Masui et al., 
2007). Over-expression of SOX2 may actually inhibit terminal differentiation 
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during neurogenesis (Bani-Yaghoub et al., 2006). In mice, Sox2 plays a vital 
role in patterning of the anterior foregut endoderm (Que et al., 2007) and 
trachea (Que et al., 2009). In the squamous epithelium of the tongue and 
palate, Sox2 expression is strongest in the basal layer where it promotes 
proliferation and stabilisation of progenitor cells (Okubo et al., 2009). Sox2 is 
believed to achieve this through synergistic maintenance of Oct3/4 expression 
(Masui et al., 2007). In neural stem cells, Sox2 is thought to act in concert with 
factors such as c-myc, Oct4 and KLF4 – the so-called ‘Yamanaka’ factors - to 
reprogramme adult cells to induce pluripotency (Takahashi et al., 2007). In the 
adult human brain, SOX2 is understood to perform its pro-mitotic regulatory 
function through the selective up regulation of Notch 1 signalling and expression 
of cyclin-D1, which together promote entry into the cell cycle (Ellis et al., 2004). 
Mutations in SOX2 cause ocular disturbances and are associated with a range 
of learning disabilities, motor dysfunctions, and seizures (Ragge et al., 2005). 
SOX2 mutations have also been implicated in hypoplasia of the anterior 
pituitary gland, with subsequent gonadotropin deficiency (Tziaferi et al., 2008). 
SOX2 deficiency is also implicated in the rare AEG (‘Anophthalmia-Esophageal-
Genital’) syndrome (Williamson et al., 2006). Conversely, SOX2 over-
expression has been identified in a range of CNS tumours, including those of 
astroglial, ependymal, and oligodendroglial lineages (Phi et al., 2008). SOX2 
mutations are also implicated in the tumourigenesis of glioblastoma, an 
aggressive cancer in which it behaves as an oncogene (Pevny and Nicolis, 
2010). 
1.4.2 SOX2 in cancer 
The oncogenic potential of SOX2 has been investigated in human oesophageal 
and lung cancers (Garraway and Sellers, 2006; Bass et al., 2009; Hussenet and 
du Manoir, 2010). Copy number increases of the 3q26-qter chromosomal region 
are found in a majority (60-80%) of squamous cell carcinoma (SCC), including 
those in the oesophagus/head and neck region (Hussenet and du Manoir, 
2010). Analysis of the individual contribution of genes mapping to 3q26-qter 
using a shRNA screen in oesophageal cancer cell lines indicated that SOX2 
was a major contributor to tumorigenesis and may act as a lineage-survival 
oncogene (Bass et al., 2009). 
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In lung cancer (LC), SOX2 is over-expressed in both adenocarcinoma and SCC 
phenotypes (Hussenet et al., 2010; Lu et al., 2010). In mice, up-regulation of 
Sox2 causes hyperplasia of the bronchiolar epithelium and development of 
adenocarcinomas. This is attributed to the Sox2-mediated induction of cyclinD1 
expression and subsequent cell cycle promotion (Lu et al., 2010). SOX2 is thus 
considered a potential chemotherapeutic target for lung cancer (Xiang et al., 
2011). 
SOX2 may also play a role in tumour differentiation. In vivo, up-regulation of 
SOX2 induces expression of markers of squamous differentiation such as p63 
and keratin 6, thus implicating SOX2 in the differentiation pathway of SCC 
(Bass et al., 2009). This is in contrast to previous in vitro studies suggesting that 
increased SOX2 expression contributes to de-differentiation and cellular 
migration (Hussenet et al., 2010; Hussenet and du Manoir, 2010). 
1.4.3 SOX2 in oral cancer 
In normal squamous epithelium, SOX2 promotes epithelial proliferation and the 
stabilisation of basal progenitor cells (Okubo et al., 2009). Over-expression of 
SOX2 has been described in SCC arising at a range of sites, including the lung, 
oesophagus, cervix, and penis (Hussenet et al., 2010; Lu et al., 2010; Maier et 
al., 2011). Up-regulation of SOX2 has been documented in a subset of OSCC 
(Freier et al., 2010; Misuno et al., 2013; Huang et al., 2014). Two studies have 
also reported SOX2 genomic gain in OSCC (Freier et al., 2010; Kokalj Vokač et 
al., 2014). Freier et al (2010) reported that SOX2 gene copy number 
amplification was more common than SOX2 protein over-expression, occurring 
in >50% of OSCC. SOX2 positivity has also been detected in up to 90% of 
OPMD in an isolated study by Qiao et al (2013). The authors also identified co-
expression of SOX2 and Oct4 - a feature not detected in the normal squamous 
epithelium - in up to 60% of OPMD (Qiao et al., 2013). 
There is also evidence that SOX2 over-expression portends poor clinical 
outcomes in OSCC, particularly metastasis to cervical lymph nodes (Du et al., 
2011; Michifuri et al., 2012; Huang et al., 2014). Michifuri et al (2012) drew 
attention to the heterogeneous expression of SOX2 in a group of 80 mixed-
stage OSCC, categorising the SOX2 pattern as either peripheral or diffuse. The 
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authors identified a positive correlation between the diffuse pattern of SOX2 
staining and risk of metastasis to cervical lymph nodes (Michifuri et al., 2012). 
These findings suggest that SOX2 has an oncogenic function in oral 
carcinogenesis. This contention is supported by earlier functional studies of 
oesophageal and lung SCC (Bass et al., 2009; Hussenet et al., 2010; Hussenet 
and du Manoir, 2010; Lu et al., 2010). There is emerging evidence that 
suggests SOX2 is significant in the maintenance and functioning of oral cancer 
stem cells (CSC) (Boumahdi et al., 2014). Oral CSC show up-regulation of 
SOX2 and OCT4 in vitro (Lim et al., 2011; Bourguignon et al., 2012; Misuno et 
al., 2013). However, further work is required to delineate the contribution of 
SOX2 to the maintenance, survival, and proliferation of CSC (Routray and 
Mohanty, 2014). 
1.5 The PAX gene family 
The PAX (‘paired-box’) gene family comprises a group of nine genes that 
encode transcription factors with crucial roles in embryonic development and 
organ formation (Dahl et al., 1997; Chi and Epstein, 2002; Wang et al., 2008). 
PAX genes have been widely conserved through evolution. They are shared 
between mammalian species and orthologues have been identified in 
organisms as diverse as birds, fish, and frogs (Dahl et al., 1997). PAX genes 
are characterised by a common ‘paired-box’ 128-amino acid DNA-binding 
domain, which was first identified in Drosophila (Bopp et al., 1986; Wang et al., 
2008). The transcriptional activities of PAX genes regulate processes such as 
cellular proliferation, differentiation, migration, and survival (Chi and Epstein, 
2002; Robson et al., 2006). Mammalian PAX genes are classified into four 
subgroups according to the presence or absence of two further regions: a 
homeodomain and octapeptide structural motif (Robson et al., 2006). 
Mostly active during embryogenesis and early growth, expression of PAX genes 
gradually declines following completion of development. Residual expression 
and capacity for re-expression persist into adult life, however, when PAX genes 
are involved in maintaining stem cell pluripotency and directing the regeneration 
of normal or damaged tissues (Chi and Epstein, 2002). Studies of mice with 
either spontaneous or induced mutations of PAX genes confirm their vital role in 
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embryogenesis. Mutants are distinguished by overall reduction in growth, and 
malformation/absence of organs (Dahl et al., 1997; Chi and Epstein, 2002). 
Mutations of PAX genes are known to cause developmental abnormalities in 
humans. For example, PAX3 mutations have been identified in patients with 
Waardenburg syndrome (Wollnik et al., 2003) and deletions of PAX6 are 
implicated in the aetiology of aniridia (Davis et al., 2008). Their involvement in 
stem cell renewal, differentiation, and migration suggests that PAX genes have 
significant potential to contribute to neoplasia - frequently characterised by the 
recapitulation of developmental processes - should their expression become 
dysregulated (Robson et al., 2006). 
1.5.1 PAX9 in development and disease 
In humans, PAX9 is located on chromosome 14q12 and belongs to group one 
of the PAX gene family. It is highly similar to the other member of this group, 
PAX1. In addition to the paired-box domain, both genes are characterised by 
the presence of an octapeptide structural motif and the absence of the 
homeodomain that features in groups II – IV (Peters et al., 1998; Robson et al., 
2006). PAX9 has been identified in a wide range of vertebrates, including 
chicken, mice and zebra fish. 
In mice, Pax1 and Pax9 exhibit similar expression patterns in the sclerotome, 
i.e. the ventro-medial region of somites, which subsequently forms the vertebral 
column (Neubuser et al., 1995). They demonstrate overlapping expression 
patterns in structures derived from the endodermal epithelium of the pharyngeal 
pouches, including thymus, parathyroid glands, ultimobranchial bodies, 
Eustachian tubes, and tonsils. There is extensive Pax9 expression in the neural 
crest-derived mesenchymal tissues that are important in the development of 
teeth and the craniofacial region (Neubuser et al., 1997; Peters et al., 1998). 
The importance of Pax9 function during development has been emphasised by 
a study using transgenic mice in which Pax9 was inactivated. Pax9-deficient 
mice die shortly after birth, display a cleft secondary palate, and lack all teeth, 
highlighting the role of Pax9 in neural crest-derived tissues. Furthermore, 
organs derived from the endodermal pharyngeal pouches - thymus, parathyroid 
glands and ultimobranchial bodies - are also absent (Peters et al., 1998). Tooth 
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development in Pax9-deficient mutants is arrested at the ‘bud stage’, and the 
expression of other inductive mesenchymal genes such as Bmp4, Msx1, and 
Lef1 is strongly decreased (Neubuser et al., 1995). 
Heterozygous mutations in PAX9 cause familial and sporadic cases of 
hypodontia and oligodontia (Stockton et al., 2000; Mostowska et al., 2003), 
congenital conditions affecting 5-10% of humans in which variable numbers of 
teeth are missing (hypodontia defined as < six teeth, and oligodontia as >six 
teeth, both excluding third molars) (Rose, 1966). The role of Pax9 in facilitating 
dental field patterning and the ‘minimum dosage’ of Pax9 expression required 
for normal dental morphogenesis have been defined using novel mouse models 
for hypodontia and oligodontia (Kist et al., 2005). Reduced levels of wild-type 
Pax9 mRNA resulted in fewer teeth (ranging from hypodontia to severe 
oligodontia) and defective formation of enamel with subsequently increased 
rates of attrition and formation of reparative dentine (Kist et al., 2005). 
In addition to its role in structures derived from the endoderm and neural crest, 
PAX9 has also been implicated in the regional differentiation of the mammalian 
surface ectoderm. This gives rise to the epidermis of the skin, squamous 
epithelium lining the oral cavity, and a range of appendages including lingual 
papillae and salivary glands (Jonker et al., 2004). Although Pax9 expression in 
mice is normally absent in the epidermis, it is continuously expressed in the 
lingual epithelium. Here, it is believed to regulate key aspects of epithelial 
differentiation, notably the morphogenesis of filiform papillae (FP). In mice, FP 
are small, conical structures on the dorsal surface of the tongue that are 
believed to enhance retention of food during mastication. They are 
characterised by a distinctive anterior-posterior polarity that reflects differential 
expression of specific keratins (Iwasaki, 2002). Pax9-deficiency in mice results 
in down-regulated expression of so-called ‘hard keratins’ (e.g. Krt1-5, Krt1-24) 
that form the posterior aspect of FP, and concomitant up-regulation of ‘soft 
keratins’ e.g. Krt2-1, Krt2-17. These ‘soft keratins’ are commonly expressed in 
the epidermis but are absent in normal lingual epithelium, indicating mis-
differentiation of the tongue epithelium into epidermis (Jonker et al., 2004).  
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1.5.2 A potential role for PAX9 in cancer 
In addition to their normal expression in the epidermis in humans, the ‘soft 
keratins’ Krt2-1 and Krt2-17 are over-expressed in dysplastic lesions of the oral 
squamous epithelium (Bloor et al., 2003). This suggests that the underlying 
alterations in the differentiation pathway of epithelium in Pax9-deficient mice 
may be similar to those occurring in epithelial dysplasia (Jonker et al., 2004).  
Our preliminary observations using biopsy samples of the human tongue have 
demonstrated progressive down-regulation of PAX9 expression in dysplastic 
epithelium and the complete absence of PAX9 expression in OSCC 
[unpublished data]. This is consistent with the study by Gerber et al (2002), who 
studied biopsies of the human oesophagus. Using a monoclonal antibody to 
PAX9, which shows nuclear expression in normal oesophageal epithelium, this 
study revealed PAX9 expression to be lost/significantly reduced in a majority of 
cancers and pre-cancerous lesions. Furthermore, it identified an inverse 
relationship between PAX9 expression and clinical course: a decrease in the 
proportion of PAX9-positive cells correlated with an increase in the malignant 
behaviour of lesions. This suggests that PAX9 plays a pivotal role in the 
differentiation of the oesophagus epithelium and provides evidence to support a 
function for PAX9 in cancer (Gerber et al., 2002). 
PAX1 and PAX9 are generally regarded as having a weaker association with 
cancer than other PAX genes due to the absence of the homeodomain that 
characterises groups II – IV (Robson et al., 2006). Group II and group III PAX 
genes have an established role in promoting tumourigenesis. Conserved 
chromosomal translocations have now been identified in several – often 
aggressive – cancers.  These include alveolar rhabdomyosarcoma 
(translocations in PAX3/PAX7), follicular thyroid carcinoma (PAX8) and non-
Hodgkin lymphomas (PAX5) (Robson et al., 2006). The precise mechanisms 
involved are still unclear. PAX5 protein is thought to regulate p53 transcription 
(Stuart et al., 1995) and PAX8 to regulate the apoptosis suppressor Bcl-2 
(Hewitt et al., 1997). To date, however, PAX6 is the only family member directly 
implicated in tumourigenesis in vivo, in the development of a pancreatic cystic 
adenoma in a transgenic mouse (Yamaoka et al., 2000). This finding has led to 
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further work assessing the potential of PAX6 as a chemopreventive target 
(Robson et al., 2006). 
Although the potential role of PAX9 in squamous epithelial cancers is regarded 
as that of a tumour-suppressor gene, there is evidence that ‘driver gene’ 
candidacy cannot be entirely excluded. Together with the transcription factor 
genes TTF-1 and NKX2-8, PAX9 has been identified within the amplified 
chromosomal region 14q13.3 in lung cancer (LC), leading to over-expression of 
all three genes. Furthermore, PAX9 expression contributes to the survival of 
lung cancer cell lines in vitro. This has led to the suggestion that PAX9, in 
combination with TTF-1 and NKX2-8, may act as an oncogene in LC (Kendall et 
al., 2007). There is also evidence that PAX9 interacts with c-myb, a proto-
oncogene that enhances the survival of SCC cell lines and is implicated in the 
pathogenesis of a range of cancers (Lee et al., 2008). These findings are 
consistent with the functions of other PAX family members that have been 
identified using in vitro studies (Muratovska et al., 2003). A follow-up study has 
shown that PAX9 has only minimal prognostic value in predicting lung cancer 
outcome; however, the evidence is complicated by the partial retraction of this 
paper (Hsu et al., 2009). In contrast, other work has identified allelic loss at 
14q13.3 in a subset of LC, suggesting that in certain tumours PAX9 and factors 
such as NKX2-8 may perform tumour-suppressor rather than oncogenic 
functions (Harris et al., 2011). 
1.6  Animal models 
The paucity of reliable biomarkers to identify the pre-cancerous lesions at 
greatest risk of malignant progression has been acknowledged (Kanojia and 
Vaidya, 2006). In part, this reflects the limited availability of suitable animal 
models in which to study the mechanisms of OSCC formation and test 
substances that may halt/reverse these processes (Czerninski et al., 2009). 
While molecular analysis of human biopsy samples is the ideal, tissue from 
each of the multiple stages in the evolution of a particular lesion (i.e. 
hyperplasia, dysplasia, carcinoma in-situ) is usually not available. By contrast, 
tissue from animal models allows each stage of precancerous development to 
be reproduced and made readily available for histological and molecular 
analysis (Herzig and Christofori, 2002; Wong, 2009). 
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Surrogate animal models that are currently recognised to recapitulate the 
conditions of the human oral cavity include the rat tongue and Syrian hamster 
buccal pouch (Eveson and MacDonald, 1978; Kanojia and Vaidya, 2006; 
Mognetti et al., 2006). Mouse models (tongue, oral cavity) have also been 
widely used. They are comparatively advantageous because of the potential to 
easily manipulate the mouse genome and the availability of many mouse 
mutants (Brudno et al., 2004). Spontaneous cases of OSCC are rare in animals 
(Thurman et al., 1997). However, development of OSCC has been induced in 
animal models through several methods: chemical induction, xeno-
transplantation, and transgenesis (Mognetti et al., 2006). 
1.6.1 Chemical induction of OSCC in animal models 
Several chemical carcinogens have been applied to animal models, including 
arecaidine, coal tar, and polycyclic aromatic hydrocarbons such as DMBA (7, 
12-dimethylbenz(a)anthracene and 9,10-dimethyl-1,2–benzanthracene) 
(Kanojia and Vaidya, 2006). DMBA was one of the first carcinogens 
successfully used to induce OSCC in animals (Salley, 1954). However, as a 
potent irritant it caused non-specific inflammation, epithelial necrosis, and 
proliferation of granulation tissue, which together obscured the interpretation of 
precancerous lesions. There is also evidence that OSCC induced by DMBA is 
histologically different to that of human OSCC (Kanojia and Vaidya, 2006; 
Mognetti et al., 2006). Chemical induction using 4-nitroquinoline 1-oxide (4-
NQO) avoids many of these problems and is currently the preferred model for 
studying OSCC carcinogenesis in mice (Vered et al., 2005). 
1.6.2 4-Nitroquinoline 1-oxide (4-NQO) 
4-NQO is a synthetic, water-soluble carcinogen that was derived from quinoline 
in the late 1950s (Nakahara et al., 1957). Initially developed as a possible 
chemotherapeutic agent, it was found that local application induced cancers of 
the skin and labial/lingual mucosa of mice (Fujino et al., 1965). A publication in 
the early 1970s described a comprehensive 4-NQO animal model in which 
topical application of 4-NQO over seven months generated cancers of the hard 
palate, tongue base, gingiva, and stomach in rats (Wallenius and Lekholm, 
1973). 4-NQO is now known to result in a spectrum of pre-cancerous as well as 
cancerous lesions, including hyperplasia, squamous cell papilloma (a benign 
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exophytic neoplasm), various grades of epithelial dysplasia and, most 
significantly, OSCC (Tang et al., 2004; Kanojia and Vaidya, 2006). Crucially, 
these changes occur in the absence of non-specific inflammatory changes: 4-
NQO is less irritant than other chemical carcinogens such as DMBA, and the 
histology is similar to that of human OSCC (Eveson and MacDonald, 1978). 
Although early studies were confined to topical application, work has since 
shown that systemic exposure to 4-NQO, which can be readily added to 
drinking water, causes similar and more reproducible changes (Tang et al., 
2004). 4-NQO may induce cancers of the lung following subcutaneous injection 
(Imaida et al., 1989). However, following oral ingestion it has a recognised 
fidelity to the oral cavity and oesophagus. Necroscopy studies have failed to 
demonstrate either cancers or precancerous lesions elsewhere in the digestive 
tract (stomach, intestine, and bowel) or other viscera (liver, lungs) of mice (Tang 
et al., 2004). The localisation of 4-NQO induction to the oral cavity and 
oesophagus is attributed to the high concentration of diaphorase, a reductase 
that is required to activate 4-NQO, in the mucosa at these sites (Kanojia and 
Vaidya, 2006). 
1.6.3 4-NQO method of action 
The carcinogenic action of 4-NQO is potentiated by reduction of its nitro group 
to 4-hydroxy-aminoquinoline-1-oxide (4-HAQO). 4-HAQO is implicated in the 
formation of DNA adducts and undergoes further metabolism and acetylation to 
form the seryl-AMP-enzyme complex that introduces quinoline groups into DNA 
(Kanojia and Vaidya, 2006). In vivo, the 4-HAQO metabolite preferentially 
reacts with guanine residues (Tada, 1976). The acetylated metabolite, seryl-
AMP-enzyme complex, also reacts through its 3rd and 4th positions with guanine 
at N2 and C8 respectively (Fronza et al., 1992). It is these adducts, which 
induce a guanine to adenosine substitution, that are implicated in the high 
mutagenicity of 4-NQO (Kanojia and Vaidya, 2006; Vitale-Cross et al., 2009). 
As noted previously, nitrosamines such as NNK (4-(methylnitrosamino)-1-(-3-
pyridyl)-1-butanone) are among the most significant carcinogens in tobacco and 
preferentially bind to guanine residues to induce nucleotide transversions. 4-
NQO is also associated with the induction of p53 mutations (Heniford et al., 
1993) and exertion of potent oxidative stress by producing free-radical oxygen 
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species, such as the superoxide radical. These changes are similar to the 
molecular and genetic alterations induced by tobacco (Hecht, 2003; Kanojia and 
Vaidya, 2006). Additionally, recent evidence has suggested that 4-NQO induces 
up-regulation of the Wnt/β-catenin pathway, inappropriate activation of which is 
implicated in a range of human cancers (Fracalossi et al., 2010). 
Together, the site fidelity of and genetic alterations induced by the 4-NQO 
model simulate key aspects of oral/oesophageal SCC and it is therefore 
considered a valid model for the study of human OSCC. However, despite its 
recognition as the best available experimental system to date, the 4-NQO 
model is associated with certain limitations. In animals, 4-NQO-induced OSCC 
tend to be well differentiated. By contrast, most human OSCC range from 
moderately to poorly differentiated (Nauta et al., 1996). There is a markedly 
reduced tendency for 4-NQO-induced OSCC to metastasize to loco-regional 
lymph nodes in comparison with human OSCC. Conversely, patterns of local 
invasion may be more aggressive, with neural invasion reported as a typical 
finding in 4-NQO models. These suggest underlying differences in the biology of 
cancerous cells generated by the 4-NQO model. Although careful optimisation 
of dosage mitigates this complication, 4-NQO-induced OSCC often exhibits a 
multifocal distribution. Despite the phenomenon of field cancerisation, an initial 
multifocal presentation of OSCC in humans is rare (Hasina et al., 2009). 
1.6.4 Experimental protocols for 4-NQO induction of carcinogenesis in 
mouse models 
Over the past 15 years, workers have attempted to optimise an experimental 
protocol for the 4-NQO model. Parameters such as the duration, site, and 
mechanism of carcinogen application, along with the overall duration of 
treatment and point of sacrifice, have been adjusted (Vitale-Cross et al., 2009). 
Although lesions in the oral cavity may be induced by brushing the mucosa with 
highly-concentrated 4-NQO solutions, administration via drinking water is 
currently preferred due to its ease and reproducibility (Kanojia and Vaidya, 
2006; Vitale-Cross et al., 2009). 
Early studies administering 4-NQO via drinking water used low doses, ranging 
from 10–20 µg/mL, for periods of up to 50 weeks. These dosages induced a 
spectrum of genetic mutations, pre-cancerous lesions, and SCC within the oral 
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cavity (Ma et al., 1999; Ide et al., 2001). Although one study identified dysplastic 
epithelial changes following an exposure time as short as two weeks (Nauta et 
al., 1996), workers have consistently reported a latent period between the start 
of induction and the detection of epithelial dysplasia/OSCC of up to eight weeks 
(Dayan et al., 1997; Tang et al., 2004; Vered et al., 2005). 
Tang et al (2004) were the first to administer a higher dose of 100 µg/mL to 
CBA and C57/Bl6 mice. They demonstrated induction of pre-neoplastic and 
neoplastic lesions in 100% of mice exposed over a 16–week period. This study 
was the first to compare the outcomes of topical and systemic administration of 
4-NQO and to identify the development of oesophageal SCC in addition to 
lesions of the oral cavity. Tang et al (2004) also found that 100% of mice on a 
dosage of 50 ug/mL demonstrated premalignant changes after the same 16-
week period. A more recent study has confirmed the suitability of administering 
a 100 µg/mL dosage, which is not reported to result in undue 
morbidity/mortality. This group found that a sufficient incidence of OSCC was 
induced after as little as eight weeks to enable assessment of a 
chemotherapeutic agent (Hasina et al., 2009). 
1.6.5 The 4-NQO model and chemotherapy 
Chemotherapy may extend the latent period of carcinogenesis and help to 
maintain patients’ quality of life in the terminal stages of cancer. The 4-NQO 
mouse model has been used in a range of studies assessing the action and 
efficacy of chemotherapeutic agents. For example, the MTOR (Mammalian 
Target of Rapamycin) signalling pathway is a recognised therapeutic target. 
Rapamycin administration has been shown to halt progression of precancerous 
lesions and promote regression of OSCC using the 4-NQO model (Czerninski et 
al., 2009). Anti-angiogenic agents, such as ABT-510 and Vandatanib, have also 
been validated in reducing the incidence of dysplasia and OSCC induced by 4-
NQO (Hasina et al., 2009; Zhou et al., 2010). Erlotinib, an inhibitor of the EGFR-
STAT3 signalling pathway, has been shown to result in a 69% decrease in 
epithelial dysplasia/OSCC compared to controls (Leeman-Neill et al., 2011). 
The chemopreventive potential of dietary xanthophylls has also been explored 
using the 4-NQO model, in a study that found both astaxanthin and canthaxin 
consumption to be associated with significantly lower cancer rates than controls 
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(Tanaka et al., 1995). The potent chemopreventive all-trans retinoic acid, an 
isomer of 13-cis-retinoic acid that regulates epithelial cell proliferation, has been 
developed using a 4-NQO model to trial loading microspheres and optimise 
concomitant celecoxib anti-inflammatory therapy (Park et al., 2005). 
1.6.6 Genetic induction of OSCC in mouse models 
Studies using transgenic and knockout mice have contributed to our current 
understanding of tumourigenesis. A range of tumours has been replicated in 
transgenic models, but genetic modifications resulting in OSCC in mice are still 
rare (Mognetti et al., 2006). Transgenic models are limited by poor penetrance 
in mice with heterologous promoters, who may express non-physiological levels 
of the transgene product. Conversely, homozygous knockout mice may fail to 
complete embryogenesis or die shortly after birth (Mognetti et al., 2006). Other 
confounding factors include a tendency to develop multiple primary tumours 
and, later, failure to develop metastases. It may also be difficult to translate 
experimental findings regarding isolated mutations in transgenic models to 
humans, where tumours represent numerous sequential genetic alterations 
(Fearon and Vogelstein, 1990; Frijhoff et al., 2004). 
Notwithstanding these difficulties, transgenic models have been successfully 
used to assess the contribution of specific genetic alterations to the 
development of OSCC. These include a study of the role played by the K-ras 
oncogene in promoting OSCC, in a mouse model that used tetracycline as an 
inducer of transgene expression in basal keratinocytes (Vitale-Cross et al., 
2004b). Transgenic mouse models have also helped to delineate the function of 
Smad4 and p53 mutations in OSCC (Opitz et al., 2005; Redman et al., 2005; 
Bornstein et al., 2009). 
It has been suggested that combining the 4-NQO model with a transgenic 
model in which mice are defective in a certain gene would better reflect the 
complex contribution of genetic and environmental factors during the formation 
of OSCC (Wong, 2009). To date, a limited number of studies have combined 
these models. The role of p53 in 4-NQO-induced OSCC formation has been 
studied by a group who applied the 4-NQO model to mice with a dominant-
negative p53 mutation. Using micro-array and gene mapping analysis, this 
study identified a reduction in p53-dependent apoptosis and cell-cycle arrest 
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pathways that consequently led to increased cell proliferation (Zhang et al., 
2006). A combined 4-NQO/transgenic model has contributed to the evidence 
implicating HR-HPV in the aetiology of OPSCC (El-Mofty, 2007). Application of 
4-NQO to mice transgenic for the HPV oncogenes E6/E7 demonstrated that 
these mutants had significantly increased susceptibility to developing OSCC 
(Strati et al., 2006). Another ‘combined model’ has also been used to test the 
hypothesis that the nucleotide excision repair gene XPA (xeroderma 
pigmentosum group A) has a protective effect during oral carcinogenesis (Ide et 
al., 2001). 
1.6.7 Investigating a potential tumour-suppressor role of Pax9 in OSCC 
A transgenic mouse line, Pax9flox, has been developed that permits conditional, 
tissue-specific inactivation of Pax9 (Kist et al., 2007). Conditional inactivation 
has been achieved by crossing Pax9flox mice with a transgenic strain, K14-Cre, 
which expresses Cre recombinase from the keratin 14 promoter that is active in 
the basal keratinocytes of stratified squamous epithelia (Vasioukhin et al., 
1999). Tongues of conditional Pax9-deficient mutants exhibit fissuring and a 
smooth, discoloured surface macroscopically. Histopathological examination 
and scanning electron microscopy further reveal loss of filiform papillae, 
reduced thickness of the lamina propria, and focal hyperplastic epithelial 
growths (Figure 1-2). One aged Pax9-deficient mutant developed an adenoma 
of the Harderian gland, a specialised lacrimal gland present in mice. Genome 
wide expression analyses of tongue tissue from these mutants have shown 
deregulation of numerous genes involved in epithelial differentiation as well as a 
slight reduction of tumour suppressor gene expression [unpublished data]. We 
therefore hypothesise that exposing Pax9-deficient mice to 4-NQO may induce 
more extensive and more rapid pre-cancerous changes and progression to 
OSCC than in 4-NQO treated control mice. 
1.6.8 Normal lingual microanatomy of the Pax9-deficient mouse 
The normal mouse tongue shares many of its micro-anatomical features with 
the normal human tongue. The dorsal surface is covered by specialised 
mucosa. The ventral surface is covered by non-specialised lining mucosa. 
Squamous epithelium lining both surfaces is separated from the underlying 
musculature by a thin lamina propria. 
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In both humans and mice, the dorsal tongue is lined by specialised squamous 
epithelium that is characterised by orthokeratosis and the presence of 
numerous filiform papillae (Figure 1-2). In humans, the ventral tongue is lined by 
non-specialised squamous epithelium, which is thinner than the dorsal 
epithelium and has a flat basement membrane. In mice, however, the ventral 
epithelium shows orthokeratosis, is only slightly thinner than the dorsal 
epithelium, and has an undulating rete outline. Keratinisation of the ventral 
surface enables the mouse epithelium to withstand greater frictional forces 
during mastication than the human tongue. This variation is likely to reflect the 
mouse diet, which is generally coarser than that of humans. 
The tongue of the Pax9-deficient mouse is characterised by a smooth dorsal 
surface. This is due to failure of development of filiform papillae. Although 
rudimentary, malformed filiform papillae may be detected, they are short and 
sparse (Figure 1-2). The dorsal surface is also characterised by fissures and 
thinning of the lamina propria (Figure 1-2).  
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Figure 1-2 Normal micro-anatomy of the tongue of control (wild-type) and 
Pax9-deficient mice 
A) The dorsal surface of the control mouse. B) Scanning electron microscopy shows well-
organised filiform papillae. C) Filiform papillae are also seen histologically. D) The dorsal 
surface of the Pax9-deficient mouse is relatively smooth and shows fissuring (arrows). E) 
Scanning electron microscopy shows loss of filiform papillae and evidence of fissuring (arrow). 
F) Histologically, there are sparse filiform papillae that are short and malformed. The epithelium 
is thinner than the control (bars). There is also thinning of the lamina propria (arrows).  
H&E images taken at x100 magnification.  
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1.7 Oral keratinocyte cell lines 
1.7.1 Primary culture of normal oral keratinocytes 
In vitro, normal human somatic cells exhibit limited replicative capacity. 
Replicative potential is limited despite optimisation of cells’ nutritional and 
mitogenic requirements (Smith and Pereira-Smith, 1996; Sedivy, 1998). This 
phenomenon is termed senescence. It reflects the erosion of telomeric DNA 
with each successive cellular replication. Telomeres are located at the ends of 
chromosomes and prevent the chromosomes from forming end-to-end fusions. 
When shortened, however, telomeres trigger the onset of senescence. In 
primary culture, cells will generally proliferate at first. However, following ~50 to 
100 successive replications there is sufficient erosion of telomeres to trigger 
senescence (Allsopp et al., 1992). Normal oral keratinocytes undergo 
senescence following an average of three to four passages (Prime et al., 1990). 
Growth in vitro may supported by co-culturing keratinocytes with mesenchymal 
cells, e.g. mitocyn C-treated 3T3 fibroblasts (Rheinwald and Green, 1975). 
Normal, non-neoplastic human fibroblasts may become immortalised and 
successfully evade senescence in vitro (Bodnar et al., 1998). Immortalisation 
occurs due to ectopic expression of the catalytic subunit of telomerase, hTERT. 
The hTERT catalytic subunit is usually expressed only by malignant cells 
(Meyerson et al., 1997). This subunit enables the cells to synthesise telomeres, 
and thus prevent telomere-induced cellular senescence (Feng et al., 1995). 
It has been documented that, in vitro, normal oral keratinocytes may 
spontaneously evade senescence and become immortal (Boukamp et al., 
1988). Immortal keratinocytes are also characterised by the ectopic expression 
of hTERT. However, immortalisation also requires a gain-of-function mutation in 
the p16INK4A gene. There is a complex pattern of p16INK4A protein expression 
that regulates senescence in a pathway that is independent of telomere-induced 
shortening. An oral keratinocyte cell line that exhibits both ectopic expression of 
hTERT and over-expression of p16INK4A has been generated. This 
OKF6/hTERT cell line evades senescence without exhibiting abnormalities of 
either growth or differentiation (Dickson et al., 2000). 
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1.7.2 OSCC cell lines 
Two of the oldest cancer cell lines are derived from the oral cavity (Eagle, 1955; 
Moore et al., 1955). For many years, however, OSCC cell lines have proved 
difficult to culture and characterise (Krause et al., 1981). In vitro, keratinocytes 
derived from OSCC exhibit diverse phenotypes, and may show characteristics 
of both normal and malignant cells (Parkinson, 1989). Useful markers of 
malignancy in vitro include resistance to terminal differentiation (Rheinwald and 
Beckett, 1980), altered expression of TGF-β cell surface receptors (Shipley et 
al., 1986), and changing patterns of oncogene expression (Field and 
Spandidos, 1987). 
By contrast to their clinical behaviour in vivo, cells cultured from OSCC may 
show little or no growth. Lack of growth may be due to inappropriate cell culture 
conditions, or insufficient numbers of cancer stem cells (CSC) (Rheinwald and 
Beckett, 1981). OSCC-derived keratinocytes may be cultured under similar 
conditions to normal keratinocytes. However, OSCC-derived cells vary in their 
dependence on mesenchymal support. Mesenchymal support may actually 
compromise the growth of some OSCC-derived cells. Factors derived from 
OSCC cultures may be cytotoxic to 3T3 cells, further complicating culture 
conditions (Rupniak et al., 1985; Prime et al., 1990). 
Despite the challenges that the primary culture of malignant oral keratinocytes 
presents, a range of OSCC-derived cell lines has now been established (Prime 
et al., 1990; Edington et al., 1995). These cell lines are valuable tools in the 
study of oral carcinogenesis. They have been characterised with regard to the 
expression of cytokeratin, vimentin, and involucrin (Sugiyama et al., 1993; 
Prime et al., 1994a), and tumorigenicity following both subcutaneous and 
orthotopic transplantation in athymic mice (Prime et al., 1994b; Paterson et al., 
2002). They have also been characterised with regard to H-ras and p53 
mutations (Yeudall et al., 1993; Yeudall et al., 1995), inhibitory response to 
TGF-β1 (Prime et al., 1994a), autocrine production of TGF-β isoforms (Fahey et 
al., 1996) and expression of TGF-β cell surface receptors (Prime et al., 1994a). 
Several lines have been successfully transfected with plasmid DNA (Paterson 
et al., 2002). The literature to date suggests that these cell lines will provide 
excellent models of oral carcinogenesis both in vitro and in vivo. 
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1.8 Conclusion 
This review has highlighted the global burden of OSCC, the limitations of the 
treatment modalities currently available, and the consequent need to develop 
biomarkers that improve the management and prognostication of patients with 
OPMD and OSCC. 
The literature suggests that EGFR gene copy number is a potential biomarker in 
OPMD and OSCC. However, the nature, prevalence, and biological significance 
of EGFR gene copy number alterations in the early stages of oral 
carcinogenesis remain unclear. Similarly, there is emerging evidence that SOX2 
may have an oncogenic function in oral carcinogenesis, is critical to the survival 
of cancer stem cells, and correlates with clinical outcomes in OSCC. However, 
there is only a limited number of SOX2 studies available in the literature, 
particularly studies that describe SOX2 expression in OPMD. Evidence from an 
isolated study of oesophageal cancer suggests that PAX9 has a tumour-
suppressor function in the squamous epithelium. To date, however, the role of 
PAX9 in oral carcinogenesis is unknown. 
1.9 Hypothesis 
This study will test the hypothesis that EGFR, SOX2, and PAX9 may be useful 
prognostic biomarkers in potentially malignant disorders and early-stage 
squamous cell carcinoma of the oral cavity. 
1.10 Aims 
1. To determine the expression profiles of EGFR, SOX2, and PAX9 in groups 
of patients with OPMD and early-stage OSCC 
2. To correlate the expression profiles of EGFR, SOX2, and PAX9 with 
patients’ characteristics and clinical outcomes 
3. To determine whether conditional Pax9-deficient mice are predisposed to 
the development of OSCC following exposure to 4-NQO 
4. To develop tools that will facilitate exploration of the functional significance 
of SOX2 and PAX9 in oral carcinogenesis.  
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Chapter 2. Materials and Methods 
2.1 Human tissue samples: oral potentially malignant disorders 
Patients with oral potentially malignant disorders (OPMD) were identified 
retrospectively using two strategies: 
1) attendance at an OPMD clinic, Department of Oral and Maxillofacial 
Surgery, Newcastle-upon-Tyne NHS Hospitals (NUTH) 
2) a search of the electronic database, Department of Cellular Pathology, 
NUTH 
2.1.1 Attendance at an OPMD clinic 
The characteristics and clinical outcomes of a group of 100 patients attending 
an OPMD clinic have been published by Diajil et al (2013). Patients in the study 
presented with an OPMD. Incisional biopsy of the OPMD showed epithelial 
dysplasia. Dysplastic lesions were managed either by surveillance or laser 
excision. The study spanned a 13-year period (1997-2009). Patients were 
followed up for a minimum of 24 months. The study excluded patients who had 
either a history of oral/upper aero-digestive tract malignancy or a previous 
OPMD. 
2.1.2 Electronic database of the Cellular Pathology Department 
A systematic search of the pathology database was carried out using SNOMED 
codes. The search identified a group of patients with oral squamous cell 
carcinoma (OSCC) who had previously undergone a biopsy (or multiple 
biopsies) of an OPMD at the same mucosal subsite. The OPMD was managed 
either by surveillance or laser excision. The search spanned a 13-year period 
(1997 - 2009). The search identified a total of 67 cases in which OSCC was 
preceded by an OPMD. This group was refined by excluding cases with a 
history of oral/upper aero-digestive tract malignancy; OSCC formation at a 
separate mucosal subsite to the index OPMD; less than six months between 
index OPMD biopsy and OSCC diagnosis (the index biopsy may have 
insufficiently sampled an existing OSCC); cases with non-dysplastic OPMD 
diagnosed with specific clinico-pathological entities, e.g. chronic hyperplastic 
candidosis or lichen planus; cases in which the clinical presentation and 
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histological features were suggestive of the clinical entity proliferative verrucous 
leukoplakia (PVL). 
A separate search of the electronic database identified patients with biopsies 
that showed normal oral mucosa. The search spanned a six-year period (2007-
2012) and identified a total of 24 cases. These cases were used as controls for 
immunohistochemical analysis (section 2.4). 
2.1.3 Histopathological specimens 
Haematoxylin and eosin (H&E) stained sections and formalin-fixed paraffin-
embedded (FFPE) blocks were retrieved from the Department of Cellular 
Pathology archive for the OPMD identified by the searches. Cases that satisfied 
the study’s inclusion criteria and had sufficient material for further assays were 
selected for further analysis. Serial 4 µm sections were taken from each block. 
Individual sections were mounted on coated slides (Superfrost Plus, Thermo 
Fisher Scientific, UK). Sectioning was carried out in the Department of Cellular 
Pathology by Biomedical Scientists. 
2.1.4 Histological grading of epithelial dysplasia 
H&E sections were reviewed by two pathologists (Dr M. Robinson and Prof. P. 
Sloan). The grade of epithelial dysplasia was scored independently for each 
case. Epithelial dysplasia was graded using two classification systems: 
1) Squamous Intra-epithelial Neoplasia (SIN) classification (Barnes et al., 
2005) 
2) Binary (low-grade/high-grade) classification (Kujan et al., 2006 ). 
All discordant cases were reviewed at a meeting between the pathologists and 
assigned a single grade by consensus. 
2.1.5 Clinical outcomes 
Clinical outcomes were categorised into four groups: 1) no adverse outcome; 2) 
local recurrence; 3) new lesion; and 4) malignant transformation, after Diajil et al 
(2013). The criteria for each of these categories is summarised in Table 2-1.  
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Table 2-1 Categories of clinical outcome for oral potentially malignant 
disorders 
 
Clinical outcome category Criteria 
No adverse outcome No evidence of local recurrence, new lesion 
formation, or malignant transformation after 
minimum 24-month follow-up period 
Local recurrence Recurrence of epithelial dysplasia at the same 
mucosal subsite 
New lesion Development of a new epithelial dysplasia at a 
separate mucosal subsite 
Malignant transformation Progression from epithelial dysplasia to oral 
squamous cell carcinoma 
 
Adapted from Diajil et al (2013). 
 
2.1.6 Data collection and management 
For each OPMD the following data were collected and entered into an Excel 
spreadsheet: 
 patient’s demographic data (sex and age at initial OPMD biopsy) 
 oral mucosal subsite of the OPMD 
 date of index OPMD biopsy 
 patient’s risk factors (alcohol and tobacco habits) 
 clinical management of the index OPMD (laser excision or surveillance) 
 histological grade of epithelial dysplasia (SIN and binary classification) 
 clinical outcome (Table 2-1) 
 date of any subsequent histological diagnosis (e.g. local recurrence of 
epithelial dysplasia) 
 for the subset of cases that underwent malignant transformation, the 
histological differentiation and pStage of the subsequent OSCC was also 
recorded.  
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2.2 Human tissue samples: early-stage OSCC 
Patient data for the early-stage oral squamous cell carcinoma (OSCC) group 
was collected by Mr M. Kennedy during his Masters’ research project. 
2.2.1 Patients 
Patients were identified retrospectively using a systematic database search. 
The search identified consecutive cases of early-stage (i.e. pStage I/II) OSCC 
managed by the Head & Neck Multi-Disciplinary Teams (HNMDT) at NUTH and 
Sunderland Royal Hospital (SRH). The search spanned an eight-year period 
(2000-2008). The search involved three stages: 
1) A primary search of the DAHNO (DAta for Head and Neck Oncology) 
national cancer database 
2) Data from the DAHNO database was then cross referenced with data 
recorded by HNMDT at NUTH and SRH 
3) Electronic pathology reports archived at the Department of Cellular 
Pathology were used to verify the diagnosis/histological differentiation 
and pStage of each OSCC (the Department of Cellular Pathology 
provides diagnostic pathology services to HNMDT at both NUTH/SRH). 
 
The search excluded cases with: OSCC at pStages III and IV; OSCC of the lip 
and oropharynx; non-surgical primary management (i.e. 
radiotherapy/chemotherapy); a previous diagnosis of head and neck cancer; a 
history of radiotherapy to the head and neck region for non-malignant 
conditions; patients without follow-up. 
The disease status, length of post-surgical follow up, and survival data for cases 
that satisfied the study’s criteria were verified using: 
 Hospital patient administration systems, which record: 
o attendance at outpatient clinics 
o most recent survival in patients discharged from the HNMDT 
o date of death (where applicable) 
 General medical practitioners’ records, to establish survival status of 
patients with no recent hospital follow-up  
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 HNMDT clinic correspondence and records, which record: 
o patients’ treatment 
o local recurrence and other adverse outcomes 
o last known disease status 
 Hospital notes, for a small number of patients for whom survival/disease 
status could not be determined from the other sources above. 
2.2.2 Histopathological specimens 
H&E stained sections and FFPE blocks were retrieved from the Department of 
Cellular Pathology archive. H&E sections were reviewed by one pathologist (Dr 
M. Robinson) to identify a representative block with sufficient remaining material 
for further assays. Blocks were serially sectioned by trained laboratory staff in 
the Department of Cellular Pathology. 
2.2.3 Data collection and management 
For each OSCC, the following data were collected and entered into an Excel 
spreadsheet: 
 patients’ demographic data (sex and age at OSCC diagnosis) 
 the oral mucosal subsite of the OSCC 
 date of the index OSCC diagnosis 
 histological grade of differentiation (Broders’ classification) 
 clinical outcomes (disease-free survival and overall survival) 
 the date of any subsequent histological diagnosis. 
 
2.3 Human tissue samples: OSCC that transformed from OPMD 
The pathology database was used to identify the pStage, histological grade of 
differentiation, and any subsequent diagnoses for patients with OSCC that 
transformed from a pre-existing OPMD. Details of patients’ demographics and 
risk factors were already available from the OPMD database. Clinical follow-up 
data (including overall survival and disease status) was obtained from HNMDT 
meeting records. The data were entered into an Excel spreadsheet.  
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2.4 Immunohistochemical staining and analysis 
2.4.1 Automated immunohistochemistry 
For all human OPMD/early-stage OSCC cases, SOX2 and EGFR 
immunohistochemistry (IHC) was performed on 4 µm sections using an 
automated platform (Ventana Benchmark Autostainer, Ventana Medical 
Systems Inc, USA). Staining was carried out in the Department of Cellular 
Pathology by Biomedical Scientists. SOX2 protein expression was detected 
using a proprietary rabbit monoclonal antibody (anti-SOX2 SP76 clone, Cell 
Marque Corporation, USA). EGFR protein expression was detected using a 
proprietary rabbit monoclonal antibody that binds specifically to the EGFR 
internal domain (anti-EGFR 5B7 clone, Ventana Medical Systems Inc, USA). 
Staining was performed using protocols recommended in the manufacturers’ 
instructions. Morphologically normal squamous epithelium provided a positive 
internal control for each section. A negative control, with primary antibody 
omitted, was performed for each staining batch. 
2.4.2 Manual immunohistochemistry protocol 
During this project, manual IHC was performed in order to detect a range of 
proteins in human, mouse, and cell culture-generated specimens (cell pellets 
and Surepath™ preparations). Details of each antibody and the specimens on 
which they were used are summarised in Table 2-2. 
Whilst optimising the manual staining protocol for each antibody, IHC was 
performed on sections of human normal oral mucosa. 
Once optimised, manual IHC was performed in batches of between eight and 
12 slides. For sections of human OPMD/OSCC and mouse tongues, 
morphologically normal squamous epithelium provided a positive internal 
control for each slide. When IHC was performed on cell culture-generated 
specimens, the batch of slides included one slide with a section of human 
normal oral mucosa as the positive control. 
For each of the antibodies, manual IHC was performed using a commercially-
available kit (DAKO, Glostrup, Denmark).  
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The following description outlines the standard protocol used for manual IHC: 
 Sections de-waxed in fresh xylene (4x 5 mins immersions) 
 Sections hydrated through graded alcohols: 
o 99% (x2), 95%, and 70% (5 mins each) 
 Slides immersed in distilled water (10 mins) 
 Slides transferred to citrate buffer, pH 6 (Sigma-Aldrich, UK) 
 Slides placed in an automated decloaker (MenaPath, A Menarini 
Diagnostics, UK) for antigen retrieval: 
o Heated to 125°C and held at 20-25 psi for 30 secs 
 (TBS rinse*) 
 Periphery of each slide dried carefully and silicone fast well (FastWells, 
Interchim, France) firmly applied 
 Endogenous peroxidase blocked with 300 µl hydrogen peroxide (5 mins) 
 (TBS rinse*) Antibody solutions made up (see Table 2-2). 
 Slides incubated with 300 µl primary antibody solution (45 mins) 
o Incubated at room temperature in a humid reaction chamber 
placed on an automated horizontal rocker 
 (TBS rinse*) 
 PAX9 only: slides incubated with 300 µl secondary antibody (45 mins) 
 (TBS rinse*) 
 Incubated with 300 µl horseradish peroxidase-labelled polymer (30 mins) 
 (TBS rinse*) 
 Incubated with 3,3'-Diaminobenzidine (DAB) solution (5 mins) 
 Rinsed in tap water to stop DAB reaction (5 mins) 
 Sections counterstained in Harris’ haematoxylin (5 secs) 
 Slides placed in Scott’s Bluing solution (30 secs) 
 Sections dehydrated through graded alcohols 
o 70%, 95%, 99% (x2) (5 mins each) 
 Slides immersed in fresh xylene (2x 5 mins) 
 Coverslips placed (Leica CV5030 Coverslipper, Leica, UK). 
* N.B. TBS Rinse: tris-buffered saline (TBS) at pH 7.6 (2x 5 mins)  
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Table 2-2 Summary of antibodies used for each protein assay/specimen by manual immunohistochemistry 
 
Protein 
assay 
Specimens Primary antibody Secondary antibody 
Dilution Details Dilution Details 
PAX9 Human OPMD/OSCC 
Mouse tongues 
Cell pellets 
Surepath™ preparations 
1/40 Pax-9 (7C2) 
Rat Anti-Mouse Monoclonal 
Abcam*  
1/100 Immunoglobulins/HRP P0450 
Rabbit Anti-Rat Polyclonal 
DAKO 
 
SOX2 Mouse tongues 
Cell pellets 
Surepath™ preparations 
1/100 Sox2 (D6D9)  
Rabbit monoclonal 
Cell Signalling Technology 
N/A N/A 
Ki67 Mouse tongues 1/100 Ki67 (SP6) 
Rabbit monoclonal 
Abcam 
N/A N/A 
P53 Mouse tongues 1/50 p53 (7F5) 
Rabbit monoclonal 
Cell Signalling Technology 
N/A N/A 
*Although this PAX9 antibody is now commercially available, we used aliquots of the supernatant generated by hybridoma cells prior to marketing. The precise 
concentration of the antibody was therefore unknown. 
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2.4.3 Digital image analysis of immunohistochemical staining 
Following IHC, slides were scanned using an Aperio CS2 Scanscope™ platform 
(Leica Biosystems, UK) at x20 magnification. For human OPMD/OSCC and 
mouse tongues, the corresponding H&E sections were also scanned. Electronic 
files were uploaded to the Aperio Spectrum system for digital image analysis 
(Spectrum Version 11.1.0.751©, Aperio Technologies, Inc, Leica Biosystems, 
UK). H&E sections were used to guide the annotation of areas on the 
corresponding IHC-stained sections according to morphology (i.e. areas of 
histologically normal epithelium, epithelial dysplasia, and OSCC). Areas were 
annotated using a freehand pen tool (Figure 2-1). Wherever there was sufficient 
material, a minimum of 1000 cells were selected per morphological area. 
Annotated areas were then analysed using two standardised Aperio algorithms 
(nuclear algorithm: PAX9, SOX2, Ki67, and p53; cellular algorithm: EGFR 
(Cregger et al., 2006)). The algorithms generated a range of parameters, 
including the total number of nuclei/cells analysed; the percentage of positive 
nuclei/cells (PPN/PPC); and the percentage of strongly-positive nuclei/cells 
(3+PN/3+PC). These values were exported into an Excel spreadsheet and 
collated prior to statistical analysis.  
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Figure 2-1 Digital image analysis using Aperio software 
Areas for digital image analysis were selected using a freehand pen tool (green arrow, red 
outline). The Aperio nuclear algorithm detected and stratified nuclei according to their signal as 
either negative (0, blue), weakly positive (1+, yellow), positive (2+, orange), or strongly positive 
(3+, red). The algorithm used the percentages of 0, 1+, 2+ and 3+ nuclei to calculate the overall 
percentage of positive nuclei (PPN) and the percentage of strongly positive nuclei (3+PN).  
Adapted from a screenshot taken using the Aperio Scanscope software at x100 magnification.  
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2.5 In situ hybridisation for EGFR chromosome 7 
2.5.1 Automated staining 
The EGFR in situ hybridisation (ISH) signal was assessed by a dual colour 
technique using proprietary reagents (INFORM EGFR-Chromosome 7 dual 
colour assay, Ventana Medical Systems Inc, USA). This technique detects both 
the EGFR gene (using silver ISH, seen as black nuclear dots) and chromosome 
7 centromeres (using Ultraview Alkaline Phosphatase Red ISH, seen as red 
nuclear dots) on the same section. Staining was performed by Biomedical 
Scientists in the Department of Cellular Pathology, using the Ventana 
Benchmark Autostainer according to the manufacturer’s instructions. DNA 
probes were omitted from negative controls. 
2.5.2 Scoring and interpretation of ISH-stained sections 
Dual-stained ISH sections were examined independently by two pathologists 
(Dr M. Robinson, Timothy Bates). Morphologically normal squamous epithelium 
was used to calibrate the appearance of disomy (seen as two black dots and 
two red dots). According to the predominant nuclear signal, each case was 
assigned to one of the descriptive categories described for non-small cell lung 
carcinoma (Figure 2-2). Actively dividing and overlapping cells were not 
assessed. All discordant cases were reviewed at a meeting between the 
pathologists and assigned a single grade by consensus.  
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Figure 2-2 Interpretation of dual EGFR gene and chromosome 7 ISH stained 
sections 
EGFR ISH may detect a diverse spectrum of nuclear signals. Normal epithelium is expected to 
show disomy. The in situ hybridisation signals that are interpreted as amounting to genomic 
gain in lung cancer (high polysomy, >15 copies, and clusters) are rare in OPMD. For the 
analysis of the OPMD group, these signals were therefore grouped alongside cases showing 
trisomy and low polysomy in a single ‘abnormal EGFR gene copy number’ category. However, 
for the analysis of the early-stage OSCC group, only the categories currently validated as 
indicating EGFR genomic gain were considered. 
Adapted from ‘Interpretation Guide: Ventana Inform EGFR DNA Probe’, Roche. 
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2.6 Mouse model of oral carcinogenesis 
2.6.1 Experimental outline 
4-nitroquinolone 1-oxide (4-NQO) is a chemical carcinogen that induces 
formation of oral squamous cell carcinoma (OSCC) in mice (Kanojia and 
Vaidya, 2006). This feasibilty study was designed to optimise 4-NQO-induced 
OSCC formation in Pax9-deficient mutant mice. The purposes of the study were 
analogous to those of a phase I clinical trial in humans, i.e. to identify the 
response of Pax9-deficient mutants to 4-NQO treatment, to identify the tolerable 
4-NQO dose range for Pax9-deficient mutants, and to identify any potential side 
effects/systemic toxicity that may be induced by 4-NQO treatment (Cancer 
Research UK, 2013). 
Prior to the 4-NQO experiment, mutant (K14Cre-Pax9flox/flox) and control 
(Pax9flox/flox) mice had been crossed using three different genetic backgrounds: 
C57Bl/6J, FVB/NJ, and a hybrid strain (C57Bl/6J crossed with FVB/NJ). This 
generated similar numbers of Pax9-deficient mutant and control mice. Mutant 
mice were characterised by the tissue-specific inactivation of Pax9 in the oral 
cavity and upper aerodigestive tract. This is due to the K14-Cre promoter 
sequence, which induces transcription of Cre-recombinase. Cre-recombinase 
mediates DNA recombination either side of the floxed Pax9 sequence, and 
effectively excises the Pax9 gene. The mutant phenotype shows loss of filiform 
papillae from the squamous epithelium of the dorsal tongue. The dorsal tongue 
may also show fissuring. Control mice lack the activity of the K14-Cre promoter 
and therefore express normal levels of Pax9. Control mice therefore exhibit a 
wild-type phenotype with morphologically normal tongues that include filiform 
papillae. 
Groups of mutant and control mice were exposed to 4-NQO administrered via 
drinking water. Three different concentrations of 4-NQO were used: 10, 20, 50 
µg/ml. Exposure to 4-NQO was continued for up to 28 weeks. Mice were 
sacrificed humanely at planned intervals for analysis. Any mice that 
unexpectedly became sick as a result of 4-NQO treatment were also sacrificed. 
The experiment was carried out in the Functional Genetics Unit (FGU) at the 
Institute of Genetic Medicine, International Centre for Life, Newcastle University. 
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2.6.2 Preparation of 4-NQO solutions 
The concentration of the stock 4-NQO solution was 50 mg/ml. The stock 
solution was prepared by dissolving 1 g of 4-NQO powder in 20 ml of dimethyl 
sulphoxide (DMSO) (Sigma-Aldrich, UK). 1.5 ml of the stock solution was 
aliquoted into 2 ml Eppendorf tubes. Aliquots were stored at -20ºC in a light-
proof container in the main laboratory. 
The concentration of the experimental 4-NQO solution to be added to the 
drinking water was 5 mg/ml. The experimental solution was made up on 
treatment days. One aliquot of stock 4-NQO solution was added to 13.5 ml of 
propylene glycol (1:10 dilution). The experimental solution was transferred to 
the FGU and stored at 4ºC in a light-proof container prior to treatment. 
2.6.3 4-NQO administration 
Each cage was supplied with a 200 ml drinking water bottle. During the active 
phase of 4-NQO treatment, 4-NQO solution was added to freshly sterilised 
drinking water at the start of each week. 200 ml of autoclaved drinking water 
was poured into a sterile water bottle, which was transferred to a designated 
fume cupboard. Experimental 4-NQO solution was then added using barrier 
tips. The quantity of experimental solution added depended on the final 
concentration of 4-NQO planned for each cage (Table 2-3). Water bottles were 
placed in a light-proof plastic sheath prior to being attached to the cage as light 
exposure may trigger decomposition of 4-NQO (Tang et al., 2004). 
 
Table 2-3 Pipetting protocol for the preparation of 4-NQO drinking water 
 
Final 4-NQO 
concentration 
(μg/ml) 
Volume of 
water (ml) 
Volume of 
experimental 4-
NQO solution (μl) 
Dilution 
50 200 2000 1/100 
20 200 800 1/250 
10 200 400 1/500 
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Any excess 4-NQO drinking water from the previous week was decanted into 
designated 2.5 litre Winchester bottles. These bottles were stored until full. Full 
bottles were sealed and then removed by waste contractors for disposal as 
hazardous chemical waste. 
2.6.4 Health and safety measures during the handling of 4-NQO 
4-NQO is carcinogenic to all mammals, including humans. Personal protective 
equipment was therefore used at all times when handling 4-NQO. This included 
a laboratory coat, nitrile gloves, a face mask, and protective glasses. 
No 4-NQO spillages occurred and no first aid measures were required during 
this experiment. However, emergency plans were formulated in conjunction with 
Newcastle University’s Health and Safety Department, as part of the COSHH 
form risk assessment for the experiment. The emergency measures are 
summarised in the Appendix. 
2.6.5 Cage cleaning and bedding changes 
Cages and bedding were replaced by trained FGU technical staff at least once 
per week. Both were potentially contaminated by 4-NQO. Cage changes were 
therefore carried out in the designated fume cupboard. Bedding was disposed 
of in double-layered clinical waste bags. The bags were incinerated according 
to the FGU’s standard waste disposal protocol. Empty cages were collected in 
autoclave bags. Cages were washed and autoclaved by FGU staff. 
2.6.6 Monitoring of mice during exposure to 4-NQO 
Mice were checked by trained FGU technical staff every day. Any mice that 
showed signs of systemic toxicity (such as hypersalivation, a hunched posture) 
due to 4-NQO treatment were immediately reported to Dr R. Kist. For humane 
reasons, any sick mice were sacrificed prior to completion of the planned period 
of 4-NQO treatment. 
Mice were weighed each week throughout the 4-NQO experiment until they 
were sacrificed. Any mouse that weighed <30% of the normal body weight for a 
mouse of their age was sacrificed for humane reasons. Throughout the 
experiment, mice were also monitored by a veterinary surgeon on a weekly 
basis. This was in compliance with Home Office regulations.  
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2.6.7 Sacrifice for macroscopical and histological analysis 
Mice were sacrificed using the FGU’s standard CO2 gas chamber facility. The 
chamber first was inverted to remove residual CO2. This was to avoid the 
distress that sudden exposure to high concentrations of CO2 may cause the 
mice. The chamber was lined with a paper towel. Mice were placed in the 
chamber and the lid sealed. CO2 was turned on at a low concentration (10-20% 
CO2) until mice became drowsy (usually after ~1-2 mins). The CO2  
concentration was gradually increased to ~50-60%. Mice were left for a further 
2-3 mins until no signs of life were evident. The CO2  was turned off. Firm finger 
pressure was applied to the hind limb of each mouse. If pressure elicited a 
reflex, the lid was sealed and CO2  exposure resumed. When no reflexes were 
elicited, mice were removed for autopsy. 
2.6.8 Autopsy procedures 
Mice were pinned out supine on a cork board and sprayed with 70% ethanol. 
Using sharp-ended scissors, a transverse incision was made in the pelvic 
region. Blunt dissection was then used to separate skin from the peritoneal 
fascia. A sagittal skin cut was made towards the sternum. Resulting skin flaps 
were then pinned laterally. 
The abdominal cavity was accessed through the peritoneal fascia. Each of the 
major organs (stomach, liver, spleen, intestines, kidneys) was inspected. 
The thorax was accessed by fracturing the sternum in the midline using blunt-
ended scissors. The heart, lungs, and oesophagus were inspected. In cases 
with a possible oesophageal tumour, the oesphagus was blunt dissected off 
surrounding thoracic viscera and fixed separately. 
A midline sagittal skin incision was made from the root of the neck towards the 
lower border of the mandible. Skin was blunt dissected away from the cervical 
fascia. The cervical fascia was dissected off the underlying salivary glands. The 
salivary glands were removed for separate fixation. 
A subset of mice showed tumours arising on the buccal mucosa/lip. These were 
dissected off surrounding structures prior to opening the oral cavity. 
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The oral cavity was accessed via bilateral sagittal incisions from the labial 
commissure to the retromolar region. Large, blunt-ended scissors were then 
used to fracture the temporomandibular joint/ramus of the mandible. The 
mandible, tongue, and floor of mouth were then dissected away from the 
surrounding structures and pinned out separately on cork board. 
The tongue was dissected away from the floor of mouth and mandible. Forceps 
were used gently to elevate the tip of the tongue. Sharp-ended scissors were 
used to make a small transverse incision through the lingual frenum. The 
tongue was separated by blunt dissection through this incision, working postero-
laterally towards the tongue base. 
2.6.9 Fixation and cut-up 
All tissue separated from the main specimen (tongue, salivary glands, 
oesophagus, and tumours of the lip/buccal mucosa) was transferred to a 15 ml 
Falcon tube containing 10% buffered formalin. The tissue was incubated at 
room temperature on a rocker for 24 hours to facilitate thorough fixation. The 
main specimen was fixed in 10% buffered formalin and archived. 
Following 24 hours of fixation, tongues were subdivided in the coronal plane. 
Small tongues were bisected into anterior and posterior halves. Larger tongues 
were trisected into anterior, middle, and posterior thirds. In the majority of 
cases, the anterior portion was further bisected in the sagittal plane. 
2.6.10 Processing, embedding, and sectioning 
Each piece of tongue tissue was placed in an individual cassette (except the 
bisected anterior portions, which were placed in a single cassette). The tissue 
was processed in the Department of Cellular Pathology by Biomedical 
Scientists, using a routine overnight processing protool. 
Processed tissue was embedded on the most anterior cut surface (medial cut 
surface for bisected anterior portions). To screen all the tongues, a first-face 
section was cut at 4 µm and stained with H&E. In selected cases, ribbons were 
subsquently cut through all remaining tissue. Every tenth section was mounted 
on a glass slide and stained with H&E. All unstained sections were mounted on 
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coated slides (Superfrost Plus, Thermo Fisher Scientific, UK) for further assays. 
Unstained sections were stored at 4ºC to minimise antigen degradation. 
2.7 Cell Culture Techniques 
For all cell culture techniques, unless otherwise stated, reagents were of 
molecular biology grade and obtained from either Sigma-Aldrich, UK, or Lonza, 
UK. Apart from the lentivirus transfections (section 2.9), all cell culture 
procedures were performed in a level 2 containment tissue culture facility in the 
School of Dental Sciences, using a Safe Flow 1.2 laminar flow cabinet (BioAir 
Solutions, UK). 
2.7.1 Maintenance of oral squamous cell carcinoma cell lines 
Nine commercially-available OSCC-derived cell lines were cultured. The cell 
lines were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM/F12 1:1 
Mixture, with 15 mM Hepes and 0.6 µg/ml L-glutamine). The final DMEM 
solution also contained 10% (v/v) foetal bovine serum (FBS), 10 mL penicillin 
streptomycin, and 0.5 ug/ml hydrocortisone 21-hemisuccinate sodium salt. Cells 
were cultured in 75 cm2 flasks and incubated in a dedicated cell-line incubator 
(InCu Safe, Sanyo Electronics, Japan). The incubator provided a humidified 
atmosphere of 5% CO2/95% air and a temperature of 37ºC. Cells were 
inspected daily for confluence and to screen for contamination using a Leica 
DM IL inverted-phase contrast microscope (Leica Microsystems, UK). The 
culture medium was replenished every three to four days. 
A control OKF6/hTERT cell line was cultured in keratinocyte serum-free media 
with 0.6 µg/ml L-glutamine. The final culture medium also contained 0.2 ng/ml 
human recombinant epidermal growth factor, and 20 µg/ml bovine pituitary 
extract (Life Technologies, Paisley, UK). The OKF6/hTERT cells were 
maintained and subcultured in conditions otherwise identical to the OSCC-
derived cell lines. 
2.7.2 Subculture and cell number determination 
Cells were sub-cultured every five to seven days or whenever ~90% confluent. 
Culture medium was decanted and the cells washed with phosphate-buffered 
saline (PBS). The cells were enzymatically detached from the floor of the flask 
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by incubating with 0.025% (v/v) trypsin solution for 5 mins at 37º C. Trypsin was 
neutralised by the addition of an equal volume of epithelial medium. The cell 
suspension was centrifuged at 1000 rpm for 5 mins at 4˚C (Jouan CR3i 
Multifunction Centrifuge, Thermo Scientific, USA). The supernatant was 
aspirated and discarded. The cell pellet was re-suspended in 5 ml of epithelial 
medium. The cell number was determined by counting the number of cells 
present in 20 µl of cell suspension loaded onto a Bright-Line haemocytometer 
(Hausser Scientific, USA). Cells were counted across sixteen squares in each 
of four quadrants of the haemocytometer. The mean of all four quadrants was 
calculated. The mean was multiplied by 1 x 104 to give the number of cells per 
ml of the cell suspension. The cells were finally re-seeded at a density of 5 x 
105 cells per 75 cm2 flask. 
2.7.3 Long-term cell storage 
Stocks of OSCC-derived and control OKF6/hTERT cell lines were maintained in 
liquid nitrogen for long-term storage. The cell number was determined (as 
above, section 2.7.2). 5 x 105 - 1 x 106 cells were then re-suspended in DMEM 
with 20% (v/v) FBS and 10% (v/v) DMSO. The cell suspension was transferred 
to cryotube ampoules (CRYO-STM, Greiner Bio-one, UK). The cryotubes were 
placed in a -80ºC freezer for 12-24 hours (Ultra Low, Sanyo Electronics Ltd, 
Japan). Cryotubes were then transferred to liquid nitrogen at a temperature of 
approximately -196ºC. The level of liquid nitrogen in the storage container was 
checked on a weekly basis. Fresh liquid nitrogen was added when necessary. 
2.7.4 Retrieval of cells for culture 
To retrieve cells from long-term liquid nitrogen storage, the cryotube ampoules 
were thawed rapidly in a water bath (temperature of 37ºC). The cryotube 
ampoules were quickly sterilised by wiping with 70% alcohol solution. The 
thawed cell suspension was then added to a 10 ml Falcon tube containing 
epithelial medium that had been pre-heated to 37ºC. The suspension was then 
centrifuged at 1000 rpm for 5 mins at 4˚C (Jouan CR3i Multifunction Centrifuge, 
Thermo Scientific, USA). The supernatant was aspirated and discarded. The 
cell pellet was re-suspended in 5 ml epithelial medium. The cell suspension was 
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transferred to a 25 cm2 tissue culture flask. Cells were maintained in culture as 
described in section 2.7.1. 
2.7.5 Mycoplasma testing 
The cell cultures were tested regularly for Mycoplasma infection using a 
proprietary kit (Mycoplasma Plus PCR Primer Set, Agilent Technologies, USA). 
Following subculture, 100 μl of supernatant was aspirated and transferred to a 
1.5 ml Eppendorf tube. The supernatant was heated to 95˚C on a heat block for 
5 mins and then pulsed in a micro-centrifuge for 5 secs at room temperature. 10 
μl of StrataClean resin was added to the supernatant and mixed by gentle 
flicking. The mix was then centrifuged for 5-10 secs at room temperature to 
pellet the resin component. The supernatant was aspirated and transferred to a 
fresh 1.5 ml Eppendorf tube. A standard PCR master mix was made up 
according to the manufacturer’s instructions. For each cell line, 5 μl of the 
treated supernatant was added to 45 μl of the master mix solution. The PCR 
cycle recommended by the manufacturer was run on a T100™ Thermal Cycler 
(BioRad, Berkeley, USA). The PCR product was run on a high grade 2% 
agarose gel with a 100 base-pair ladder. 
2.7.6 Preparation of agarose cell pellets 
Cells from a >90% confluent 75 cm2 flask were enzymatically detached using 
trypsin as for standard subculture (section 2.7.2). Trypsin was neutralised by 
the addition of an equal volume of epithelial medium. The cell suspension was 
centrifuged at 1000 rpm for 5 mins at 4˚C. The cell pellet was then re-
suspended in 10% buffered formal saline, transferred to a 15 ml Falcon tube, 
and incubated for 1 hour at room temperature. The suspension was then 
centrifuged at 10,000 rpm for 10 mins at room temperature. The supernatant 
was aspirated and discarded. The cell pellet was re-suspended in 200 μl PBS 
and transferred to a 1.5 ml Eppendorf tube. 
A 2% agarose gel was made up in PBS. 1 g of agarose powder (SeaKem® LE 
Agarose) was added to 50 ml PBS, and microwaved at a low heat. The agarose 
gel and cell pellet were equilibrated in a water bath heated to 60˚C. Following 
equilibration, 200 μl agarose gel was added to the cell pellet. The pellet was re-
suspended using a glass Pasteur pipette. The agarose cell suspension was 
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gently vortexed and then centrifuged at 13,000 rpm at room temperature. The 
pellet was allowed to cool for 1 hour at room temperature. When firm, the pellet 
was loosened from the sides of the tube by adding a few drops of 10% buffered 
formalin. The pellet was removed from the tube and longitudinally bisected 
using a scalpel. Both halves were placed in a histology cassette and immersed 
in 10% buffered formalin. The cassette was transferred to the Department of 
Cellular Pathology and processed using a routine overnight programme. The 
two halves of the pellet were embedded in wax and serially sectioned at 4 μm 
by Biomedical Scientists. 
2.7.7 Preparation of cell monolayers 
Following subculture, 250 x103 cells were seeded onto glass chamber slides 
(LAB-TEK, Thermo Fisher Scientific, USA). The chambers slides were 
incubated for two to three days under standard conditions until the cells 
were >90% confluent. The slides were transferred to ice and the culture 
medium was decanted. The cell monolayers were rinsed with 2 x PBS washes. 
2 ml of 4% buffered formal saline was added to both chambers and the slides 
were incubated at 37⁰C for 15 mins. The formal saline was removed and the cell 
monolayers washed with 2x PBS rinses. 2 ml PBS was added to each chamber 
and the slides were then stored at 4˚C until required for immunohistochemistry. 
2.7.8 Preparation of Surepath™ slides for immunohistochemistry 
Surepath™ slides were prepared in the Department of Cellular Pathology by 
Biomedical Scientists. Following subculture (2.7.2) the cell pellet was re-
suspended in 10 ml CytoRich® Red alcohol-based fixative (TriPath Imaging, 
Inc, USA). The cell suspension was incubated for 30 mins. The cell suspension 
was then centrifuged for 5 mins at 1500 rpm at 4⁰C (Hettich Centrifuge, DJB 
Labcare Ltd, UK). The supernatant was aspirated and discarded. 1 ml of tris-
buffered water was added to the pellet. The tube was then vortexed for 15 secs 
to disperse and mix the cell pellet. Settling chambers were attached to 
Surepath™ slides. 200 μl of cell suspension was added to each slide. The 
slides were incubated at room temperature for 10 mins. The settling chambers 
were removed and the excess fluid was decanted. Slides were transferred to 
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and stored in a Coplin jar containing 95% alcohol until required for 
immunohistochemistry. 
2.8 Standard transfection of OSCC cell lines using the T-REx™ system 
The transfection of H314 and H400 with the PAX9 over-expression/SOX2 
knockdown constructs was originally planned using the T-REx™ system 
(Invitrogen, Life Technologies, Paisley, UK). The transfections were outsourced 
to a commercial company (Dundee Cell Products Ltd, Whitehall House, 33 
Yeaman Shore, Dundee, DD1 4BJ: No. SC303525). Unfortunately, the 
transfections were unsuccessful and standard transfection of H314 and H400 
with T-REx™ plasmids was eventually abandoned (see Chapter 6, section 6.5). 
Therefore, only a brief overview of the original experimental design and relevant 
methods are summarised here. 
2.8.1 Experimental outline 
The T-REx™ system is a tetracycline-regulated mammalian expression system 
in which the chosen cell line is serially transfected with two separate plasmids. 
The system uses regulatory elements from the E. coli Tn10-encoded 
tetracycline resistance operon (Hillen et al., 1983; Hillen and Berens, 1994). 
The main components include: 
 pcDNA6/TR© - this is the regulatory plasmid that constitutively expresses 
the Tet-repressor (TetR) molecule under the control of the human 
cytomegalovirus (CMV) promoter (Postle et al., 1984) 
 pcDNA4/TO©/lacZ – this is the inducible expression plasmid that 
contains the gene of interest under the control of the human CMV 
promoter and two ‘tetracycline-on’ (TetO) sites 
o this plasmid also contains the lacZ gene, which expresses β-
galactosidase upon induction with tetracycline as a control 
 Tetracycline to induce expression of the gene of interest and the lacZ 
control.  
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In the T-REx™ system, the TetR molecule that is constitutively expressed by 
the regulator plasmid binds to the TetO sequence in the inducible expression 
plasmid. This blocks transcription of the gene of interest. On addition, 
tetracycline binds the TetR molecule. Binding induces a conformational change 
that leads to dissociation from the TetO sequence. Expression of the gene of 
interest is then promoted by the CMV sequence (Yao et al., 1998) (Figure 2-3). 
Generation of the PAX9 pcDNA4/TO©/lacZ plasmid is summarised briefly in 
Chapter 6. The SOX2 pcDNA4/TO©/lacZ plasmid was designed using the 
BLOCK-iT™ inducible shRNAi Entry Vector kit (Invitrogen, Life Technologies, 
Paisley, UK). Addition of tetracycline would lead to expression of SOX2 shRNAi, 
which would knockdown endogenous SOX2 expression. However, generation 
of the SOX2 pcDNA4/TO©/lacZ plasmid was abandoned following failure of the 
initial transfections.  
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Figure 2-3 The T-Rex™ inducible expression system 
1) The regulator plasmid, pcDNA6/TR©, generates high levels of tetracycline-repressor (TetR) 
protein under the control of a cytomegalovirus (CMV) promoter sequence. 2) The TetR molecule 
forms a homodimer that binds to the ‘Tetracycline-on’ (TetO) sequence in the inducible 
expression plasmid, pcDNA™4/TO/lacz. 3) Tetracycline binds with high affinity to the TetR 
molecules and induces a conformational change. There is cleavage of the homodimer and 
dissociation from the TetO sequence in the pcDNA™4/TO/lacz plasmid. 4) The gene of interest 
(PAX9 is shown in this example) is de-repressed and transcription is promoted by the TATA 
box.  
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2.8.2 Cell lines and attempted transfections 
In order to minimise the risk of using contaminated cell lines for the 
transfections, fresh stocks of H314 and H400 cells were sent directly to Dundee 
Cell Products (DCP) from the European Collection of Cell Cultures, Public 
Health England. DCP received the cell lines at passage numbers 15 (H314 - 
#06092003) and 18 (H400 - #06092006). The cell lines were thawed down, 
maintained, and subcultured by DCP Biomedical scientists according to 
standard protocols specified by the ECCC. These are the same protocols as 
those used during the selection of suitable cell lines at Newcastle University 
(see section 2.7). DCP initially used Lipofectamine® 2000 Transfection Reagent 
(Life Technologies, Paisley, UK). Calcium phosphate was also used in later 
attempts at the transfections. Approximately 150-200 µg of plasmid 
pcDNA6/TR© DNA was used to transfect each cell line. Further information 
regarding the experimental difficulties encountered by DCP are described in 
Chapter 6. 
2.9 Lentivirus transfection of cell lines 
The lentivirus transfections were performed in a level 3 containment tissue 
culture facility in the Dermatology Research Laboratory, School of Medicine, 
Newcastle University. The experimental plan for the lentivirus transfections is 
summarised in the Appendix and further discussed in Chapter 6. The following 
sections summarise the standard protocol used for each of the lentivirus 
transfections. 
2.9.1 Transfection of lentivirus-producing 293T cells with target DNA 
sequence 
 Day 1: 293T cells were seeded into 100 mm tissue culture dishes. Cells 
were seeded at a density of 2-3 x 105 cells/ml in 10 ml of complete growth 
medium 
 Day 2: The lentivirus transfection solution was prepared (components 
detailed in Table 2-4). The plasmid solution was added to the calcium 
chloride (CaCl2) solution. The combined plasmid/CaCl2 solution was then 
added drop wise (one drop per second) to the 2x HeBS solution. Air was 
continuously passed through the HeBS solution while adding each drop in 
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order to prevent precipitation. The transfectant solution was incubated for 30 
mins at room temperature before being added drop-wise to the 293T cells. 
 Day 3: The 293T culture medium was aspirated and discarded in a sealed 
container as hazardous chemical waste. 293T cells were gently washed with 
10 ml PBS to eliminate residual precipitate. 15 ml of fresh complete growth 
medium was added gently to avoid disrupting the cells. The plate was 
incubated for three days under standard conditions 
 Day 6: When the 293T cells were >90% confluent, the lentivirus particles 
were harvested from the supernatant. The supernatant was gently aspirated 
from the culture dish, transferred to a sterile 50 ml Falcon tube, and 
centrifuged (2000 rpm, 4˚C, for 20 mins) to pellet cell debris. The 
supernatant was then filtered into fresh 15 ml Falcon tubes through an 
Acrodisc® syringe 0.45 μm filter (Pall Corporation, USA) to remove any 
residual debris. Recombinant lentiviral solution was stored at -80˚C until 
required. 
 
Table 2-4 Pipetting protocol for day 2 lentiviral transfectant solution 
 
Component Quantity 
DNA mixture 
pMD2.G envelope plasmid 
pCMVdeltaR8.91 packaging plasmid 
Lentivirus transfer vector 
Special water  
 
5 μg 
15 μg 
20 μg 
(make up to 250 μl) 
Calcium chloride solution 250 μl 
2x HeBS 500 μl 
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2.9.2 Transduction of OSCC cell line with recombinant lentivirus solution 
 Day 1: The OSCC cell line selected for transfection was sub-cultured under 
standard conditions (section 2.7.2) and the pellet re-suspended. 2 x 104 cells 
were seeded into each well of a six-well plate. Two six-well plates were 
seeded for each cell line 
 Day 4: The OSCC cell line was transduced when cells were 50-70% 
confluent. The transduction solution comprised 3 ml of recombinant lentiviral 
solution; 9 ml of DMEM without penicillin/streptomycin; and 6 μl polybrene. 
The culture media was decanted from the six-well plates and cells were 
rinsed in PBS (x2). 2 ml of lentiviral/DMEM mix was added to each well. The 
plates were centrifuged at 1300 rpm for 1.5 hours. The supernatant was 
decanted and cells washed with 2x PBS. 2 ml culture media was added to 
each of the wells. The transduced cells were incubated under standard 
conditions until >90% confluent 
 Day 7: The transduced OSCC cells were subcultured. 0.5 ml of trypsin was 
used per well. The cell suspension was seeded into a 25cm2 flask and 
incubated under standard conditions. After 24 hours, the culture media was 
replaced with fresh media that contained antibiotic to select transduced 
clones (either 0.5 µg/ml puromycin or 5 µg/ml blasticidin). 
2.9.3 Doxycycline induction and fluorescence imaging 
Following one week of culture in the selection antibiotic (either puromycin or 
blasticidin) the transduced cells were expanded until there were sufficient cells 
for maintenance, characterisation, and long-term storage (2.7.3). 
Cells for initial characterisation were seeded into six-well plates at a density of 1 
x 105 cells per well. At 24 hours, the culture media was replaced and the cells 
treated with doxycycline at six different concentrations: 0, 25, 50, 100, and 500 
ng/ml, and 1 µg/ml. When the majority of wells were confluent, the cells were 
inspected using an inverse fluorescence microscope (Leica DMI4000B, Leica 
Microsystems, UK) and TRITC/CY3.5 (tetramethylrhodamine 
Isothiocyanate/Cyanine) filter (excitation wavelength -532 nm; excitation 
wavelength - 570 nm). Fluorescent images were taken for cases with positive 
signals and to also confirm the absence of a signal in negative cases. Light 
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microscopic images were taken to confirm the relative confluence of the 
induced cells. All images were taken at x100 magnification. 
2.10 Molecular biology and biochemical techniques 
2.10.1 RNA extraction from cultured cells 
Following subculture, cells selected for RNA isolation were seeded into a six-
well plate at a density of 2 x 104 cells per well. The cells were incubated under 
standard conditions. When the cells were >90% confluent, the plates were 
transferred to ice. The culture medium was decanted and cells washed with 
PBS (2x). 1 ml of TRIzol® reagent (Life Technologies, Paisley, UK) was added 
to each well and pipetted vigorously to lyse the cells thoroughly. The lysate was 
transferred to a 1.5 ml Eppendorf tube and stored at -80°C until required. 
2.10.2 RNA purification from the TRIzol® lysate 
A 2 ml phase-lock gel tube (5 Prime, UK) was centrifuged at 11,000 g for 30 
secs. The lysate was added to the tube and incubated at room temperature (5 
mins). 200 μl chloroform was added and the tube was shaken vigorously (15 
secs). Following incubation at room temperature (3 mins) the tubes were 
centrifuged at 11,000 g at 4°C for 15 mins (Centrifuge 5417B, Eppendorf, 
Germany). The aqueous phase was transferred to a non-stick RNAse-free tube 
(Ambion® Life Technologies, UK). 500 µl isopropanol was added and mixed by 
inversion to precipitate the RNA. Following incubation at room temperature (10 
mins) the samples were centrifuged at 11,000 g at 4°C for 20 mins. 
 
The supernatant was decanted and the RNA pellet washed by adding 1 ml of 
70% ethanol. Samples were vortexed and centrifuged at 7,000 g at 4°C for 5 
mins. The supernatant was decanted. The RNA pellet was air-dried for ~5 mins 
and dissolved in 30 µl RNAse-free water. The solution was incubated at 55°C 
for 5 mins with an open lid to facilitate RNA dissolution and ethanol evaporation. 
1 µl RNAse inhibitor was added to each sample. The samples were transferred 
to ice. The RNA concentration was determined (NanoDrop 2000 UV-Vis 
Spectophotometer, Thermo Scientific, UK). Samples were stored at -80⁰C until 
required.  
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2.10.3 Reverse transcription of RNA to generate cDNA samples 
The RNA concentration of each sample was adjusted to 400 ng/µl. RNA 
integrity was checked by running 1 µl of RNA solution on a 1% TBE gel. 5 µl of 
RNA solution was subsequently used for reverse transcription (see first 
reaction, below). The remaining RNA solution was stored at -80⁰C. 
Reverse transcription was carried out using a commercially available kit 
(Precision NanoScript™ Reverse Transcription Kit, Primer Design, 
Southampton, UK). Barrier tips were used throughout. The protocol involved 
two separate reactions: 
1. In the first reaction, 5 µl RNA (400 ng/µl) was added to 3.5 µl nuclease-
free water and 5.5 µl oligodT primer (180 ng/µl), using 0.5 ml RNA free 
Eppendorf tubes. The solution was heated to 70⁰C for 5 mins and placed 
on ice 
2. In the second reaction, the product from the first reaction was added to 
11 µl of mix two (see Table 2-5 for pipetting protocol) and mixed by 
gentle flicking. The mix was heated to 37⁰C for 2 hours, then 70⁰C for 15 
mins to stop the reaction, then cooled and placed on ice. 
 
5 µl of the PCR product was added to 20 µl nuclease-free water to make a 1:5 
diluted experimental solution. The remaining PCR product was retained as a 
stock solution. Both were stored at -20⁰C until required. 
 
Table 2-5 Pipetting protocol for RNA reverse transcription mix two 
 
Reagent Quantity (µl) 
Nuclease-free water 3 
10mM dNTP 1.5 
RNAase inhibitor 0.5 
5x M-MLV reaction buffer 5 
M-MLV RT enzyme 1 
Total 11 
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2.10.4 Semi quantitative reverse transcription polymerase chain reaction 
The primers for PAX9, SOX2, and ACTB reverse transcription polymerase 
chain reaction (RT-PCR) were designed using software from and supplied by 
eurofins mwg operon (Eurofins Genomics, Ebersberg, Germany). For each 
sample, 1 µl experimental cDNA solution (2.10.3) was added to a standard 
master mix (see Table 2-6). 
Table 2-6 Pipetting protocol for PAX9, SOX2, and ACTB RT-PCR 
 
Reagent Quantity (µl) 
cDNA (1:5 dilution) 1 
5 x Green GoTaq buffer (15mM MgCl2) 5 
10mM dNTP 0.5 
Forward primer* 0.5 
Reverse primer** 0.5 
GoTaq-Polymerase (HotStart) 0.15 
Nuclease free water  17.35 
Total 25 
 
*Forward primers: hPAX9-RT1-F; hSOX2-Endo-F2; hACTB-RT1-F 
**Reverser primers: hPAX9-RT1-R; hSOX2-Endo-R2; hACTB-RT1-R 
 
The PCR products were run on a 2% agarose gel (SeaKem® LE Agarose, 
Lonza, UK). The gel was imaged using ultraviolet light (GelDoc-It®2 Imager, 
UVP, Germany). The gel was photographed and saved as a tagged image 
format file (TIFF). The TIFF image was opened and the bands were analysed 
using the densitometry tool. Rectangles of equal size were placed over each 
band (numbers 1 - 30) and the resulting measurements were saved and 
exported into an Excel spreadsheet. The total density was divided by the total 
background and the result was calculated for each gene. Normalisation was 
achieved by dividing the score for PAX9 or SOX2 by the score for ACTB. 
Values were then ranked. 
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2.10.5 Quantitative real-time polymerase chain reaction 
Quantitative real-time reverse transcription PCR (qPCR) was performed to 
analyse DNA amplification during the exponential phase and thus detect 
quantitative differences between the expression of PAX9/SOX2 in each sample. 
Commercially-available TaqMan® probes for PAX9, SOX2, and ACTB were 
added to a TaqMan® Universal Master Mix (both from Applied Biosystems, Life 
Technologies, UK) were used to perform qPCR on cDNA samples from the 
H314 and H400 pTRIPZ™ cell lines. The samples, probes, and master mix 
were pipetted according to the manufacturers’ instructions. Triplicate samples 
were then loaded onto 96-well plates. The plates were run on an Applied 
Biosystems® 7500 Real-Time PCR machine (Life Technologies, UK). 
The fluorescent probes containing each gene of interest (PAX9, SOX2) included 
a reporter dye (FAM-6) at the 5’ end, and a non-fluorescent quencher dye at the 
3’ end. The quencher dye normally suppresses fluorescence of the reporter 
dye. However, during PCR amplification the probes are cleaved by the 5’-3’ 
nuclease activity of DNA polymerase. Reporter and quencher dyes are 
separated, increasing the fluorescence signal. PCR products accumulate with 
each replication cycle. A threshold fluorescence value is determined for each 
cycle - this is the cycle threshold (Ct) value. The Ct value detects the point at 
which fluorescence from accumulated PCR product exceeds the predetermined 
background value. A sample with a low Ct value therefore has a high level of 
the gene of interest as the threshold is achieved early. 
A reference gene, ACTB, was amplified at the same time as PAX9/SOX2. 
ACTB is theoretically expressed at a constant level across all the samples. 
Relative differences in the PAX9/SOX2 levels of each sample were then 
calculated using the comparative Ct method described by Livak and Schmittgen 
(2001). 
1. ∆Ct = Ct(gene of interest) – Ct (housekeeping gene) 
2. ∆∆Ct = ∆Ct(expression) – ∆Ct (control) 
3. 2-∆∆Ct 
These calculations were performed using an Excel spreadsheet. The mean fold 
values were then used to rank samples according to the level of PAX9/SOX2.  
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2.10.6 Protein isolation from cultured cells 
Following subculture, the cell line selected for protein isolation was seeded into 
a six-well plate (2 x 104 cells per well). The cells were incubated under standard 
conditions until >90% confluent. 
The six-well plates were placed on ice. The culture medium was aspirated and 
discarded. Cells were washed with PBS (2x). 120 µl of RIPA buffer (Sigma-
Aldrich, UK) containing protease inhibitor and sodium deoxycholate were added 
to each well. The cells were scraped off the bottom of the plate using a cell 
scraper (Corning®, Sigma-Aldrich, UK). The cell lysate was aspirated at 
transferred to a 1.5 ml Eppendorf tube. The tube was vortexed for 30 secs. The 
cell lysate was stored at -80°C until required. 
2.10.7 Protein quantification 
Protein samples were thawed on ice and sonicated briefly (3x 3 secs). The 
samples were centrifuged at 13,000 rpm at 4ºC for 10 mins and returned to ice. 
Protein was quantified using the Pierce BCA Protein Assay Kit (Thermo 
Scientific, UK). A 96-well plate was set up with 2 x 25 µl of each template 
sample in rows one and two. 5 µl of protein lysate was added to 70 µl of distilled 
water in row three and mixed thoroughly. 2 x 25 µl aliquots were pipetted into 
rows four and five as triplicate repeats. 200 µl of Pierce solution was added to 
each well. The plate was incubated at 37ºC for 30 mins. The plate was read 
using a SoftMax Pro® Microplate reader (Miratech, UK) at a wavelength of 562 
nm. Data was exported to an Excel spreadsheet to the mean protein quantity for 
each sample. 
Protein samples were aliquoted and diluted to produce a uniform quantity of 
protein. The precise quantity varied according to the range of concentrations 
determined for each cell line. Each aliquot was adjusted by adding RIPA buffer 
(Sigma-Aldrich, UK) to equilibrate the protein suspensions. 4x LDS sample 
buffer and 10x sample reducing agent (NuPAGE®, Life Technologies) were 
then added to each aliquot. Quantities were varied for each sample so that 
every 10 µl contained: 1 µl of 10 x reducing agent; 2.5 µl LDS; and 6.5 µl 
protein sample. 
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2.10.8 Western blotting 
Protein samples were thawed and heated to 70˚C on a heat block (10 mins). 
Tubes were pulsed briefly to remove condensation and briefly vortexed. Pre-
cast polyacrylamide gels (NuPAGE® Novex® 4-12% Bis-Tris Gels, Life 
Technologies) were placed in a tank filled with running buffer (NuPAGE® MES 
SDS, Life Technologies). 500 µl of antioxidant was added to the central 
chamber of the tank. Protein samples were loaded on the gel with a 10-170 kDa 
protein ladder (PageRuler Prestained Protein Ladder, Pierce Protein Products, 
Thermo Scientific, UK). The gel was run at 200 V for 30 mins. 
The gel was removed and placed on PDVF membrane (Sigma-Aldrich, UK) in a 
transfer cassette lined by sponge and filter paper. The cassette was placed in a 
tank containing transfer buffer (NuPAGE® Transfer Buffer, Life Technologies) 
with 200 ml methanol and 2 ml of antioxidant (NuPAGE® Antioxidant, Life 
Technologies). The tank was placed in an ice bucket. The transfer was run at 
100V for 1 hour. 
The primary antibody solution was made up in a 50 ml Falcon tube. 1 g of 
bovine serum albumin powder and 40 µl of sodium azide were added to 20 ml 
of TBS Tween. The solution was mixed thoroughly. The primary antibody was 
added at a concentration of 1/1000. The PDVF membrane was transferred to 
the antibody solution and incubated overnight at 4˚C on a mixer. 
The secondary antibody solution was made up in a 50 ml Falcon tube. 1 g of 
milk powder was added to 20 ml TBS Tween and mixed thoroughly. The 
secondary antibody was added at a concentration 1/1000. 
After washing with TBS Tween, the membrane was transferred to the 
secondary antibody solution and incubated at room temperature on a mixer (1 
hour). The membrane was washed and placed on cling-film. 2 ml of low 
sensitivity enhanced chemiluminescent substrate (Themo Scientific, UK) was 
added to the membrane drop-wise and incubated for 5-10 mins. 
The membrane was placed between acetate sheets in a transfer cassette. The 
cassette was taken into the dark room. An X-ray film (Kodak, USA) was 
removed and placed on top of the acetate sheet. The cassette was closed an 
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incubated for 1 min. The film was removed and placed in developer for ~30 
secs. A light viewer was used to assess the presence of bands. If bands were 
feint then the film was returned to the developer solution. The film was then 
rinsed in water and placed in fixing solution. The film was rinsed then allowed to 
air dry. 
2.11 Statistical Analysis 
Statistical analysis was performed using SPSS for Windows (version 21, SPSS 
Inc., Chicago, Illinois, USA). The selection and interpretation of specific tests 
was informed by discussion with Dr Simon Kometa, a statistician at Newcastle 
University. 
Continuous data was first explored using a descriptive analysis. This analysis 
generated mean average values and standard deviations for each subgroup. 
The analysis included a Shapiro-Wilk and Kolmogorov–Smirnov tests of 
normality. The Shapiro-Wilk test result was used due to the relatively small 
numbers of cases in each subgroup (<50 cases).  
A Shapiro-Wilk test result of p>0.05 indicated that the data had a normal 
distribution. Normally distributed data were analysed using parametric tests. For 
comparison of multiple subgroups analysis was performed using a one-way 
analysis of variance (ANOVA) test with the Bonferroni correction. Binary 
comparisons were performed using the independent sample T-test. Results 
were considered significant at p<0.05. 
A Shapiro-Wilk test result of p<0.05 indicated that the data significantly deviated 
from a normal distribution. These data were analysed using non-parametric 
tests. For comparison of multiple subgroups analysis was performed using the 
Kruskal–Wallis test with the Bonferroni correction. Binary comparisons were 
performed using the Mann-Whitney U-test. Results considered as significant at 
p<0.05. 
Kaplan-Meier time-to-event analysis was performed using Log Rank (Mantel-
Cox) calculations. For OPMD, adverse outcome or malignant transformation 
were designated as the defined event (=1). For early-stage OSCC, adverse 
outcome or death from disease was designated as the defined event (=1). 
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Cases were grouped according to a range of criteria (e.g. grade of epithelial 
dysplasia; T-category). 
Receiver-operator curves (ROC) were generated by plotting the cumulative 
frequency distribution of a given characteristic (e.g. high grade epithelial 
dysplasia) for detecting a positive result (e.g. malignant transformation). The 
curve plotted the true positive rate against the false positive rate (1-specificity). 
Cases were classified using a binary score (0, 1) according to the characteristic 
under analysis (e.g. low grade epithelial dysplasia = 0; high-grade epithelial 
dysplasia = 1). The ROC indicated the sensitivity of the characteristic in 
detecting the chosen positive result as a function of fall out. Fall out is equal to 1 
– specificity and indicates the probability of a case that is negative for the given 
characteristic having a score of 1. 
Ordinal data generated by the scoring system was analysed by cross tabulation. 
The Kappa test was used to analyse agreement between two independent 
scores (e.g. grade of epithelial dysplasia and EGFR ISH score). The Pearson’s 
Chi-squared test was used to analyse the significance of the distribution of 
cases according to row and column classifiers (Field, 2013). 
2.12 Photomicrography 
All photomicrographs were taken with an Axiocem HRc camera on an Axioplan 
2 microscope using AxioVision software v.4.3 (Carl Zeiss, Germany) and 
processed usng Adobe Photoshop v7.0 (Adobe Systems, Inc.). 
2.13 Ethical Approval 
The study had a favourable ethical opinion from the National Research Ethics 
Service (NRES) Committee North East, Sunderland (REC reference: 
11/NE/0118).  
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Chapter 3. EGFR Protein Expression and Gene Copy Number in 
Potentially Malignant Disorders and Early-Stage Squamous 
Cell Carcinoma of the Oral Cavity 
3.1 Introduction 
3.1.1 Oral squamous cell carcinoma 
Oral squamous cell carcinoma (OSCC) is a major global healthcare problem 
(Jemal et al., 2011). The incidence of OSCC is increasing in the developed 
world, particularly among young adults (Schantz and Yu, 2002; Garavello et al., 
2010). OSCC is associated with poor outcomes. Up to 50% of patients 
diagnosed with OSCC will die of the disease within five years (Barnes et al., 
2005; Warnakulasuriya, 2009). Outcomes for patients with OSCC may be 
improved if the disease is identified in its earliest stages (Goodson and 
Thomson, 2010). Patients diagnosed with OSCC are staged using the ‘Tumour, 
Node, Metastasis’ (TNM) classification that has been developed by the 
International Union Against Cancer, Switzerland (Sobin et al., 2009). This study 
focused on patients with pStage I and II (‘early-stage’) OSCC. An early-stage 
OSCC may measure up to 4 cm in maximum dimension; however, it has not 
metastasised either to regional lymph nodes or distant sites (Sobin et al., 2009). 
3.1.2 Oral potentially malignant disorders 
OSCC may be preceded by clinically-recognisable lesions, termed oral 
potentially malignant disorders (OPMD) (van der Waal, 2009). OPMD 
encompass a broad spectrum of entities, including proliferative verrucous 
leukoplakia, chronic hyperplastic candidosis, and oral submucous fibrosis 
(Barnes et al., 2005). This study focused on lesions that presented clinically as 
either white, red, or mixed white/red patches, and subsequently showed 
epithelial dysplasia on histological examination. There is continuing debate as 
to how the spectrum of changes that characterise epithelial dysplasia should be 
classified. Therefore, this study applied both the ‘Squamous Intra-epithelial 
Neoplasia’ (SIN) classification (Barnes et al., 2005) and the binary ‘high-grade’ 
versus ‘low-grade’ classification described by Kujan et al (2006 ). 
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3.1.3 Epidermal growth factor receptor: a prognostic lung cancer 
biomarker 
Epidermal growth factor receptor (EGFR) is a cell surface tyrosine kinase 
receptor that is expressed in most epithelial tissues (Citri and Yarden, 2006). 
EGFR protein expression and gene copy number are currently used in the 
prognostication of non-small cell lung carcinoma (Nicholson et al., 2001; Hirsch 
et al., 2003) and the prediction of its response to EGFR-targeted 
chemotherapeutic agents (Takano et al., 2005 ). 
3.1.4 EGFR is a candidate biomarker in oral carcinogenesis 
EGFR is considered a candidate biomarker in oral carcinogenesis. Over-
expression of EGFR protein has been reported in up to 90% of OSCC and is 
associated with poor clinical outcomes (Grandis and Tweardy, 1993a; Grandis, 
1998; Kumar et al., 2008). In OPMD, over-expression of EGFR protein is 
associated with an increased risk of malignant transformation (Ries et al., 
2013).  
EGFR genomic gain is associated with poor clinical outcomes in OSCC (Freier 
et al., 2003; Rössle et al., 2013; Ryott et al., 2009). There is evidence that 
OPMD with abnormal EGFR gene copy number are at an increased risk of 
malignant transformation compared to OPMD with normal EGFR gene copy 
number (Benchekroun et al., 2010; Poh et al., 2012). 
3.2 Aims 
The aims of this chapter are: 
1. To summarise the patient characteristics, clinical outcomes, and 
histopathological features of a group of OPMD and a group of early-
stage OSCC cases. These data also underpin the analysis of two novel 
biomarkers, SOX2 and PAX9, which is described in Chapter 4 
2. To describe the profiles of EGFR protein expression and EGFR gene 
copy number in the two groups 
3. To correlate the EGFR protein expression and gene copy number 
profiles with the patient characteristics and clinico-pathological features 
of each group.  
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3.3 Results 
3.3.1 OPMD group: patient characteristics, mucosal subsite, and 
histological grade of epithelial dysplasia 
A total of seventy-eight OPMD satisfied the study’s inclusion criteria and had 
sufficient remaining material for further assays (n = 78). The cases were 
identified using two distinct strategies: 1) attendance at an oral epithelial 
dysplasia clinic; 2) a search of the electronic database at the Department of 
Cellular Pathology. The majority (72%) of cases were identified using the first 
strategy. Both strategies are detailed further in Chapter 2 (section 2.1). 
Overall, the group of OPMD had a male predominance (62.8% males; 
male:female ratio = 1.7:1). The mean age was 58.6 years (range: 30 - 94). The 
majority of patients either smoked tobacco during the study period (i.e. from 
1997 to 2009) or were former tobacco smokers. Similarly, the majority of 
patients either consumed alcohol during the study period or had a history of 
alcohol consumption (Table 3-1). The majority of OPMD presented on the floor 
of mouth or ventro-lateral surface of the tongue. Smaller proportions involved 
subsites such as the buccal mucosa or palate (Table 3-1). 
The epithelial dysplasia present in each OPMD was assigned to a single 
histological grade according to the worst area. Using the SIN classification, 
there was moderate agreement between the two independent scoring 
pathologists (Kappa value - 0.678; 95% confidence interval 0.544 - 0.812). SIN 
1 was the single commonest histological grade. The remaining cases were 
evenly distributed between SIN 2 and SIN 3 (Table 3-1). 
There was also moderate agreement between the two scoring pathologists 
when epithelial dysplasia was graded according to the binary classification 
(Kappa value - 0.697; 95% confidence interval 0.541 - 0.853). By contrast to the 
SIN classification, however, high-grade epithelial dysplasia was the commonest 
histological grade (Table 3-1).  
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Table 3-1 Characteristics of the group of cases with oral potentially 
malignant disorders (n = 78) 
 
Characteristic Number (%) 
Alcohol consumption: 
During study period 
Prior to but not during study period 
None 
Not known 
 
56 (71.8) 
3 (3.8) 
7 (9.0) 
12 (15.4) 
Tobacco consumption: 
During study period 
Prior to but not during study period 
None 
Not known 
 
45 (57.8) 
13 (16.6) 
13 (16.6) 
7 (9.0) 
Mucosal subsite: 
Tongue 
Floor of mouth 
Buccal mucosa 
Masticatory mucosa 
 
36 (46.1) 
29 (37.2) 
5 (6.4) 
8 (10.3) 
Histological grade of dysplasia: 
SIN classification: 
SIN 1 
SIN 2 
SIN 3 
Binary classification: 
High-grade epithelial dysplasia 
Low-grade epithelial dysplasia 
 
 
31 (39.7) 
23 (29.5) 
24 (30.8) 
 
44 (56.4) 
34 (43.6) 
Clinical outcome (end of study period): 
No adverse outcome 
Adverse outcome: 
Local recurrence 
New lesion 
Malignant transformation to OSCC 
 
30 (38.5) 
48 (61.5) 
15 (19.2) 
11 (14.1) 
22 (28.2) 
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3.3.2 Clinical management of and outcomes for patients with OPMD 
Each of the 56 cases identified using strategy 1) were managed by laser 
excision. The majority (54%) of these cases had no adverse outcome. The 
remainder had adverse outcomes, proceeding to develop either a local 
recurrence (26%) or a new dysplastic lesion (20%). Consistent with its design 
and purpose, each of the 22 cases identified by strategy 2) underwent 
malignant transformation. The majority (73%) of these cases had been 
managed by surveillance. 
When OPMD identified using both strategies were combined, the overall 
majority of cases had an adverse outcome (either local recurrence, new lesion 
formation, or malignant transformation). Malignant transformation was the single 
most common adverse outcome (Table 3-1). Kaplan-Meier time-to-event 
analysis did not detect a significant correlation between clinical outcome and 
either patient demographics (age, sex) or risk factors (tobacco/alcohol 
consumption). Similarly, there was no correlation between clinical outcome and 
the mucosal subsite of the OPMD [data not shown]. 
3.3.3 Grade of epithelial dysplasia and clinical outcome of OPMD 
Kaplan-Meier time-to-event analysis did not identify a significant correlation 
between the risk of malignant transformation and grade of epithelial dysplasia 
when stratified according to the SIN classification (Figure 3-1A). By contrast, 
there was a significant correlation when epithelial dysplasia was graded using 
the binary classification. OPMD with high-grade epithelial dysplasia were 
significantly more likely to undergo malignant transformation than cases with 
low-grade epithelial dysplasia (Figure 3-1B). Used in isolation, however, high-
grade epithelial dysplasia showed low sensitivity (72.7%; positive predictive 
value – 36.4%) and low specificity (50%; negative predictive value - 82.4%) for 
detecting the subset of OPMD that were destined to undergo malignant 
transformation. Table 3-4 summarises the sensitivity/specificity values of high-
grade epithelial dysplasia for detecting cases that underwent malignant 
transformation, alongside the corresponding values for EGFR protein 
expression and EGFR gene copy number.  
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Figure 3-1 Kaplan Meier time-to-event analysis showing malignant 
transformation in OPMD stratified according to grade of epithelial dysplasia 
Colour index: Blue line – SIN 1/low-grade epithelial dysplasia; green line – high grade epithelial 
dysplasia (SIN 2 – pale green; SIN 3 – dark green). 
A) There was no correlation between the risk of malignant transformation and epithelial 
dysplasia when cases were graded using the SIN classification (p>0.05, ᵡ2 value - 3.79, 2 d.f.). 
B) By contrast, there was a significant correlation between the risk of malignant transformation 
and epithelial dysplasia when cases were graded according to the binary classification (p<0.05, 
ᵡ2 value - 4.97, 1 d.f.).  
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3.3.4 Clinico-pathological features of OSCC arising from OPMD 
Twenty-two of the 78 OPMD in the study underwent malignant transformation to 
OSCC (Table 3-1). The mean transformation time (i.e. the interval from the 
index OPMD biopsy to the first OSCC diagnosis) was 27.2 months (s.d. - 5.4 
months). The OSCC was managed by surgical excision in 20 cases and by 
chemoradiotherapy in two cases. 
Three of the subsequent OSCC were among the group of early-stage OSCC 
described in the following section (see 3.3.5). The majority of the remaining 
cases were also classified as early-stage OSCC. However, there were three 
cases which involved the alveolar mucosa and showed evidence of bone 
invasion. These cases were therefore classified as category T4, pStage IV. The 
clinico-pathological features of the cases are summarised in Table 3-2. The 
cases had a mean disease-free survival of 43.7 months (s.d. – 8.1 months) and 
mean overall survival of 50.2 months (s.d. - 8.8 months).  
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Table 3-2 Clinico-pathological features of OSCC arising from OPMD (n = 22) 
 
Characteristic Number (%) 
Mucosal subsite: 
Tongue 
Floor of mouth 
Buccal mucosa 
Masticatory mucosa 
 
11 (50) 
7 (32) 
1 (4.5) 
3 (13.5) 
Histological grade of differentiation: 
Well differentiated 
Moderately differentiated  
Poorly differentiated 
 
6 (27) 
13 (59) 
3 (14) 
pStage: 
pStage I 
pStage II 
pStage IV 
pStage unavailable 
 
14 (64) 
3 (13.5) 
3 (13.5) 
2 (9) 
Overall survival: 
Alive: 
Free from disease 
Deceased: 
Free from disease 
With disease 
Lost to follow-up 
 
 
9 (41) 
 
8 (36.5) 
3 (13.5) 
2 (9) 
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3.3.5 Early-stage OSCC group: patient characteristics, mucosal subsite, 
pStage, and histological differentiation 
A total of ninety-two early-stage OSCC satisfied the study’s inclusion criteria 
and had sufficient remaining material for further assays (n = 92). The group had 
a male predominance (58.7% males; male:female ratio = 1.4:1). The mean age 
was 61.8 years (range: 33 - 93). The majority of cases presented on the ventro-
lateral tongue and floor of mouth. Smaller proportions involved subsites such as 
the buccal mucosa, gingiva/alveolar ridge, or palate (Table 3-3). Moderately 
differentiated OSCC was the single commonest group when cases were 
grouped according to tumour morphology. The majority of cases were at pStage 
I (i.e. the tumour had a maximum dimension of <2 cm). 
3.3.6 Clinical outcomes of patients diagnosed with early-stage OSCC 
The overall survival and disease status of patients with early-stage OSCC are 
summarised in Table 3-3. The mean overall survival time was 55.9 months (s.d. 
- 24.4 months). The mean disease-free survival time was 46.8 months (s.d. - 
25.2 months). 
Sixty-seven patients were alive at the end of the study period: 
 Sixty-six of these patients were alive and free from disease. However, 
several patients in this group had been treated for adverse outcomes during 
the study period. These included: 
o Local recurrence (seven cases) 
o Second primary tumour formation (two cases) 
o Regional cervical lymph node metastasis (one case) 
 One patient was alive with disease. This patient had developed a local 
recurrence. The index tumour was a well differentiated squamous cell 
carcinoma arising on the buccal mucosa, pStage I.  
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The remaining 25 cases died during the study period. 
 Fifteen of these patients died free from disease. However, three of these 
patients had been successfully treated for adverse outcomes prior to death. 
These included: 
o Local recurrence (two cases) 
o Regional cervical lymph node metastasis (one case) 
 Ten patients died from disease: 
o One patient succumbed to the index tumour, a moderately 
differentiated squamous cell carcinoma arising on the ventro-lateral 
tongue, pStage II 
o Each of the nine remaining cases experienced adverse outcomes 
subsequent to apparently successful management of the index 
tumour. These included:  
 Local recurrence (two cases) 
 Regional cervical lymph node metastasis (four cases) 
 Loco-regional recurrence (one case) 
 Second primary tumour formation (one case) 
 Distant metastasis (pulmonary metastasis, one case). 
 
The clinical outcomes of early-stage OSCC did not correlate with patient 
characteristics (age, sex); mucosal subsite; or pStage [data not shown]. Kaplan-
Meier time-to-event analysis did not detect a correlation between clinical 
outcome and histological differentiation (Figure 3-2).  
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Table 3-3 Characteristics of the group of cases with early-stage oral 
squamous cell carcinoma (n = 92) 
 
Characteristic Number (%) 
Mucosal subsite: 
Tongue 
Floor of mouth 
Buccal mucosa 
Masticatory mucosa 
 
49 (53.3) 
20 (21.7) 
9 (9.8) 
14 (15.2) 
Histological grade of differentiation: 
Well differentiated 
Moderately differentiated  
Poorly differentiated 
 
20 (21.6) 
63 (68.5) 
9 (9.9) 
pStage: 
pStage I 
pStage II 
 
75 (81.5) 
17 (18.5) 
Overall survival: 
Alive: 
Free from disease 
With disease 
Deceased: 
Free from disease 
With disease 
 
67 (72.8) 
66 (71.7) 
1 (1.1) 
25 (27.2) 
15 (16.3) 
10 (10.9) 
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Figure 3-2 Kaplan-Meier time-to-event analysis comparing overall and disease 
free survival in the group of early-stage OSCC stratified according to 
histopathological differentiation 
Colour index: Blue line – well differentiated; pale green line – moderately differentiated; dark 
green line – poorly differentiated. 
Kaplan-Meier time-to-event analysis showed that histological grade of differentiation in early-
stage OSCC did not correlate with clinical outcome measured in terms of either A) disease-free 
survival (p>0.05, ᵡ2 value - 1.3, 2 d.f.) or B) overall survival (p>0.05, ᵡ2 value – 2.2, 2 d.f.).  
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3.3.7 Normal epithelium: EGFR protein expression and gene copy 
number in normal tissue used as an internal control 
Normal epithelium was annotated for image analysis in a subset of 60 cases (30 
OPMD and 30 OSCC). The mean number of cells analysed per case was 3341 
(range: 661 - 10594). The mean percentage of positive cells (PPC) was 85.3% 
(range: 58.1% - 98.9%). The mean percentage of strongly-positive cells (3+PC) 
was 20.4% (range: 0.8% - 56.1%). Nuclei in the normal epithelium consistently 
showed disomy, the gene copy number signal that is expected for normal, 
healthy epithelium (Figure 3-4C). 
3.3.8 OPMD: EGFR protein expression 
Dysplastic epithelium was annotated for image analysis in each of the 78 
OMPD. The mean number of cells analysed per case was 2455 (range: 1175 - 
9638). The mean PPC was 85.4% (range: 54.8% - 99.7%). The mean 3+PC 
was 33.8% (range: 0% - 68.7%). 
Comparison of image analysis data showed that EGFR protein was over-
expressed in dysplastic epithelium relative to normal epithelium (Figure 3-3 and 
Figure 3-4). The majority (66.6%) of dysplastic areas had PPC values that were 
higher than the mean PPC value of the normal epithelium. However, a pairwise 
comparison showed that the mean PPC values of dysplastic and normal 
epithelium did not differ significantly (p>0.05, Independent T-test). The majority 
(78.2%) of dysplastic areas also had 3+PC values that were higher than the 
mean 3+PC value of normal epithelium. A pairwise comparison showed that 
dysplastic epithelium had a significantly higher mean 3+PC value than normal 
epithelium (p<0.01, Independent T-test, Figure 3-3). 
There was a positive correlation between grade of epithelial dysplasia and 
EGFR protein expression (Figure 3-4). High-grade epithelial dysplasia had a 
significantly higher mean 3+PC value relative to low-grade epithelial dysplasia. 
Similarly, cases with SIN 2 and SIN 3 had a significantly higher mean 3+PC 
value than cases with SIN 1 (One-way ANOVA; Bonferroni correction, Figure 
3-3). 
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Mean 3+PC values did not differ significantly when OPMD were grouped 
according to the four individual clinical outcomes [data not shown]. OPMD with 
adverse outcomes (i.e. local recurrence, new lesion formation, or malignant 
transformation) had a significantly higher mean 3+PC value than cases with no 
adverse outcome (Figure 3-3). However, the difference between the mean 
3+PC values of OPMD that underwent malignant transformation and those 
which did not (i.e. OPMD with no adverse outcome, local recurrence, or new 
lesion formation) was not statistically significant (Figure 3-3). This was 
confirmed by Kaplan-Meier time-to-event analysis (Figure 3-5B). High EGFR 
protein expression (defined as a 3+PC value greater than the mean 3+PC value 
of the normal epithelium) had low sensitivity and specificity for detecting cases 
that were destined to undergo malignant transformation (Figure 3-6 and Table 
3-4). No significant differences in PPC/3+PC values were detected when cases 
were analysed according to patient demographics (age, sex), risk factors 
(alcohol/tobacco habits), or OPMD mucosal subsite [data not shown].
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Figure 3-3 Bar chart comparing the mean EGFR 3+PC values of normal epithelium and OPMD stratified according to grade of epithelial 
dysplasia and clinical outcome 
The mean 3+PC of dysplastic epithelium was significantly higher than the mean for normal epithelium (p<0.01). The mean 3+PC of high-grade epithelial dysplasia 
was significantly higher than the mean for low-grade epithelial dysplasia (p<0.0001). Cases with SIN 2 and SIN 3 had a significantly higher mean 3+PC than cases 
with SIN 1 (p<0.05 and p<0.01 respectively). OPMD with adverse outcomes had a significantly higher mean 3+PC than cases with no adverse outcome (p<0.01). 
However, there was no significant difference between the mean 3+PC values of OPMD that underwent malignant transformation and those which did not (n.s. – not 
significant). 
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3.3.9 OPMD: EGFR gene copy number 
Each OPMD was assigned to either a ‘normal’ or ‘abnormal’ category according 
to its predominant EGFR gene copy number signal. This approach to the 
interpretation of EGFR gene copy number in OPMD has been applied in a 
previous study (Benchekroun et al., 2010). It is further detailed in Chapter 2, 
Figure 2.2. An abnormal EGFR gene copy number signal was detected in a 
total of 16 OPMD (20.5% of cases). 
Fifteen of these cases showed either trisomy or low polysomy (Figure 3-4I): 
 Eight subsequently underwent malignant transformation. Each showed high-
grade epithelial dysplasia (six cases graded as SIN 2; two cases as SIN 3) 
 Seven cases did not progress to OSCC: 
o Two cases had no adverse outcome 
o However, five of these cases had other adverse outcomes: 
 Local recurrence (four cases) 
 New lesion formation (one case). 
One case showed clusters, a signal that is considered evidence of genomic 
gain according to the manufacturer’s scoring system (Figure 3-4L). The patient, 
a 58 year-old male, had a history of both alcohol and tobacco consumption. The 
OPMD biopsy showed high-grade dysplasia (also graded as SIN 3). Malignant 
transformation was diagnosed after a 17-month interval. 
Kaplan-Meier time-to-event analysis detected a significant correlation between 
abnormal EGFR gene copy number and the risk of malignant transformation 
(Figure 3-5). Receiver-operator curve analysis was used to compare the 
reliability of abnormal EGFR gene copy number in detecting cases destined to 
undergo malignant transformation relative to high-grade epithelial dysplasia and 
high EGFR protein expression (Figure 3-6). This analysis showed that abnormal 
EGFR gene copy number was the most reliable marker of malignant 
transformation. Reliability was further enhanced when abnormal EGFR gene 
copy number and high-grade epithelial dysplasia were combined to form a 
single marker (i.e. positive cases had both high-grade epithelial dysplasia and 
an abnormal EGFR gene copy number (Figure 3-5C and Figure 3-6). Overall, 
60% of cases with both high-grade epithelial dysplasia and an abnormal EGFR 
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gene copy number signal underwent malignant transformation (Figure 3-7). The 
superior detection of this combined marker was confirmed by comparison of 
sensitivity/specificity and positive/negative predictive values of all four markers 
(i.e. high-grade epithelial dysplasia, high EGFR protein expression, abnormal 
EGFR gene copy number, and high-grade epithelial dysplasia/abnormal EGFR 
gene copy number combined). These values are summarised in Table 3-4.  
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Figure 3-4 Comparison of EGFR protein expression and EGFR gene copy 
number in normal mucosa and OPMD 
A) Normal mucosa at the edge of an OPMD biopsy. B) In normal epithelium, EGFR protein 
expression is strongest in the basal/parabasal layers. C) Nuclei of normal keratinocytes show 
disomy. D) Low-grade epithelial dysplasia. E) There is increased EGFR protein expression 
relative to the normal epithelium. F) However, nuclei continue to show disomy. G) and J) High-
grade epithelial dysplasia. H) and K) EGFR protein expression is increased relative to both 
normal epithelium and low-grade epithelial dysplasia. I) The first example of high-grade 
epithelial dysplasia shows low polysomy (3-4 nuclear signals in <40% of cells). L) The second 
example shows clustered EGFR gene copy number signals, consistent with genomic gain. 
H&E & EGFR IHC x100 magnification; EGFR ISH x400 original magnification. 
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Figure 3-5 Kaplan-Meier time-to-event analysis showing malignant 
transformation in OPMD stratified according epithelial dysplasia, EGFR protein 
expression, and EGFR gene copy number 
Colour index: Blue line - low grade epithelial dysplasia, low EGFR protein expression, normal 
EGFR gene copy number; negative combined score. Green line - high-grade epithelial 
dysplasia; high EGFR protein expression; abnormal EGFR gene copy number; positive 
combined score. 
 
A) There was a significant correlation between malignant transformation and high-grade 
epithelial dysplasia (p<0.05, ᵡ2 value - 4.97, 1 d.f.). B) There was a significant correlation 
between malignant transformation and abnormal EGFR gene copy number (p<0.0001; ᵡ2 value - 
13.9, 1d.f.). C) A significant correlation was also identified when abnormal EGFR gene copy 
number and high-grade epithelial dysplasia were combined (p<0.0001; ᵡ2 value - 16.1, 1d.f.). D) 
By contrast, there was no correlation between malignant transformation and high EGFR protein 
expression (p>0.05).   
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Figure 3-6 Receiver-operator curve analysis comparing the detection of 
OPMD destined to undergo malignant transformation by epithelial dysplasia, 
EGFR protein expression, and EGFR gene copy number 
Colour index: Blue – high grade epithelial dysplasia; green – high EGFR protein expression; 
cream – abnormal EGFR gene copy number; purple – combined high grade epithelial dysplasia 
and abnormal EGFR gene copy number; yellow – reference line. 
The combined marker (high-grade epithelial dysplasia and abnormal EGFR gene copy number) 
has the greatest area beneath the curve. This suggests it is the most reliable detector of OPMD 
destined to undergo malignant transformation. Both abnormal EGFR gene copy number and the 
combined category show an asymptotic significance of p<0.05. By contrast, high-grade 
epithelial dysplasia and high EGFR protein expression are not significant at p<0.05, suggesting 
they do not reliably detect OPMD that undergo malignant transformation.  
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Figure 3-7 Diagnostic algorithm showing distribution of OPMD that underwent 
malignant transformation according to grade of epithelial dysplasia and EGFR 
gene copy number signal 
The majority (60%) of OPMD that transformed to OSCC showed both high-grade epithelial 
dysplasia and an abnormal EGFR signal. This was more than double the proportion of cases 
with high-grade epithelial dysplasia and a normal EGFR signal, and more than triple the 
proportion of cases that were negative for both markers (i.e. cases with low-grade epithelial 
dysplasia and a normal EGFR signal).  
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Table 3-4 Detection of OPMD that underwent malignant transformation using 
high-grade epithelial dysplasia, high EGFR protein expression, and abnormal 
EGFR gene copy number 
 
 High-grade 
epithelial 
dysplasia 
High EGFR 
protein 
expression 
Abnormal 
EGFR gene 
copy number 
Combined 
dysplasia/gene 
copy number 
Sensitivity 72.7 72.7 40.9 40.9 
Specificity 50 14.0 87.5 89.1 
Positive 
predictive 
value 
36.4 30.2 56.3 60.0 
Negative 
predictive 
value 
82.4 50.0 79.0 79.0 
 
3.3.10 OSCC arising from OPMD cases: EGFR protein expression 
Malignant transformation occurred in 22 OPMD (section 3.3.4). Biopsy material 
was available for analysis in 21 of these cases. The mean number of cells 
analysed per case was 10,240 (range: 2442 – 30,730). The mean PPC was 
88.5% (range: 66.8 – 99.7%). The mean 3+PC was 37.9% (range: 13.9 – 
68.7%). 
The mean 3+PC for the group of transformed OSCC was significantly higher 
than the mean 3+PC for the normal epithelium (p<0.0001, Independent T-test; 
Figure 3-8). It was also significantly higher than the mean 3+PC for OPMD. The 
difference was significant when comparing both the entire group of OPMD and 
the subset that underwent malignant transformation (p<0.0001, Independent T-
test). However, the mean PPC value for transformed OSCC did not differ 
significantly from the mean PPC of normal epithelium (p>0.05, Independent T-
test). 
The mean PPC and 3+PC values for transformed OSCC were lower than the 
corresponding values for early-stage OSCC (Figure 3-8). However, neither of 
these trends was statistically significant (p>0.05, Independent T-test (PPN) and 
Mann-Whitney U-test (3+PN)).  
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Figure 3-8 Bar chart comparing EGFR protein expression of normal mucosa 
with early-stage OSCC and the group of OSCC that transformed from OPMD 
EGFR protein was over-expressed in both early-stage OSCC and the group of transformed 
OSCC relative to normal mucosa. For early-stage OSCC, both the mean PPC and 3+PC values 
were significantly higher than the corresponding values of the normal mucosa (p<0.0001, 
Independent T-tests). The mean 3+PC of the transformed OSCC group was also significantly 
higher (p<0.0001, Mann-Whitney U-test). Differences between the mean PPC and 3+PC values 
of early-stage and transformed OSCC were not statistically significant.  
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3.3.11 OSCC arising from OPMD cases: EGFR gene copy number 
The majority of the OSCC cases in this subset showed an aberrant EGFR gene 
copy number, either an abnormal signal (seven cases) or EGFR genomic gain 
(five cases). Just less than half of the cases showed a normal EGFR signal 
(nine cases). 
The differences between the EGFR gene copy number category of the index 
OPMD and the subsequent OSCC are summarised in Table 3-5. In one-third of 
cases (seven cases, 33%) the transition from the index OPMD to OSCC was 
associated with a move to a higher EGFR gene copy number category: 
 In five cases, the index OPMD showed a normal EGFR signal which 
progressed in the subsequent OSCC to either an abnormal EGFR signal 
(three cases) or EGFR genomic gain (two cases) 
 In two cases, the index OPMD showed an abnormal EGFR signal which 
progressed in the subsequent OSCC to EGFR genomic gain. 
 
However, in the majority of cases (12 cases, 57.1%) the index OPMD and 
subsequent OSCC showed the same EGFR gene copy number signal: 
 In the single case of OPMD that showed clusters (i.e. EGFR genomic 
gain) clusters were also detected in the subsequent OSCC 
 An abnormal EGFR gene copy number signal was detected in both 
OPMD and OSCC in four cases 
 A normal EGFR signal was detected in seven cases. 
 
In two cases, the index OPMD showed an abnormal EGFR gene copy number 
but the subsequent OSCC showed a normal signal.  
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Table 3-5 Summary of the EGFR gene copy number categories assigned to 
the OPMD that underwent malignant transformation and the subsequent OSCC 
 
EGFR gene copy number signal  
Number (%) 
OPMD OSCC  
Normal Normal 7 (33) 
Normal Abnormal 3 (14) 
Normal Genomic gain 2 (10) 
Abnormal Normal 2 (10) 
Abnormal Abnormal 4 (19) 
Abnormal Genomic gain 2 (10) 
Genomic gain Genomic gain 1 (5) 
Total 21 (100) 
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3.3.12 Early-stage OSCC: EGFR protein expression 
Areas of OSCC were annotated for image analysis in each of the 92 cases. The 
mean number of cells analysed per case was 10219 (range: 578 - 38509). The 
mean PPC was 99.4% (range: 82.7% - 100%). The mean 3+PC was 39.4% 
(range: 0.1% - 79.2%). 
Comparison of image analysis data showed that EGFR protein was over-
expressed in early-stage OSCC relative to the normal epithelium (Figure 3-8, 
Figure 3-9). OSCC had higher PPC and 3+PC values than the corresponding 
mean values for normal epithelium in 98.9% and 73.9% of cases, respectively. 
Pairwise comparisons showed that these differences were both statistically 
significant (p<0.0001, Independent T-test; Figure 3-8). Small differences 
between the PPC and 3+PC values of OSCC stratified according to 
differentiation were not significant (p>0.05, One-way ANOVA with Bonferroni 
correction, Figure 3-9E, H, and K). There was no correlation between the mean 
PPC/3+PC values when analysed according to patient demographics (age, 
sex), OSCC mucosal subsite, or pStage. There was no correlation between 
PPC/3+PC values and either overall or disease-free survival [data not shown]. 
3.3.13 Early-stage OSCC: EGFR gene copy number 
Of the 92 cases in the study, one case was excluded from EGFR gene copy 
number analysis due to technical difficulties that hampered interpretation. 
Satisfactory staining in the remaining 91 cases enabled the scoring pathologists 
to reach a consensus. 
EGFR genomic gain was identified in 23 (24.7%) early-stage OSCC. EGFR 
genomic gain was visualised as either high polysomy (11 cases) or clusters (12 
cases) (Figure 3-9). All of the cases that showed EGFR genomic gain were at 
pStage I. EGFR genomic gain was associated with a reduction in mean overall 
survival time (50.2 months compared to 57.7 months for cases with normal 
gene copy number) and mean disease-free survival (45.6 months compared to 
47.7 months for cases with normal gene copy number). However, Kaplan-Meier 
time-to-event analysis showed that neither of these trends was statistically 
significant (both p>0.05). 
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3.3.14 Correlation between EGFR expression and EGFR gene copy 
number 
There was a positive correlation between EGFR gene copy number and EGFR 
protein expression. EGFR protein expression was significantly higher in OPMD 
with abnormal EGFR gene copy number than in cases with normal EGFR gene 
copy number (p<0.0001, mean values of 49.9% (s.d. - 12.1) and 29.3% (s.d. - 
15.7) respectively). EGFR protein expression was significantly higher in OSCC 
with EGFR genomic gain relative to cases with no genomic gain (p<0.01, mean 
values of 51.2% (s.d. - 21.9) and 35.9% (s.d. - 22.5) respectively).  
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Figure 3-9 EGFR protein expression and gene copy number in normal mucosa 
and early-stage oral squamous cell carcinoma stratified according to 
histopathological differentiation 
A) Normal mucosa. B) EGFR protein expression is strongest in the basal/parabasal layers. C) 
Nuclei of normal keratinocytes show disomy. D) Well differentiated OSCC. E) There is 
increased EGFR protein expression relative to the normal epithelium. F) Nuclei show low 
polysomy. G) Moderately differentiated OSCC. J) Poorly differentiated OSCC. H) and K) EGFR 
protein expression is increased relative to the normal epithelium in the corresponding EGFR 
stains, but intensity is similar to that of the well differentiated OSCC shown in B). I) EGFR in situ 
hybridisation shows high polysomy (3-4 nuclear signals in >40% of cells). L) Clustered gene 
copy number signals are seen in the example of poorly differentiated OSCC. 
H&E & EGFR IHC taken at x100 magnification; EGFR ISH at x400 original magnification.  
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3.4 Discussion 
Oral squamous cell carcinoma (OSCC) is a global healthcare problem (Jemal et 
al., 2011). In the UK, the incidence of OSCC rose by a third during the decade 
to 2010. There are now ~6500 new cases annually (Cancer Research UK, 
2010). In much of the developed world, the increase in incidence has been 
greatest among young adults (Schantz and Yu, 2002; Garavello et al., 2010). 
3.4.1 Patient characteristics and risk factors 
In the present study, most patients with OPMD/early-stage OSCC were in their 
6th to 7th decades. This demographic profile is consistent with the prevalence of 
traditional risk factors that were identified in the OPMD group. Alcohol and 
tobacco consumption are well recognised for their carcinogenic potential and 
synergistic interactions (Danaei et al., 2005; Hashibe et al., 2009). 
Over the past decade, it has emerged that human papillomavirus (HPV) 
infection is significant in the aetiology of a subset of oropharyngeal squamous 
cell carcinomas (Schache et al., 2011; Robinson et al., 2012). There is 
emerging evidence that HPV positivity may have prognostic significance in 
squamous cell carcinoma presenting at non-oropharyngeal sites, including the 
oral cavity (Chung et al., 2014). However, the proportion of HPV-positive OSCC 
is low (~3%). This suggests that HR-HPV infection is not a major aetiological 
agent in oral carcinogenesis (Salazar et al., 2014). Interestingly, however, HPV 
infection has been implicated in the formation of a subset of OPMD (Angiero et 
al., 2010) and specific histopathological features have been described for this 
subset of cases (Lerman and Woo, 2014). However, to date convincing 
evidence for the contribution of HPV infection to OPMD and OSCC formation 
has yet to emerge (Lopes et al., 2011; Lingen et al., 2013; McCord et al., 2014; 
Nankivell et al., 2014). Given the contrasting role of HPV in the formation of 
OSCC and oropharyngeal squamous cell carcinoma, the exclusion of 
oropharyngeal lesions is an important strength of the present study. It seems 
plausible that other risk factors associated with the increased incidence of 
OSCC in young adults are yet to be identified. It is conceivable that future 
studies may show a reduction in the prevalence of alcohol and tobacco 
consumption relative to the present study. 
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3.4.2 Classification and grading of epithelial dysplasia 
The current edition of the World Health Organisation (WHO) Classification of 
Head and Neck Tumours details three systems for classifying epithelial 
dysplasia (Barnes et al., 2005). Of these, the 2005 WHO Classification is most 
widely used by both diagnostic pathologists and clinicians in the UK. The WHO 
Classification is used in the Department of Cellular Pathology and was applied 
to the original diagnosis of OPMD in the present study. However, there were too 
few cases of carcinoma in-situ (CIS) to support valid statistical comparisons. 
The present study therefore applied the ‘Squamous Intraepithelial Neoplasia’ 
(SIN) classification, which combines CIS and severe epithelial dysplasia in a 
single category, SIN 3. 
It is well recognised that the grading of oral epithelial dysplasia is prone to inter-
observer variation (Kujan et al., 2007). Furthermore, it is documented that the 
grade of epithelial dysplasia does not accurately predict clinical outcomes, 
particularly the risk of malignant transformation (Dost et al., 2014). A binary 
system for grading epithelial dysplasia has been developed in an attempt both 
to reduce inter-observer variation and enhance the predictive value of the 
assigned dysplasia grade (Kujan et al., 2006). The present study confirms the 
superior prognostic value of the binary system compared to the SIN 
classification. However, the correlation identified between high-grade epithelial 
dysplasia and malignant transformation in the present study was fairly weak. 
Used in isolation, high-grade epithelial dysplasia had low sensitivity and 
specificity for detecting cases of OPMD destined to undergo malignant 
transformation. This supports the view that there may be fundamental 
limitations to the predictive value of a morphological diagnosis, irrespective of 
the accuracy and reliability of the classification system upon which it is based 
(Kujan et al., 2007; Dost et al., 2014). This in turn highlights the need for 
biomarkers that reliably detect the subset of OPMD that are at greatest risk of 
malignant transformation (Mishra, 2012).  
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3.4.3 Rate of malignant transformation in OPMD 
There is wide variation in the documented rates of malignant transformation in 
OPMD (Liu et al., 2011; Warnakulasuriya et al., 2011; Dost et al., 2014). 
Overall, nearly one-third of OPMD in the present study underwent malignant 
transformation. This rate is considerably higher than the 2.6% reported by 
Warnakulasuriya et al (2011) in a UK-based study of more than 1300 OPMD 
patients. It is also higher than the 7% rate of malignant transformation recently 
reported by Diajil et al (2013), from whose study many of our OPMD cases were 
drawn. This high rate is an artefact of using two different strategies to identify 
OPMD cases. Strategy 2), the retrospective search of the Department of 
Cellular Pathology database, identified OSCC with previous OPMD biopsies. 
Including cases identified by this strategy therefore increased the proportion of 
OPMD that underwent malignant transformation. It is likely that the rate of 7% 
reported by Diajil et al (2013) in a cohort of consecutive cases is a more 
accurate indication of the rate of malignant transformation in OPMD. 
The heterogeneous approach to identifying cases leads to a further limitation of 
the present study: variable management of OPMD patients, with some 
undergoing laser excision, and others being managed by surveillance. The 
majority of the OPMD that underwent malignant transformation were managed 
by surveillance. By contrast, the majority of OPMD managed by laser excision 
had no adverse outcome. The present study was not designed to evaluate the 
clinical efficacy of laser excision in reducing the risk of malignant 
transformation. However, it is conceivable that some cases managed by 
surveillance may not have proceeded to OSCC had they been managed by 
laser excision. 
3.4.4 EGFR protein expression and gene copy number as cancer 
biomarkers 
EGFR protein expression and gene copy number are used in both the 
prognostication of non-small cell lung carcinoma (Nicholson et al., 2001; Hirsch 
et al., 2003) and prediction of its response to EGFR-targeted chemotherapeutic 
agents (Takano et al., 2005 ). Since EGFR protein over-expression in OSCC 
was first documented (Grandis and Tweardy, 1993a) it has been hoped that 
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EGFR would prove a similarly effective biomarker and chemotherapeutic target 
for patients with OPMD/OSCC. However, the literature to date has consistently 
drawn attention to the complexity of the EGFR pathway and consequent 
limitations of its clinical utility as a biomarker in OSCC/OPMD (Forastiere, 2007; 
Gusterson and Hunter, 2009; Rosin and Califano, 2010). Recently, EGFR gene 
copy number has emerged as a potential biomarker that may complement 
EGFR protein expression (Erjala et al., 2006; Forastiere, 2007); however, the 
prevalence and clinical significance of EGFR gene copy number increases in 
OSCC are not well defined (Chung et al., 2006; Agulnik et al., 2007; Temam et 
al., 2007; Pectasides et al., 2011). Moreover, it remains unclear whether it is 
appropriate to apply criteria validated for the interpretation of EGFR gene copy 
number signals in non-small cell lung carcinomas to other cancers. 
3.4.5 EGFR protein is up-regulated in OPMD and early-stage OSCC 
Our data confirm that EGFR protein expression is increased in the majority of 
OPMD and OSCC (Grandis and Tweardy, 1993a; Ries et al., 2013). The 
ubiquity of EGFR over-expression highlights the critical role played by the 
EGFR pathway in oral carcinogenesis, but limits its clinical utility as a biomarker 
for stratifying patient management. A smaller proportion of OPMD showed 
EGFR over-expression compared to OSCC. The biological significance of this is 
uncertain, but it supports the contention that the effects of EGFR are likely to be 
more significant in the later stages of oral carcinogenesis (Ryott et al., 2009). 
Alternatively, increased EGFR expression may represent a bystander change, 
reflecting, but not driving, tumour progression, which would account for the lack 
of correlation with disease-specific clinical outcomes (Forastiere, 2007; 
Gusterson and Hunter, 2009; Rosin and Califano, 2010). 
The high prevalence of EGFR over-expression in the current study is in contrast 
to data recently reported by Rössle et al (2013). The latter study reported EGFR 
over-expression in just 19.3% of early stage OSCC involving the tongue. 
However, although the study was similar in its focus on pStage I and II OSCC, it 
was limited by subjective semi-quantitative assessment of tissue cores. It is also 
possible that different thresholds were used to define EGFR over-expression to 
those used in the current study. Furthermore, it is our experience that EGFR 
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expression shows tumour heterogeneity and tissue microarray sampling may 
not correlate with measurements taken from whole sections. 
3.4.6 EGFR protein expression correlates with grade of dysplasia but not 
clinical outcome in OPMD 
Our data confirm the positive correlation between EGFR expression and grade 
of epithelial dysplasia reported by Ries et al (2013). In contrast to this earlier 
study, however, we were unable to identify a significant correlation between 
EGFR over-expression and the risk of malignant transformation. This correlation 
has also been  documented in a recent comprehensive study of 148 OPMD 
(Nankivell et al., 2013). Both of these studies analysed whole sections using 
subjective semi-quantitative assessment (Nankivell et al., 2013; Ries et al., 
2013). The absence of a correlation in the current study may reflect the 
application of digital image analysis; as in the study by Rössle et al (2013), it is 
also possible that different thresholds were used to define EGFR over-
expression. On balance, the high prevalence of increased EGFR expression in 
our study makes positive correlations with clinical parameters less likely. 
3.4.7 Detecting significant EGFR gene copy number changes in OPMD 
A fifth of OPMD in the present study showed abnormal EGFR gene copy 
number. Only one case showed unequivocal EGFR genomic gain as defined 
using the current criteria for non-small cell lung cancer. This supports data from 
OSCC EGFR gene copy number studies, which suggest that EGFR genomic 
gain is a late event in oral carcinogenesis (Freier et al., 2003; Rössle et al., 
2013; Ryott et al., 2009). It is striking, however, that the majority of OPMD with 
abnormal EGFR gene copy had adverse clinical outcomes, and over half 
progressed to OSCC. This is in concordance with evidence from two recent 
studies, which suggest abnormal (or, ‘increased’) EGFR gene copy number is a 
relatively early feature of OPMD that are destined to undergo malignant 
transformation and may precede gross EGFR genomic gain (Benchekroun et 
al., 2010; Poh et al., 2012). Both of these studies used fluorescence ISH (FISH) 
rather than the chromogenic ISH (CISH) technique used in the current study, 
but the results are comparable. Benchekroun et al (2010) studied EGFR FISH 
in a subset of 49 OPMD, applying a definition of FISH positivity that 
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encompassed all EGFR gene copy number abnormalities, including trisomy and 
low polysomy. While one case showed EGFR gene copy number amplification 
using conventional criteria, a further 41% of cases showed FISH positivity 
according to their modified criteria. FISH-positive OPMD had significantly higher 
rates of malignant transformation compared to those with normal EGFR gene 
copy number (p<0.001). A recent study by Poh et al (2012) also supports the 
application of a lower threshold for detecting EGFR gene copy number 
abnormalities. In a study of 20 OPMD, one case showed clusters (i.e. EGFR 
genomic gain using the current criteria). However, the authors also reported that 
any gain in EGFR gene copy number was strongly associated with an increased 
risk of malignant transformation, irrespective of whether the genomic gain was 
low or high; EGFR genomic gain was also associated with a reduced time to 
malignant transformation (Poh et al., 2012).  
It is a limitation of the current study that neither EGFR mutation status nor 
downstream targets of increased EGFR gene copy number/protein were 
evaluated. It is conceivable that EGFR gene copy number may represent a 
‘surrogate’ for other genetic and molecular abnormalities and simply reflect 
chromosomal instability. Nevertheless, the positive correlation identified 
between EGFR gene copy number and protein over-expression suggests that 
EGFR genomic gain is likely to be functionally significant. 
3.4.8 Abnormal EGFR gene copy number in OPMD may indicate an 
increased risk of malignant transformation 
Our data suggest that the detection of EGFR gene copy number abnormalities 
may be a useful tool for identifying OPMD at high risk of adverse outcomes, 
particularly malignant transformation. The data indicate that while EGFR gene 
copy number abnormalities are relatively specific for identifying high-risk OPMD, 
they have low sensitivity. Low sensitivity may reflect the temporal relationship of 
the index biopsy to the transformation event, as it is conceivable that EGFR 
gene copy number abnormalities may have accumulated within an altered field 
after the index biopsy. 
Data from the group of OSCC that transformed from OPMD provide some 
evidence to support this hypothesis. The majority of cases in this subset had a 
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higher EGFR gene copy number category in the OSCC relative to the index 
OPMD. The EGFR gene copy number signal of the OPMD was already either 
abnormal or increased in a further one-quarter of cases, and the signal was 
maintained in the subsequent OSCC. The transition from OPMD to OSCC was 
associated with a move to a lower EGFR gene copy number category in just 
two cases. Although it is conceivable that this represents either the selection of 
a different clone, given the marked heterogeneity of EGFR gene copy number 
signal, it is also possible that this represents a sampling error. 
Although low sensitivity may limit the utility of abnormal EGFR gene copy 
number as an isolated biomarker in OPMD, its specificity means that it could 
have added predictive value in the context of a broader panel of more sensitive 
biomarkers. In isolation, grade of epithelial dysplasia does not reliably predict 
clinical behaviour. However, our data show that the reliability of these two 
markers is increased when they are combined. This finding signals the potential 
value of EGFR gene copy number as part of a panel of molecular biomarkers. 
3.4.9 Prevalence and prognostic significance of EGFR genomic gain in 
OSCC 
A quarter of early-stage OSCC in the present study showed EGFR genomic 
gain. This is higher than the prevalence of 9% reported in a recent tissue-
microarray study by Rössle et al (2013). As with EGFR protein expression, 
however, it is our experience that OSCC exhibit heterogeneous ISH patterns. It 
seems plausible that this difference may also reflect a methodological artefact. 
Nevertheless, the proportion of cases with EGFR genomic gain in the current 
study is still towards the lower end of the range of values reported in earlier 
studies (Freier et al., 2003; Ryott et al., 2009). Interestingly, the prevalence of 
EGFR genomic gain in the subset of OSCC that had transformed from OPMD 
was similar to that of the entire early-stage OSCC group. 
Our study did not identify a significant correlation between EGFR genomic gain 
and clinical outcome in OSCC. This is in contrast to a previous study by Temam 
et al (2007), which reported a 9% five-year survival rate for patients with EGFR 
genomic gain compared with 71% five-year survival rate for patients with no 
genomic gain. Although the study used quantitative real-time PCR, its findings 
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have been supported by FISH studies (Freier et al., 2003; Chung et al., 2006). 
However, all of these studies included a wide range of clinical stages (including 
stages III and IV). The absence of a correlation in the present study may reflect 
its narrower inclusion criteria and focus on early-stage OSCC. This 
interpretation is supported by the association between EGFR and late-stage 
OSCC (Grandis and Tweardy, 1993b; Grandis and Tweardy, 1993a). In their 
comparable study of early-stage OSCC of the tongue, Rössle et al (2013) were 
also unable to identify a significant correlation between EGFR gene copy 
number and clinical outcome. 
3.4.10 EGFR-targeted chemotherapeutic agents 
There is evidence to suggest that EGFR gene copy number may help to predict 
the response of head and neck cancers to EGFR-targeted agents. For example, 
high EGFR gene copy number has been shown to predict which patients have 
an increased likelihood of response to erlotinib therapy (Agulnik et al., 2007). 
The present study was not designed to investigate patients’ response to EGFR-
targeted agents or other clinical interventions: none of the patients received 
EGFR-targeted therapy and the OPMD group was heterogeneous, including 
cases managed by surveillance and laser excision (Diajil et al., 2013). Despite 
these limitations, however, our data support the view that a sub-group of OPMD 
and OSCC harbour gene copy number abnormalities. Whether this sub-group 
has differential responses to EGFR-targeted agents or other therapies remains 
to be tested. 
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3.5 Conclusion 
This study highlights the potential clinical utility of EGFR gene copy number 
assessment for predicting malignant transformation of OPMD. Abnormal EGFR 
gene copy number indicates an increased risk of malignant transformation in 
OPMD. In the majority of cases, the transition from OPMD to OSCC is 
associated either with maintenance or accumulation of EGFR gene copy 
number abnormalities or progression to EGFR genomic gain. This supports the 
view that EGFR gene copy number abnormalities continue to accumulate within 
an altered field following an index OPMD biopsy. EGFR genomic gain is present 
in a quarter of early-stage OSCC, but does not correlate with their clinical 
outcomes. Abnormal EGFR gene copy number and EGFR genomic gain 
correlate with increased EGFR protein expression in both OPMD and OSCC. 
However, although EGFR protein expression is over-expressed in the majority 
of OPMD and early-stage OSCC, it does not correlate with clinical outcomes in 
either group. 
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Chapter 4. Expression of Two Novel Biomarkers in Potentially 
Malignant Disorders and Early-Stage Squamous Cell 
Carcinoma of the Oral Cavity 
4.1 Introduction 
The previous chapter detailed the protein expression and gene copy number 
profiles of epidermal growth factor receptor (EGFR) in patients with oral 
potentially malignant disorders (OPMD) and early-stage oral squamous cell 
carcinoma (OSCC). EGFR is an established prognostic and predictive 
biomarker in non-small cell lung carcinoma (Nicholson et al., 2001; Hirsch et al., 
2003; Takano et al., 2005 ). EGFR has been studied as a candidate biomarker 
in oral carcinogenesis since EGFR protein over-expression in OSCC was first 
reported more than 20 years ago (Grandis and Tweardy, 1993a; Grandis and 
Tweardy, 1993b). 
This chapter will examine the protein expression profiles of two novel 
biomarkers, SOX2 and PAX9, in the same two groups of patients, i.e. those with 
OPMD and early-stage OSCC. SOX2 and PAX9 are transcription factors with 
vital roles in the regulation of development and differentiation. SOX2 is a 
potential oncogene in squamous cell carcinoma (SCC) of the lung. There is 
emerging evidence that SOX2 has a similar role in OSCC. By contrast, PAX9 is 
a potential tumour-suppressor gene in oesophageal SCC. To date, the 
expression profile and potential role of PAX9 in oral carcinogenesis has yet to 
be described. 
4.1.1 SOX2 is a potential oncogene in oral carcinogenesis 
The SOX family of genes encode transcription factors that play critical roles in 
the regulation of development. These roles include the induction/suppression of 
stem cell proliferation and maintenance of stem cell pluripotency (Chew and 
Gallo, 2009). 
SOX2 protein is expressed in the normal oral squamous epithelium. It promotes 
epithelial proliferation and the stabilisation of basal progenitor cells (Okubo et 
al., 2009). SOX2 protein is over-expressed in OPMD (Qiao et al., 2013) and 
OSCC (Freier et al., 2010). Genomic amplification of SOX2 has also been 
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detected in OSCC (Freier et al., 2010; Kokalj Vokač et al., 2014). These 
findings suggest that SOX2 has an oncogenic function in oral carcinogenesis. 
This contention is supported by earlier studies of squamous cell carcinoma 
(SCC) of the lung and oesophagus (Bass et al., 2009; Hussenet et al., 2010; 
Hussenet and du Manoir, 2010; Lu et al., 2010). In vitro studies suggest that 
increased SOX2 expression contributes to de-differentiation in SCC (Hussenet 
et al., 2010; Hussenet and du Manoir, 2010). However, SOX2 is also implicated 
in the differentiation pathway of SCC arising in the lung. Up-regulation of SOX2 
induces expression of markers of squamous differentiation, such as p63 and 
keratin 6 (Bass et al., 2009). This suggests that SOX2 may also promote 
squamous differentiation during carcinogenesis. 
4.1.2 PAX9 is potential tumour-suppressor gene in oral carcinogenesis 
The PAX gene family encodes transcription factors that regulate stem cell 
renewal, cellular proliferation, differentiation, migration, and survival. The 
contribution of PAX genes to these processes suggests they may also play 
significant roles in neoplasia (Chi and Epstein, 2002; Robson et al., 2006). 
PAX9 protein is expressed in the squamous epithelium of the oesophagus and 
oral cavity. It is believed to regulate key aspects of epithelial differentiation 
(Jonker et al., 2004). PAX9 expression is lost/down-regulated in oesophageal 
squamous cell carcinoma and its precursor lesions (Gerber et al., 2002). In 
these oesophageal lesions there is an inverse relationship between PAX9 
expression and clinical outcome. A decrease in the proportion of PAX9-positive 
cells correlates with increasing grade of epithelial dysplasia. PAX9 expression is 
lowest in invasive SCC (Gerber et al., 2002). These data suggest PAX9 
functions as a tumour-suppressor gene. 
This hypothesis is supported by in vitro studies of lung cancer. PAX9 is located 
on chromosomal region 14q13.3. A subset of lung cancer cell lines shows allelic 
loss of this region and loss of PAX9 expression (Harris et al., 2011). By 
contrast, other in vitro studies suggest PAX9 has an oncogenic function. PAX9 
interacts with c-myb, a proto-oncogene that enhances the survival of SCC cell 
lines and is implicated in the pathogenesis of a range of cancers (Lee et al., 
2008). PAX9 contributes to the survival of a subset of lung cancer cell lines that 
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show amplification of chromosomal region 14q13.3 (Kendall et al., 2007). These 
findings suggest that PAX9 may perform diverse roles in carcinogenesis, 
analogous to TGF-β (Paterson et al., 2001; Prime et al., 2004). 
4.2 Aims 
The aims of this chapter are: 
 To describe the profiles of SOX2 and PAX9 protein expression in groups 
of patients with OPMD and OSCC. The patient characteristics, clinical 
outcomes, and clinico-pathological features of these groups have been 
described previously in Chapter 3 
 To correlate the profiles of SOX2 and PAX9 protein expression with the   
patient characteristics, clinical outcomes, and clinico-pathological 
features of the OMPD and early-stage OSCC groups.  
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4.3 Results 
4.3.1 Expression of SOX2 and PAX9 proteins in normal squamous 
epithelium 
Normal squamous epithelium was selected for image analysis in 30 OPMD and 
30 OSCC biopsies. 
For SOX2 protein expression, the mean number of nuclei analysed per case 
was 2155 (range: 716 - 5753). The mean percentage of positive nuclei (PPN) 
was 32.5% (range: 0.4% - 72.2%). The mean percentage of strongly positive 
nuclei (3+PN) was 1.2% (range: 0% - 10.7%). 
For PAX9 protein expression, the mean number of nuclei analysed per case 
was 2412 (range: 590 - 7554). The mean PPN was 39.0% (range: 0.1% - 
83.2%). The mean 3+PN was 6.8% (range: 0% - 42.5%). 
4.3.2 SOX2 protein expression in oral potentially malignant disorders 
Dysplastic epithelium was analysed in each of the 78 OPMD. The mean number 
of nuclei analysed per case was 1328 (range: 714 - 2105). SOX2 had a 
heterogeneous expression profile in dysplastic epithelium, varying both between 
and within individual OPMD cases. 
Overall, SOX2 expression was down-regulated in dysplastic epithelium relative 
to normal epithelium (Figure 4-1). The mean PPN was 23.6% (range: 0% - 
88.3%). Dysplastic epithelium had PPN values that were lower than the mean 
PPN value of the normal epithelium in the majority (75.6%) of cases. A pairwise 
comparison showed that, across the group, dysplastic epithelium had a 
significantly lower mean PPN value relative to the normal epithelium (p<0.05, 
Independent T-test). 
However, several OPMD cases showed strong focal expression of SOX2 in the 
dysplastic epithelium (Figure 4-1F). There was also a subset of cases that 
showed strong, generalised over-expression of SOX2 (Figure 4-1H). Many of 
the cells with strong SOX2 expression exhibited basaloid morphology. The 
mean 3+PN for SOX2 was 3.2% (range: 0% - 64.4%). Although the mean 3+PN 
value for dysplastic epithelium was higher than the mean 3+PN value of the 
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normal epithelium (1.2%), this was due to a small subset of cases with very high 
3+PN values. This subset comprised four cases with 3+PN values greater than 
10%. In fact, SOX2 3+PN values of dysplastic epithelium were actually lower 
than the mean 3+PN of normal epithelium in the majority of cases (80.8%). A 
pairwise comparison showed that the difference between the mean 3+PN 
values of normal and dysplastic epithelium was not statistically significant 
(p>0.05, Mann-Whitney U-test; Figure 4-2). 
4.3.3 SOX2 protein expression correlates weakly with histological grade 
of epithelial dysplasia but not with clinical outcome 
Dysplastic epithelium graded as SIN 3 had a significantly higher mean 3+PN 
value than dysplastic epithelium graded as SIN 1 (p<0.05, Mann-Whitney U-
test, Bonferroni correction; Figure 4-2). However, differences between the mean 
3+PC values of other SIN categories were not significant (p>0.05, Mann-
Whitney U-test, Bonferroni correction). Differences between mean PPN values 
were not significant (p>0.05, One-way ANOVA, Bonferroni correction). Neither 
mean PPN nor mean 3+PN values differed significantly when SOX2 expression 
was compared in dysplastic epithelium graded using the binary classification 
(3+PN values shown in Figure 4-2). 
SOX2 expression did not differ significantly according to clinical outcome. 
Pairwise comparisons of PPN and 3+PN values of cases that underwent 
malignant transformation and those which did not (i.e. cases with no adverse 
outcome, local recurrence, or new lesion) were not statistically significant 
(p>0.05, Independent T-test and Mann Whitney U-test). Similarly, comparisons 
of the PPN and 3+PN values of cases grouped according to each of the four 
individual outcome categories were not significant (p>0.05, One-way ANOVA 
and Kruskal Wallis tests, Bonferroni correction; Figure 4-2). Kaplan-Meier time-
to-event analysis confirmed the absence of a significant correlation between 
either the PPN or 3+PN value and the risk of malignant transformation (Figure 
4-3). 
SOX2 protein expression did not differ significantly according to patients’ age; 
sex; alcohol/tobacco habits; or mucosal subsite of the OPMD [data not shown].  
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Figure 4-1 SOX2 protein expression in normal epithelium and oral potentially 
malignant disorders stratified according to histological grade of epithelial 
dysplasia 
A) Normal oral mucosa. B) SOX2 expression is strongest in the basal layer and becomes 
weaker as keratinocytes differentiate and progress towards the surface (arrow). C) SIN 1. D) 
SOX2 expression is variable but generally down-regulated, most noticeably in the basal layer. 
E) SIN 2. F) Variable SOX2 expression is also seen in SIN 2, but there is a focus of strongly-
positive cells (arrowhead). G) SIN 3. H) There is over-expression of SOX2 throughout the full 
thickness of the epithelium. The strongly SOX2-positive cells have a basaloid cytomorphology.  
Images taken at x100 magnification. 
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Figure 4-2 Bare chart comparing the mean SOX2 3+PN values of normal epithelium and oral potentially malignant disorders stratified 
according to grade of epithelial dysplasia and clinical outcome 
The mean SOX2 3+PN values of normal and dysplastic epithelium did not differ significantly at p<0.05. Cases of OPMD with SIN 3 had a significantly higher mean 
3+PN value than cases with SIN 1 (p<0.01). The mean SOX2 3+PN values did not differ significantly when OPMD were stratified according to clinical outcome. 
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Figure 4-3 Kaplan-Meier time-to-event analysis of malignant transformation in 
OPMD grouped according to SOX2 PPN and 3+PN values 
Colour index: Blue line - low SOX2 protein expression (i.e. PPN/3+PN value lower than the 
mean for the normal mucosa); green line - high SOX2 protein expression (i.e. PPN/3+PN value 
greater than mean for the normal mucosa.) 
There was no correlation between SOX2 expression and risk of malignant transformation. A) 
Malignant transformation in OPMD grouped according to SOX2 PPN value (p>0.05, ᵡ2 value – 
0.16, 1 d.f.). B) Malignant transformation in OPMD grouped according to SOX2 3+PN value 
(p>0.05, ᵡ2 value – 0.075, 1 d.f.).   
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4.3.4 PAX9 protein expression in oral potentially malignant disorders 
Dysplastic epithelium was analysed in each of the 78 OMPD. The mean number 
of nuclei analysed per case was 1197 (range: 941 - 1736). The mean PPN was 
24.6% (range: 0% - 72.8%). The mean 3+PN was 3.5% (range: 0% - 30.6%). 
PAX9 protein expression was down-regulated in dysplastic epithelium relative to 
the normal epithelium (Figure 4-4). Dysplastic epithelium had PPN and 3+PN 
values lower than the corresponding mean values of normal epithelium in 
75.6% and 84.6% of cases respectively. Pairwise comparisons showed that 
both the mean PPN and 3+PN values of dysplastic epithelium were significantly 
lower than the corresponding mean values of normal epithelium (p<0.05 
Independent T-test and p<0.01 Mann-Whitney U-test respectively; 3+PN values 
shown in Figure 4-5). 
4.3.5 PAX9 protein expression correlates with clinical outcome and 
detects cases of OPMD destined for malignant transformation 
PAX9 protein expression showed a positive correlation with clinical outcome. 
PAX9 expression was significantly higher in the dysplastic epithelium of OPMD 
with adverse outcomes and, more specifically, the subset of cases that 
underwent malignant transformation. OPMD with adverse outcomes (i.e. local 
recurrence, new lesion formation, malignant transformation) had a significantly 
higher mean PPN value than OPMD with no adverse outcome (p<0.01, 
Independent T-test; Figure 4-5). Both the mean PPN and 3+PN values were 
significantly higher in OPMD that underwent malignant transformation relative to 
cases which did not (i.e. with no adverse outcome, local recurrence, or new 
lesion formation) at p<0.0001 (Independent T-test and Mann-Whitney U-test 
respectively). 
In a comparison of OPMD stratified according to each of the four individual 
outcome groups, cases that underwent malignant transformation had 
significantly higher PPN values than cases with no adverse outcome 
(p<0.0001), local recurrence (p<0.0001), and new lesion formation (p<0.01, 
One-way ANOVA with Bonferroni correction; Figure 4-5). Corresponding 3+PN 
values showed the same trends. Small differences in the PPN and 3+PN values 
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of cases in the three non-transforming groups (i.e. no adverse outcome, local 
recurrence, new lesion formation) were not statistically significant. 
OPMD were assigned to a binary ‘high PAX9’ or ‘low PAX9’ category according 
to whether PAX9 expression was either above or below the mean PAX9 PPN 
for normal epithelium. Kaplan-Meier time-to-event analysis confirmed that there 
was a significant correlation between high PAX9 expression and malignant 
transformation (Figure 4-6B). High PAX9 expression had a stronger correlation 
with malignant transformation than either high-grade epithelial dysplasia used in 
isolation (Figure 4-6A) or in a combined category (i.e. high-grade epithelial 
dysplasia combined with high PAX9 expression, Figure 4-6C). Receiver-
operator curve analysis confirmed that high PAX9 expression was a more 
accurate predictor of malignant transformation than either high-grade epithelial 
dysplasia or the combined category (Figure 4-7). High PAX9 expression also 
had the highest positive predictive value for detecting cases that were destined 
to undergo malignant transformation (Table 4-1). 
PAX9 protein expression did not correlate with the histological grade of 
epithelial dysplasia. Using the binary classification system, the mean PPN value 
of low-grade epithelial dysplasia was significantly lower than the normal 
epithelium (p<0.05, Independent T-test, Figure 4-5). However, the difference 
between the mean PPN values of low and high-grade-epithelial dysplasia was 
not significant (p>0.05, Figure 4-5). PPN values did not differ significantly when 
cases were stratified according to the SIN classification. 3+PN values did not 
differ significantly in either classification [data not shown]. 
PAX9 protein expression did not differ significantly when stratified according to 
patients’ age or sex; alcohol/tobacco habits, or the mucosal subsite of the 
OPMD [data not shown].  
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Figure 4-4 PAX9 protein expression in normal mucosa and oral potentially 
malignant disorders stratified according to grade of epithelial dysplasia 
A) Normal oral mucosa. B) In normal epithelium, PAX9 is weakly expressed in the basal layer 
but becomes more intense as cells begin to exhibit squamous differentiation in the prickle layer 
(arrow). PAX9 expression is then progressively lost as cells migrate towards the surface. 
In dysplastic epithelium, PAX9 expression was generally down-regulated relative to the normal 
epithelium. PAX9 expression was lowest in low-grade epithelial dysplasia (C, D). Although it 
was relatively increased in high-grade epithelial dysplasia, this trend was weak and not 
statistically significant (see Figure 4-5). This was due to variability in the PAX9 expression 
among cases with high-grade epithelial dysplasia. In the first example of high-grade epithelial 
dysplasia (E, F), PAX9 expression is heterogeneous but generally down-regulated relative to 
the normal epithelium. By contrast, the second example of high-grade epithelial dysplasia (G, H) 
shows increased expression of PAX9 relative to normal epithelium. OPMD with increased PAX9 
expression relative to the normal epithelium were more likely to transform to OSCC than cases 
with low PAX9 expression (see Figure 4-5). 
Images taken at x100 magnification.  
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Figure 4-5 Bar chart comparing the mean PAX9 PPN values of normal epithelium and oral potentially malignant disorders stratified 
according to grade of epithelial dysplasia (binary classification) and clinical outcome 
PAX9 expression was significantly down-regulated in dysplastic epithelium relative to normal epithelium (p<0.001). Cases with low-grade epithelial dysplasia had a 
significantly lower mean PPN value than the normal epithelium (p<0.05). The mean PPN values of low-grade and high-grade epithelium did not differ significantly, 
however (p>0.05). Together, OPMD with adverse outcomes had a significantly higher mean PPN value than OPMD with no adverse outcome (p<0.01). Specifically, 
OPMD that underwent malignant transformation had a significantly higher mean PPN value than cases which did not (p<0.0001). The same trend was detected 
when cases that did not transform were compared as a single group (i.e. with no adverse outcome, local recurrence, or new lesion formation combined) and in each 
of their individual outcome groups 
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Figure 4-6 Kaplan-Meier time-to-event analysis showing malignant 
transformation in OPMD grouped according to grade of epithelial dysplasia, level 
of PAX9 protein expression, and a combined category 
Colour index: Blue line - low grade epithelial dysplasia, low PAX9 protein expression, negative 
combined score; green line - high-grade epithelial dysplasia; high PAX9 protein expression; 
positive combined score. 
A) There was a significant correlation between malignant transformation and high-grade 
epithelial dysplasia (p<0.05, ᵡ2 value - 4.974, 1 d.f.). B) There was also a significant correlation 
between malignant transformation and high PAX9 protein expression (p<0.0001, ᵡ2 value - 30.2, 
1 d.f.) C) There was also a significant correlation between malignant transformation and a single 
category which combined cases with high-grade epithelial dysplasia and high PAX9 protein 
expression (p<0.0001, ᵡ2 value - 21.9, 1 d.f.).  
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Figure 4-7 Receiver-operator curve analysis comparing detection of malignant 
transformation by high PAX9 expression, high-grade epithelial dysplasia, and a 
combined category 
Colour index: Blue line - PAX9 protein over-expression; green line - high-grade epithelial 
dysplasia; yellow line – combined PAX9 protein over-expression and high grade epithelial 
dysplasia; purple line – reference line. 
The curve for high PAX9 expression is consistently to the left of the curve for high grade 
epithelial dysplasia. The area beneath the curve for high PAX9 expression is thus larger than 
the area for high grade epithelial dysplasia. Moreover, the asymptotic significance for high 
PAX9 expression is p<0.0001. The asymptotic value for high grade epithelial dysplasia is not 
significant (p>0.1). The combined category is intermediate between the two, being more 
accurately predictive of malignant transformation than high grade epithelial dysplasia but less so 
than high PAX9 expression in isolation. 
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Table 4-1 Detection of OPMD that underwent malignant transformation using 
high-grade epithelial dysplasia, high PAX9 protein expression, and a combined 
category 
 
 
 
High-grade epithelial 
dysplasia 
High PAX9 
expression 
Combined 
category 
Sensitivity 
 
72.7 68.2 50 
Specificity 
 
50.0 92.9 94.6 
Positive 
predictive 
value 
36.4 79.0 78.6 
Negative 
predictive 
value 
82.4 88.1 82.8 
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4.3.6 SOX2 protein expression in OSCC transformed from OPMD cases 
Malignant transformation occurred in 22 OPMD. Biopsy material was available 
for analysis in 21 of these cases. Three cases were among the early-stage 
OSCC group which is described in a following section, 4.3.8. 
The mean number of nuclei analysed per case was 4610 (range: 699 – 11257). 
The mean PPN was 19.1 (range: 0 – 88.9%). The mean 3+PN was 2.9 (range: 
0 – 26.3). The mean PPN of the transformed OSCC group was lower than the 
mean PPN of normal epithelium (32.5%). By contrast, the mean 3+PN of the 
transformed OSCC group was higher than the normal epithelium (1.2%). 
However, neither of these trends was statistically significant (p>0.05, 
Independent T-test (PPN) and Mann Whitney U-test (3+PN)). 
The mean PPN and 3+PN values of the transformed OSCC group were lower 
than the corresponding mean values of dysplastic epithelium. This trend was 
consistent when the transformed group was compared with the dysplastic 
epithelium of all OPMD and the subset of cases that underwent malignant 
transformation. However, neither of these trends was statistically significant 
(p>0.05, Independent T-test (PPN) and Mann Whitney U-test (3+PN)). 
The progression from OPMD to OSCC was not associated with a uniform 
change in SOX2 expression. There were cases in which SOX2 protein 
expression was consistent in both the OPMD and subsequent OSCC biopsy, 
either consistently low (Figure 4-8A, B) or high (Figure 4-8C, D). There were 
also cases in which the SOX2 protein expression was increased in the OSCC 
biopsy relative to the OPMD (Figure 4-8E, F) or decreased (Figure 4-8G, H). 
The mean PPN and 3+PN values of the transformed OSCC group were lower 
than the corresponding values for early-stage OSCC outlined in section 4.3.8. 
However, neither of these trends was statistically significant (p>0.05, 
Independent T-test (PPN) and Mann Whitney U-test (3+PN)).  
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Figure 4-8 SOX2 expression in transforming oral potentially malignant 
disorders and subsequent oral squamous cell carcinomas 
Four contrasting trends in SOX2 expression were detected. In some cases, SOX2 expression 
was consistently low in both the transforming OPMD (A) and the subsequent OSCC (B). In other 
cases, SOX2 expression was consistently high in both OPMD (C) and OSCC (D). Interestingly, 
the strongly SOX2-positive cells shown in C and D were characterised by a basaloid 
cytomorphology in both the OPMD (C) and subsequent OSCC (D). By contrast, there were also 
cases in which malignant transformation was associated with either an increase in SOX2 
expression (E compared to F) or a decrease in SOX2 expression (G compared to H). 
Images taken at x100 magnification.  
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4.3.7 PAX9 protein expression in OSCC transformed from OPMD 
The mean number of nuclei analysed per case was 7558 (range: 1603 – 
22170). The mean PPN was 46.6% (range: 0.02 – 90.1%). The mean 3+PN 
was 8.3% (range: 0 – 40.3%). 
The mean PPN and 3+PN values of the transformed OSCC group were higher 
than the corresponding values for the normal epithelium (39.0% and 6.8% 
respectively). However, neither of these trends was statistically significant 
(p>0.05, Independent T-test and Mann-Whitney U-test; Figure 4-10). 
The mean PPN and 3+PN values of the transformed OSCC group were 
significantly higher than the corresponding values for dysplastic epithelium. This 
trend was consistent when the transformed group was compared with the 
dysplastic epithelium of all OPMD and the subset of OPMD cases that 
underwent malignant transformation. When the transformed OSCC group was 
compared with the dysplastic epithelium of all OPMD, the difference in both 
PPN and 3+PN values were significant at p<0.0001 (Independent T-test and 
Mann-Whitney U-test; Figure 4-10). When the transformed OSCC group was 
compared with the dysplastic epithelium of the subset of OPMD that underwent 
malignant transformation the difference in both PPN and 3+PN was significant 
at p<0.01 (Mann Whitney U-tests). 
The mean PPN and 3+PN values of the transformed OSCC group were 
significantly higher than the corresponding values for early-stage OSCC 
(p<0.0001, Independent T-test and Mann Whitney U-test; Figure 4-10). In the 
transformed OSCC group, over-expression of PAX9 protein was more evenly 
distributed in the invasive component compared to the early-stage OSCC 
group, in which PAX9 expression was heterogeneous (Figure 4-11).  
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4.3.8 SOX2 protein expression in early-stage OSCC 
Areas of OSCC were analysed in each of the 92 cases. The mean number of 
nuclei analysed per case was 6962 (range: 578 - 25806). 
SOX2 had a heterogeneous expression profile in OSCC. The mean PPN was 
30.6% (range: 0% - 93.9%). The mean PPN value of OSCC was therefore 
similar to that of the normal epithelium (32.5%). Although a slight majority of 
early-stage OSCC cases (62.0%) had PPN values lower than the mean for 
normal epithelium, a binary comparison confirmed that the difference between 
the mean PPN values was not statistically significant (p>0.5, Independent T-
test). 
Several cases showed foci of high SOX2 expression in a background of tumour 
cells in which SOX2 expression was variably down-regulated relative to the 
normal epithelium. There were also subsets of cases that showed either 
generalised over-expression or down-regulation of SOX2 (Figure 4-9). The 
mean 3+PN was 8.9% (range: 0% - 64.7%). The mean 3+PN value of early-
stage OSCC was therefore higher than the mean 3+PC of the normal 
epithelium (0.64%). This difference was significant at p<0.01 (Mann-Whitney U-
test). Just over half of early-stage OSCC cases (51.1%) had 3+PN values 
higher than the mean 3+PN of the normal epithelium. 
SOX2 expression in early-stage OSCC was increased relative to the dysplastic 
epithelium. A pairwise comparison showed that the mean 3+PN value for OSCC 
was significantly higher than the value for dysplastic epithelium (p<0.001, 
Mann-Whitney U-test). However, although the PPN value for OSCC was also 
higher than the PPN value for dysplastic epithelium, the difference was not 
statistically significant (p>0.05, Independent T-test).  
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4.3.9 SOX2 protein expression correlates with clinical outcome and 
differentiation of early-stage OSCC 
Early-stage OSCC with adverse outcomes (i.e. local recurrence, cervical lymph 
node metastasis, formation of second primary tumours/pulmonary metastasis, 
death from disease) had lower levels of SOX2 protein expression than cases 
with no adverse outcome (i.e. cases which were either alive and disease-free, 
or who had had died free from disease). Although both the PPN and 3+PN 
values were lower in OSCC with adverse outcomes the difference was only 
statistically significant when comparing PPN values (p<0.05, Mann-Whitney U-
test). 
There was an inverse relationship between SOX2 expression and histological 
differentiation (Figure 4-9). Well differentiated OSCC had the highest levels of 
SOX2 expression, with the highest mean PPN and 3+PN values. SOX2 
expression was relatively decreased in moderately differentiated OSCC and 
lowest in the subset of poorly differentiated OSCC. Poorly differentiated OSCC 
had significantly lower PPN and 3+PN values than moderately differentiated 
OSCC (p<0.01, Mann-Whitney U-tests, Bonferroni correction). 
The subset of OSCC at pStage II had significantly lower PPN and 3+PN values 
relative to those at pStage I. The differences between both values were 
significant at p<0.05 (Mann-Whitney U-test). 
SOX2 protein expression did not differ significantly according to patients’ age, 
sex, or the mucosal subsite of the OSCC [data not shown].  
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Figure 4-9 SOX2 expression in normal epithelium and early-stage oral 
squamous cell carcinoma stratified according to histopathological differentiation 
A) Normal oral mucosa. B) In normal squamous epithelium, SOX2 expression is strongest in the 
basal layer, but becomes weaker as keratinocytes differentiate and progress towards the 
surface (arrow). SOX2 expression was highest in well differentiated OSCC (C, D), where it 
recapitulated the pattern of SOX2 expression in normal epithelium. Variable expression is seen 
in moderately differentiated OSCC (E, F) with foci of strongly SOX2-postive cells (F, 
arrowhead). SOX2 expression was lowest in poorly differentiated OSCC, with complete loss of 
SOX2 expression seen in this example (G, H). 
Images taken at x100 magnification.
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4.3.10 PAX9 protein expression in early-stage OSCC 
Areas of OSCC were analysed in each of the 92 cases. The mean number of 
nuclei analysed per case was 6116 (range: 434 - 15243). The mean PPN was 
11.9% (range: 0% - 78.9%). The mean 3+PN was 0.7% (range: 0% - 9.4%). 
PAX9 protein expression was heterogeneous but generally down-regulated in 
the majority of OSCC compared to the normal epithelium (Figure 4-11). Early-
stage OSCC had lower PPN and 3+PN than the corresponding mean values of 
normal epithelium in 94.6% and 97.8% of cases respectively. Pairwise 
comparisons of the PPN and 3+PN values of OSCC and normal epithelium 
were both significant (p<0.0001, Independent T-test and Mann-Whitney U-test; 
Figure 4-10). 
PAX9 protein expression was also down-regulated in early-stage OSCC relative 
to the dysplastic epithelium. A pairwise comparison of the mean PPN value of 
OSCC and dysplastic epithelium was significant (p<0.0001, Independent T-test; 
Figure 4-10). However, mean 3+PN values did not differ significantly (p>0.05, 
Mann-Whitney U-test). 
4.3.11 Correlation of PAX9 protein expression profile with clinico-
pathological features and clinical outcomes of early-stage OSCC 
Early-stage OSCC with adverse clinical outcomes (i.e. local recurrence, cervical 
lymph node metastasis, formation of second primary tumour, formation of 
pulmonary metastases, death from disease) had significantly lower PAX9 PPN 
values than early-stage OSCC with no adverse outcome (p<0.01, Independent 
T-test). A similar trend was identified when comparing 3+PN values, but the 
difference was not statistically significant (p>0.05, Mann-Whitney U-test). 
OSCC had significantly lower PAX9 expression than normal epithelium 
irrespective of histological grade of differentiation. This trend was the same for 
both the PPN and 3+PN values at p<0.0001. Small differences in the PAX9 
expression levels of each grade were not significant (p>0.05, One-way ANOVA 
and Kruskal Wallis tests with Bonferroni correction). 
PAX9 expression was lower in OSCC at pStage II than OSCC at pStage I. Both 
the mean PPN and 3+PN values for pStage II OSCC were significantly lower 
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than the corresponding values for pStage I OSCC (p<0.05, Mann-Whitney U-
test). 
Neither the mean PPN nor the mean 3+PN value differed significantly according 
to patients’ age, sex, or the mucosal subsite of the OSCC [data not shown].  
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Figure 4-10 Bar chart comparing PAX9 PPN values of normal epithelium, 
dysplastic epithelium, OSCC arising from OPMD (mixed stages), and early-stage 
OSCC 
Early-stage OSCC had significantly lower PPN values than either normal or dysplastic 
epithelium (p<0.0001). By contrast, the group of OSCC that arose from OPMD showed 
significantly higher PPN values than dysplastic epithelium and early-stage OSCC (p<0.0001). 
Early-stage OSCC with adverse outcomes had significantly lower PPN values than OSCC with 
no adverse outcome (p<0.01).  
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Figure 4-11 PAX9 expression in early-stage OSCC and OSCC arising from 
transformed OPMD 
(A, B) Moderately differentiated early-stage OSCC. PAX9 expression is generally down-
regulated relative to the normal epithelium at the surface, particularly at the invasive front 
(arrowhead). (C, D) By contrast, in a moderately differentiated OSCC arising from a transformed 
OPMD, there is strong expression of PAX9 throughout the full thickness of the tumour. 
Images taken at x50 magnification.
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4.4 Discussion 
SOX2 and PAX9 are novel biomarkers in oral potentially malignant disorders 
(OPMD) and early-stage oral squamous cell carcinoma (OSCC). Both are 
transcription factors with vital roles in the regulation of development and 
differentiation. SOX2 is critical to the maintenance and proliferation of stem 
cells, functions which, if dysregulated, may be significant in tumorigenesis (Ellis 
et al., 2004; Masui et al., 2007; Hanahan and Weinberg, 2011). SOX2 is a 
potential oncogene in squamous cell carcinoma (SCC) of the lung. There is 
emerging evidence that SOX2 has a similar role in oral carcinogenesis (Freier 
et al., 2010; Qiao et al., 2013). By contrast, PAX9 is believed to regulate key 
aspects of squamous epithelial differentiation (Jonker et al., 2004). Evidence 
from studies of oesophageal SCC suggests that PAX9 functions as a tumour-
suppressor gene (Gerber et al., 2002). This contention is supported by in vitro 
studies of PAX9 expression in lung cancer cell lines (Harris et al., 2011). 
However, to date there no studies of expression or potential role of PAX9 in oral 
carcinogenesis. 
4.4.1 SOX2 protein expression is heterogeneous but generally down-
regulated in OPMD 
Our data show that SOX2 has a heterogeneous expression profile in OPMD 
and is down-regulated in the majority of cases. To date, the profile of SOX2 
expression in OPMD has been described in an isolated study by Qiao et al 
(2013). SOX2-positivity was detected in 90% of OPMD. Furthermore, co-
expression of SOX2 and OCT4 - a feature not detected in the normal epithelium 
- was identified in 60% of OPMD. Similar trends were also demonstrated in an 
animal model (rat). However, the study was limited by a relatively small sample 
size (n = 20 human OPMD) and semi-quantitative scoring of stained sections. 
Cases were categorised either as SOX2-positive or SOX2-negative, but the 
intensity of staining was not described. Moreover, the authors did not document 
SOX2 expression in the normal human epithelium and were thus unable to 
comment on the relative SOX2 expression levels of OPMD (Qiao et al., 2013). It 
is therefore difficult to compare our data accurately with the results of this study. 
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4.4.2 SOX2 protein expression is up-regulated in early-stage OSCC 
Our data show that SOX2 has a heterogeneous expression profile in OSCC. 
The proportions of SOX2-positive nuclei in OCCC and normal epithelium were 
similar. However, the proportion of strongly SOX2-positive nuclei was 
significantly higher in OSCC relative to normal epithelium. Up-regulation of 
SOX2 in OSCC has been reported in several studies by immunohistochemistry 
(IHC) (Freier et al., 2010; Huang et al., 2014), proteomic analysis (Misuno et al., 
2013) and in situ hybridisation (ISH) (Freier et al., 2010; Kokalj Vokač et al., 
2014). Up-regulation of SOX2 has also been described in squamous cell 
carcinomas of the lung, oesophagus, cervix, and penis (Hussenet et al., 2010; 
Lu et al., 2010; Maier et al., 2011). 
Freier et al (2010) was the first to describe SOX2 over-expression in OSCC. 
However, the authors did not report SOX2 over-expression to be a common 
feature of OSCC: high SOX2 expression was only identified in a small subset of 
cases (18.1%). By contrast, our results show that the proportion of strongly 
SOX2-positive cells was increased in OSCC relative to the normal epithelium in 
over half of cases. The methodology of the previous study differed in its use of a 
polyclonal SOX2 antibody and semi-quantitative system for scoring stained 
sections. Moreover, tissue microarrays (TMA) were used rather than whole 
sections. The heterogeneous pattern of SOX2 expression detected in the 
present study is likely to compromise a TMA-based approach. Interestingly, ISH 
data were more sensitive, detecting SOX2 gene copy number amplification in 
more than half of cases (Freier et al., 2010). 
Three studies document a correlation between high SOX2 expression and poor 
clinical outcome in OSCC, particularly metastasis to cervical lymph nodes (Du 
et al., 2011; Michifuri et al., 2012; Huang et al., 2014). The current study 
identified the opposite trend: OSCC with adverse outcomes had significantly 
lower expression of SOX2 relative to cases with no adverse outcome. The 
reasons for this apparent discrepancy are unclear, but there are several 
possible explanations: 
 Whilst the present study was confined to early-stage OSCC, the 
previous studies also encompassed late-stage OSCC. It is conceivable 
134 
 
that SOX2 expression varies between early-stage and late-stage OSCC. 
Our study was not designed to address this possibility. As only a small 
subset of cases proceeded to neck dissection, there were insufficient 
numbers to detect a correlation between SOX2 expression and lymph 
node metastases 
 The previous studies used a range of manual staining methods, by 
contrast to the automated Ventana platform used in the present study. 
These manual methods may have been subject to a range of technical 
variations between runs 
 Each of the previous studies used a different SOX2 antibody. Polyclonal 
antibodies were used in two studies (Michifuri et al., 2012; Huang et al., 
2014). These antibodies are more likely to cross react with other SOX 
family proteins and result in non-specific staining than the monoclonal 
antibody used in the present study 
 The previous studies used semi-quantitative scoring as opposed to 
digital image analysis. In one case, only digitised images of selected 
fields - rather than whole sections - were available to the scoring 
pathologist (Huang et al., 2014) 
 In the present study, 26 cases had adverse clinical outcomes. Our data 
also showed that SOX2 expression was lower in poorly differentiated 
OSCC compared with well- and moderately differentiated OSCC, and in 
pStage II OSCC compared with pStage I OSCC. However, several of 
these groups contained relatively low numbers (poorly differentiated 
OSCC – 9 cases; pStage II – 17 cases). Non-parametric tests were 
used for these comparisons, but it is conceivable that comparisons of 
groups containing higher/similar numbers might generate contrasting 
trends. 
On balance, our finding that low SOX2 expression correlates with adverse 
outcomes in OSCC needs to be interpreted cautiously, as it is in contrast to 
several published studies. Each of these has potential methodological 
limitations relative to the present study. However, they include a greater range 
of clinical stages and are thus more suitably designed to detect a relationship 
between SOX2 expression and clinical outcome in OSCC. 
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Interestingly, heterogeneous SOX2 expression was described by Michifuri et al 
(2012) in 80 mixed-stage OSCC. The authors grouped cases into one of two 
categories according to their pattern of SOX2 expression, either 1) peripheral or 
2) diffuse. The present study includes cases that are consistent with these 
patterns, peripheral (e.g. in Figure 4-9D, well differentiated OSCC) and diffuse 
(e.g. in Figure 4-8D, uniformly high SOX2 expression). However, this 
classification system does not account for cases with generalised down-
regulation/loss of SOX2 expression or the foci of strongly SOX2-postive nuclei 
in cases with variably-intense staining seen in the present study. Interestingly, 
the authors demonstrated a correlation between the diffuse pattern of SOX2 
staining and metastasis to cervical lymph nodes. It is not possible to comment 
on the correlation between staining pattern/clinical outcome in the present study 
due to the small number of cases with uniform staining patterns.  
SOX2 expression was significantly higher in OSCC relative to OPMD in a 
comparison of the two groups combined. In isolation, this finding might suggest 
that up-regulation of SOX2 is associated with malignant transformation in 
OPMD. However, analysis of SOX2 expression in the subset of transforming 
OPMD and their subsequent OSCC did not support this hypothesis, but only 
confirmed the highly variable levels of SOX2 expression at each stage of oral 
carcinogenesis. The striking heterogeneity of SOX2 expression identified across 
all groups in the present study suggests that SOX2 has limited utility as a 
diagnostic or prognostic biomarker in OPMD and OSCC. 
Such consistent variation does however raise several hypotheses as to the 
biological significance of SOX2 in oral carcinogenesis. Firstly, SOX2 may have 
multiple stage-dependent roles in oral carcinogenesis, with a spectrum of 
potential oncogenic and tumour-suppressor functions. Secondly, while some 
OPMD/OSCC may be SOX2-dependent, there may be subsets of cases that 
have acquired alternative mutations and adaptive strategies. Strong SOX2 
expression is associated with a basaloid cytomorphology and several cases 
show foci of malignant cells with intense SOX2 expression. Together, these 
findings suggest a third hypothesis: SOX2 may be significant in the 
maintenance and functioning of cancer stem cells. This hypothesis is supported 
by in vitro analysis that has demonstrated up-regulation of SOX2 and OCT4 in 
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oral cancer stem cells (CSC) (Lim et al., 2011; Bourguignon et al., 2012; Misuno 
et al., 2013). It is also consistent with the contribution of SOX2 to stem cell 
functioning in normal squamous epithelium (Okubo et al., 2009). CSC are 
accountable for resistance to therapy, local recurrence, and metastatic spread 
in head and neck squamous cell carcinoma, and are therefore important 
therapeutic targets (Routray and Mohanty, 2014). Further work is required to 
delineate the contribution of SOX2 to the maintenance, survival, and 
proliferation of CSC. However, the evidence to date suggests that SOX2 may 
be an important therapeutic target in a subset of OSCC and OPMD. It is hoped 
that future in vitro studies utilising the cell lines generated in this project will be 
useful in testing these hypotheses. 
4.4.3 PAX9 protein expression in oral carcinogenesis: two contrasting 
trends 
Our data show that PAX9 has a heterogeneous expression in oral potentially 
malignant disorders (OPMD) and oral squamous cell carcinoma (OSCC). 
Overall, there are two contrasting trends: 
1) PAX9 expression is progressively down-regulated in OPMD and OSCC 
2) PAX9 expression is up-regulated in transforming OPMD and their 
subsequent OSCC. 
4.4.4 PAX9 expression is progressively down-regulated in OPMD and 
early-stage OSCC 
This study demonstrated reduced PAX9 expression in OPMD relative to normal 
epithelium, and reduced PAX9 expression in OSCC relative to OPMD. This 
profile of progressively down-regulated PAX9 expression is consistent both with 
the role of Pax9 in the differentiation of mouse oral squamous epithelium 
(Jonker et al., 2004) and evidence from a study of oesophageal cancer that 
suggests PAX9 acts as a tumour-suppressor gene (Gerber et al., 2002). 
Pax9 is critical to regulating keratin transcription in mouse oral squamous 
epithelium. Specifically, Pax9 determines the relative proportions of ‘hard 
keratins’ (e.g. Krt1-5) and ‘soft keratins’ (e.g. Krt2-1, Krt2-17) in filiform papillae. 
The lingual epithelium of Pax9-deficient mice shows an abnormally increased 
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proportion of soft keratins (Jonker et al., 2004). Soft keratins Krt2-1 and Krt2-17 
are over-expressed in dysplastic lesions of the oral squamous epithelium in 
humans (Bloor et al., 2003). It is postulated that alterations in the differentiation 
pathway of squamous epithelium in Pax9-deficient mice is analogous to those 
occurring in human epithelial dysplasia (Jonker et al., 2004). Our data confirm 
that PAX9 in is also down-regulated in the majority of human OPMD and 
OSCC. They provide some support for the contention that down-regulation of 
PAX9 could induce alterations in the keratin composition of dysplastic 
squamous epithelium. Further analysis of the cytokeratin profile of our samples 
and correlation with PAX9 expression would be required to test this hypothesis. 
However, this overall trend does suggest that PAX9 has a tumour-suppressor 
function. 
Down-regulation of PAX9 expression has been documented in a study of 
squamous cell carcinoma (SCC) and epithelial dysplasias of the human 
oesophagus by Gerber et al (2002). The study demonstrated either loss or 
significantly reduced PAX9 expression in the majority of oesophageal SCC and 
dysplastic epithelial lesions. An inverse relationship between PAX9 expression 
and clinical course was also detected. A decrease in the proportion of PAX9-
positive cells correlated with increasingly malignant behaviour of lesions. This 
inverse trend was also identified in the current study: OSCC with adverse 
outcomes had significantly lower PAX9 expression compared to cases with no 
adverse outcome. However, the opposite trend was identified in OPMD. 
Gerber et al (2002) analysed fewer cases compared to the present study (SCC 
– 36 cases; epithelial dysplasia – 35 cases). The study was further constrained 
by its use of semi-quantitative scoring. PAX9 positivity was recorded but not the 
intensity of staining. Importantly, however, PAX9 immunohistochemical staining 
was performed using the same monoclonal antibody as in the present study, 
which shows nuclear expression in normal squamous epithelium of the 
oesophagus. 
On balance, the present study confirms the overall trend of progressively-
reduced PAX9 expression that has been documented in oesophageal cancer. 
Our data also confirm that PAX9 down-regulation is associated with adverse 
outcomes in OSCC. Together, these trends suggest that PAX9 has a tumour-
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suppressor function (Gerber et al., 2002). There is some evidence from in vitro 
studies to support this hypothesis. A study of lung cancer cell lines has 
demonstrated allelic loss at 14q13.3 and subsequent down-regulation of PAX9 
and other transcription factors such as NKX2-8 in a subset of tumours (Harris et 
al., 2011). 
4.4.5 PAX9 expression is up-regulated in transforming OPMD and their 
subsequent OSCC 
Our results demonstrate PAX9 over-expression in OPMD that underwent 
malignant transformation; PAX9 over-expression was also conserved in the 
subsequent OSCC. This pattern is in contrast to the overall trend identified for 
OPMD and early-stage OSCC, and suggests two different hypotheses: 
1) PAX9 is a critical oncogene that is transiently up-regulated in OPMD 
immediately before, during, and shortly after transformation to OSCC 
2) PAX9 is over-expressed in a subset of OPMD and OSCC, but is not a 
uniform hallmark of oral carcinogenesis. 
Our data show PAX9 over-expression is a more reliable predictor of malignant 
transformation than histological grade of epithelial dysplasia. This finding 
suggests that PAX9 over-expression is an important genetic/molecular change 
during transition from in situ epithelial dysplasia to invasive OSCC. Given the 
wider context of progressively reduced PAX9 expression in OPMD and OSCC, 
it is conceivable that PAX9 is dynamically expressed during oral 
carcinogenesis. PAX9 may be down-regulated in early/low-grade lesions, with 
consequent loss of its tumour-suppressor function. As lesions progress to 
OSCC, PAX9 is over-expressed due to its critical oncogenic function. In 
established lesions, this oncogenic function may be redundant due to the 
acquisition of further oncogenic alterations, particularly those which confer an 
advantageous metastatic capacity. PAX9 expression is thus gradually lost as 
OSCC progresses beyond the initial transformation stage. 
Evidence from in vitro studies supports the view that PAX9 performs oncogenic 
functions. PAX9 interacts with c-myb, a proto-oncogene that enhances the 
survival of SCC cell lines and is implicated in the pathogenesis of a range of 
cancers (Lee et al., 2008). Although Harris et al (2011) identified allelic loss of 
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chromosomal region 14q13.3 in a subset of lung cancer cell lines, the majority 
actually of lung cancers show amplification of this region. PAX9 and other 
transcription factor genes TTF-1 and NKX2-8 have been shown to contribute to 
the survival of lung cancer cell lines. PAX9 may therefore act as an oncogene in 
lung cancer (Kendall et al., 2007). 
The hypothesis that PAX9 is dynamically expressed in oral carcinogenesis must 
be considered cautiously, however. The present study has a cross-sectional 
rather than longitudinal design. This precludes accurate temporal description of 
PAX9 expression in individual cases. Comparisons are further hampered by 
variation in the numbers of OPMD biopsies for each case and time intervals 
between the index OPMD biopsy and subsequent OSCC biopsy. Previous 
OPMD biopsies were not available for the majority of early-stage OSCC cases 
in our study. It is open to conjecture whether these OSCC, in which PAX9 
expression was significantly lower than the OSCC arising from transformed 
OPMD, were preceded by OPMD with low or high levels of PAX9 expression. 
Animal studies – which are more amenable to uniform longitudinal studies of 
individual cases – may help to determine whether PAX9 expression is truly 
stage-dependent. 
It is conceivable that the majority of early stage OSCC were preceded by 
OPMD with low PAX9 expression. This leads to a second hypothesis, that the 
high PAX9 expression characterises a subset of OPMD and OSCC but is not 
uniformly critical to malignant transformation. Interestingly, ‘normal’ (i.e. 
relatively high) levels of PAX9 expression were reported in oesophageal SCC 
and dysplasias by Gerber et al (2002). It is possible that these oesophageal 
lesions with high PAX9 expression were biopsied at a time when they were 
undergoing malignant transformation, which would support the previous 
hypothesis. However, it may also provide further evidence that OPMD and 
OSCC can be broadly separated into two groups according to their PAX9 
expression profile. 
Together, our data show that the overall trends in PAX9 expression in 
OPMD/OSCC are very similar to those documented in oesophageal SCC and 
squamous epithelial dysplasia. This suggests that PAX9 has an important 
tumour-suppressor function. However, there is also strong evidence to suggest 
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that PAX9 also has an oncogenic function. These functions may be stage-
dependent. Alternatively, either one may predominate in individual cases. It is 
hoped that in vitro studies using the cell lines generated in this project will help 
to determine the precise contribution of PAX9 to oral carcinogenesis. 
Importantly however, our data show that PAX9 over-expression may help to 
identify OPMD at risk of progressing to OSCC. 
4.5 Conclusion 
SOX2 protein has a heterogeneous expression profile in both OPMD and early-
stage OSCC, which may limit its potential as a biomarker. SOX2 expression is 
down-regulated in the majority of OPMD and does not correlate with clinical 
outcome. Conversely, SOX2 expression is generally up-regulated in early-stage 
OSCC. This is consistent with studies of SOX2 expression in squamous cell 
carcinoma of the lung and oesophagus. However, whereas previous studies 
have documented a correlation between high SOX2 expression and poor 
clinical outcome, we found that OSCC with adverse outcomes had significantly 
lower expression of SOX2 than cases with no adverse outcome. In both OPMD 
and OSCC, SOX2 over-expression was associated with foci of basaloid cells. 
These foci may harbour oral cancer stem cells. This supports the hypothesis 
that SOX2 is functionally significant in oral carcinogenesis and is therefore a 
potential chemotherapeutic target in OPMD/OSCC. 
PAX9 expression was down-regulated in OPMD relative to normal epithelium. 
PAX9 expression in OSCC was reduced relative to both normal epithelium and 
OPMD. Furthermore, OSCC with adverse outcomes had significantly lower 
PAX9 expression compared to cases with no adverse outcome. These findings 
are concordant with a study of oesophageal squamous cell carcinoma, and 
support the hypothesis that PAX9 acts as a tumour-suppressor gene. 
Interestingly, PAX9 was over-expressed in the subset of OPMD that underwent 
malignant transformation and in their subsequent OSCC. This apparently 
paradoxical finding suggests that PAX9 may also have an oncogenic function in 
oral carcinogenesis. 
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Chapter 5. Morphological and Initial Molecular Characterisation 
of a Mouse Model of Oral Carcinogenesis 
5.1 Introduction 
5.1.1 Longitudinal studies of oral carcinogenesis 
Longitudinal studies of biomarkers in human subjects facilitate the study of 
disease processes at the cellular and molecular level (Munoz and Gange, 
1998). Patients with oral squamous cell carcinoma (OSCC) and oral potentially 
malignant disorders (OPMD) may have multiple diagnostic biopsies and surgical 
interventions during their management. Biomarkers may be analysed in biopsy 
tissue taken at various stages of OSCC formation, facilitating the longitudinal 
study of oral carcinogenesis. However, longitudinal studies are frequently 
constrained by patient drop out. Increasingly, surgical intervention is regarded 
as the preferred treatment modality for the management of OPMD. This raises 
ethical and potential medico-legal issues around the management of an OPMD 
by surveillance and repeated biopsy (Goodson and Thomson, 2010). Animal 
models are therefore comparatively advantageous for the longitudinal study of 
oral carcinogenesis, as they facilitate the generation and analysis of tissue from 
each stage of OSCC formation (Herzig and Christofori, 2002). 
5.1.2 Mouse models of oral carcinogenesis 
Mouse models of disease are widely used because the mouse genome has a 
history of being successfully manipulated (Brudno et al., 2004). Spontaneous 
OSCC formation in mice is rare (Thurman et al., 1997). OSCC formation may 
be induced chemically by the use of agents such as 4-nitroquinoline 1-oxide (4-
NQO) (Vered et al., 2005). 4-NQO induces a spectrum of precancerous 
changes alongside OSCC formation. The genetic alterations induced by 4-NQO 
are similar to those implicated in human OSCC (Kanojia and Vaidya, 2006). 
Studies using transgenic and knockout mice have made a significant 
contribution to our understanding of human disease. However, genetic 
modifications that result in OSCC formation in mice are rare (Mognetti et al., 
2006). Treating a transgenic/knockout mouse strain with 4-NQO potentially 
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simulates the complex interactions between environmental/genetic factors that 
occur during human oral carcinogenesis (Wong, 2009). 
5.1.3 Pax9 is a candidate tumour-suppressor gene in oral carcinogenesis 
Data from our analysis of human tissue samples, combined with evidence from 
the available literature, suggest that PAX9 has a tumour-suppressor function in 
oral carcinogenesis. Pax9 is conditionally inactivated when Pax9flox transgenic 
mice are crossed with K14-Cre mice (Kist et al., 2007). Aged Pax9-deficient 
mice develop fissures and hyperplastic epithelial lesions [unpublished data]. 
Whilst these lesions do not show morphological features of epithelial dysplasia 
and do not progress to OSCC, it is conceivable that they harbour molecular 
changes that are shared with those occurring in oral carcinogenesis. 
We hypothesise that Pax9 is a tumour-suppressor gene and that exposure to 4-
NQO treatment will induce more extensive pre-cancerous changes and more 
rapid progression to OSCC in Pax9-deficient mice than in controls. This chapter 
outlines the findings of a feasibility study, analogous to a phase I clinical trial, 
(Cancer Research UK, 2013), which is the first to assess the response Pax9-
deficient mice to 4-NQO treatment. 
5.2 Aims 
The aims of this chapter are: 
1. To determine the tolerable 4-NQO dose range for Pax9-deficient mice 
2. To identify potential side effects/systemic toxicity that may be induced in 
Pax9-deficient mice by 4-NQO treatment 
3. To characterise the morphological and molecular features of the oral 
mucosa of Pax9-deficient and control mice following 4-NQO treatment 
4. To characterise the morphological and molecular features of the oral 
mucosa of aged Pax9-deficient mice and compare them with those of 
mice that have been exposed to 4-NQO.  
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5.3 Results 
5.3.1 Characteristics of the group of mice treated with 4-NQO: sex, 
genotype, genetic background, and phenotype 
Sixty-eight mice were treated with 4-NQO (n = 68). At the start of 4-NQO 
treatment, the mice had a mean age of 33.8 weeks (range: 9 - 57 weeks). The 
other characteristics of these mice are summarised in Table 5-1. 
5.3.2 Weight of mice prior to and following 4-NQO-treatment 
At the start of the experiment, the mice had a mean weight of 25.7 g (range: 
16.5 – 42.3). The mean weight of control mice was 27.0 g (range: 18.5 – 42.3). 
Pax9-deficient mice generally weighed less than controls prior to 4-NQO 
treatment (mean 24.5; range: 16.5 - 33.7). However, the difference between the 
mean weights of Pax9-deficient mice and controls was not significant (p>0.05, 
Independent T-test). 
All mice were weighed following 4-NQO treatment, immediately before autopsy. 
The mice had a mean weight of 31.4 g (range: 11.6 – 52.8). The mean weight of 
the control mice was 35.4 g (range: 20.7 – 52.8). Pax9-deficient mice weighed 
less than controls following 4-NQO treatment (mean 25.5, range: 11.6 – 46.6). 
This difference was significant at p<0.0001 (Independent T-test). Weight loss in 
Pax9-deficient mice was accompanied by a range of other features, which are 
described further in section 5.3.4.  
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Table 5-1 Characteristics of the group of mice treated with 4-NQO (n = 68) 
 
Characteristic Number (%) 
Sex: 
Male 
Female 
 
31 (45.6) 
37 (54.4) 
Genotype 
Wild-type 
Pax9 mutant: 
Phenotype of Pax9 mutants* 
Complete knockout 
Partial knockout 
Normal phenotype 
 
32 (47.1) 
36 (52.9) 
 
19 (52.8) 
11 (30.6) 
6 (16.7) 
Strain: 
Black 6 
FVB 
Hybrid (Black6 x FVB) 
 
35 (51.5) 
17 (25) 
16 (23.5) 
Generation: 
F1 
N2F16 
N3 
N3F1 
N5F9 
 
16 (23.5) 
3 (4.4) 
4 (5.9) 
29 (42.6) 
16 (23.5) 
 
(*N.B. Complete knockout – complete absence of filiform papillae; partial knockout – some 
areas contain normal filiform papillae; normal – no loss of filiform papillae.)  
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5.3.3 Duration of 4-NQO treatment 
The mean duration of 4-NQO treatment was 21.1 weeks (range: 2 – 28 weeks). 
The majority of both Pax9-deficient mice and controls tolerated 4-NQO 
treatment and completed the planned duration of 4-NQO treatment (intervals 
between 22 to 28 weeks). However: 
 Four Pax9-deficient mice became sick soon after beginning 4-NQO 
treatment. They were sacrificed after just two weeks. Of these: 
o Each had a Black 6 genetic background 
o Three cases were treated with 50µg/ml 4-NQO 
o One case was treated with 20µg/ml 4-NQO 
 Ten cases were sacrificed following <20 weeks of 4-NQO treatment: 
o Six of these were Pax9-deficient mice sacrificed on humane grounds 
due to a toxic systemic response to 4-NQO 
o Four were healthy control mice. These controls were sacrificed to 
provide a comparison of the oral mucosa of controls and Pax9-
deficient mice prior to completion of the planned 4-NQO treatment 
 Twelve Pax9-deficient mice tolerated 4-NQO treatment for more than 20 
weeks. However, these mice deteriorated shortly before the end of 
treatment. They were sacrificed for humane reasons at intervals between 22 
and 28 weeks. 
 
The length of 4-NQO treatment and other characteristics of the mice that 
showed a toxic systemic response to 4-NQO treatment are summarised in 
Table 5-2. The characteristics of these mice are detailed in the next section. 
5.3.4 Toxic systemic response to 4-NQO treatment 
The majority of mice (66.2%) were healthy on completion of 4-NQO treatment, 
and showed no evidence of a toxic systemic response to 4-NQO. However, the 
tolerance of mice to 4-NQO treatment varied according to sex, genetic 
background, dose of 4-NQO, and genotype. 
A total of 23 mice showed a toxic systemic response to 4-NQO treatment (Table 
5-2). These mice were characterised by excessive saliva production, which 
caused drooling and matting of the fur around the chin and abdomen. The 
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majority of these mice were otherwise healthy. However, in a subset of nine 
mice excessive salivation was accompanied by: 
 A generalised failure to thrive 
 A reduced growth rate 
 Rapid, extreme weight loss 
 A ‘hunched’ position at rest. 
 
All of these mice were too sick to continue the experiment and were sacrificed 
for humane reasons prior to completion of their planned 4-NQO treatment. At 
autopsy, abdominal examination revealed they had only one kidney. 
Female mice were more likely to develop a toxic systemic response to 4-NQO 
treatment than male mice. 25.8% of females developed excessive salivation, 
compared with 16.2% of males. Similarly, 16.1% of females became sick, 
compared with 10.8% of males. However, cross tabulation showed that the 
association between sex and toxic systemic response was not statistically 
significant (p>0.05, Pearson ᵡ2 value - 1.7, 2 d.f.). 
The majority of the 23 mice that developed a toxic systemic response to 4-NQO 
treatment had a Black 6 genetic background (18 cases, 78.3%). Four FVB mice 
and only one hybrid developed a toxic response. A cross tabulation showed that 
there was a significant association between the Black 6 genetic background and 
the development of a toxic response (p<0.05, Pearson ᵡ2 value - 11.6, 4 d.f.). 
Thirty-seven mice were treated with a 10µg/ml concentration of 4-NQO. At the 
end of treatment, the majority of these mice (31 cases, 83.8%) were healthy. By 
contrast, less than half of the mice treated with 20µg/ml and 50µg/ml 
concentrations of 4-NQO were healthy. Of the twelve mice treated with 50µg/ml 
4-NQO, four became sick and a further three cases developed excessive 
salivation. A cross tabulation showed that the association between 4-NQO 
dosage and development of a toxic systemic response to 4-NQO treatment was 
significant (p<0.01, Pearson ᵡ2 value - 13.6, 4 d.f.). 
The majority (90.6%) of control mice were healthy on completion of 4-NQO 
treatment. There were three control mice among those who showed excessive 
salivation. However, none of the controls became sick or had to be sacrificed 
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prematurely due to a toxic systemic response to 4-NQO treatment. By contrast, 
the majority (55.6%) of Pax9-deficient mice developed a toxic systemic 
response to 4-NQO treatment; less than half of Pax9-deficient were healthy 
prior to sacrifice. Each of the nine mice that became sick as a result of the 4-
NQO treatment was Pax9-deficient. A cross tabulation confirmed that the 
association between the Pax9-deficient genotype and development of a toxic 
systemic response to 4-NQO treatment was significant (p<0.0001, Pearson ᵡ2 
value - 17.2, 2 d.f.).  
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Table 5-2 Summary of the characteristics of the mice that developed a toxic 
systemic response to 4-NQO treatment 
 
Mouse 
number. 
Sex Genotype Strain 4-NQO Condition 
at 
sacrifice Dosage 
(µg/ml) 
Duration 
(weeks) 
846 F Mutant Black6 50 14 Drooling 
925 M Mutant Black6 50 14 Sick 
926 M Mutant Black6 50 23 Drooling 
948 M Mutant  FVB 10 25 Drooling 
960 M Mutant FVB 10 27 Drooling 
965 F Mutant FVB 10 11 Sick 
971 F Control FVB 10 27 Drooling 
977 M Mutant Black6 50 2 Sick 
978 M Mutant Black6 50 8 Drooling 
980 F Mutant Black6 50 2 Sick 
981 F Mutant Black6 50 2 Sick 
983 M Mutant Black6 20 22 Sick 
985 M Mutant Black6 20 23 Drooling 
988 F Mutant Black6 20 23 Drooling 
989 F Mutant Black6 20 22 Drooling 
990 F Mutant Black6 20 22 Drooling 
997 F Mutant Hybrid 20 28 Sick 
1012 M Mutant Black6 20 2 Sick 
1015 F Control Black6 20 23 Drooling 
1016 F Mutant Black6 20 4 Drooling 
1018 F Mutant Black6 20 4 Sick 
1019 F Control Black6 20 22 Drooling 
1030 M Mutant Black6 10 22 Drooling 
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5.3.5 Autopsy features of the lingual mucosa following 4-NQO treatment 
At autopsy, only six mice had macroscopically normal tongues. Each of these 
had a control genotype (Figure 5-1A). 
Keratosis of the lateral surface of the tongue was identified in half of Pax9-
deficient mice, compared with just 15.6% of controls (Figure 5-1D). The 
association between Pax9 genotype and keratosis of the lateral tongue was 
significant (p<0.01, Pearson ᵡ2 value - 8.94, 1 d.f.). Well-defined lesions 
(plaques, papules, and nodules) were identified in the majority of both Pax9-
deficient mice and controls (Figure 5-1B, D). A cross tabulation of discrete 
lesions and genotype was not statistically significant (p>0.05, Pearson ᵡ2 value - 
0.005, 1 d.f.). A total of seventeen cases showed tumours at autopsy (Figure 
5-1D). The majority of these lesions were in Pax9-deficient mice (12 cases, 
71%). However, a cross tabulation showed that the association between 
genotype and the presence of macroscopic tumours was not significant 
(p>0.05, Pearson ᵡ2 value - 2.83, 1 d.f.).  
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Figure 5-1 Macroscopic autopsy features of the tongues of Pax9-deficient 
mice and controls following 4-NQO treatment 
A) Normal dorsal mucosa of a control mouse. B) The dorsal surface of the Pax9-deficient 
mouse shows fissuring towards the tip (arrows). There are several small, well-defined nodules 
(arrowheads). C) Normal ventro-lateral epithelium of a control mouse. D) The Pax9-deficient 
mouse shows diffuse keratosis of the lateral surface. There are several plaque-like lesions 
reminiscent of human leukoplakia (arrowheads). An exophytic tumour projects from the anterior 
ventral surface (arrow, to the right).  
A) and B) taken at 60x magnification; C) and D) taken at 160x magnification.  
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5.3.6 Histopathological features of mouse tongues following 4-NQO 
treatment 
Histopathological examination showed a broad spectrum of features. Individual 
mice were classified according to the most advanced stage of disease (Table 
5-3). A cross tabulation showed that the distribution of mice according to 
genotype and histological diagnosis was statistically significant (p<0.0001, 
Pearson ᵡ2 value – 75.9, 10 d.f.). 
Normal epithelium was seen in 20 cases, with even numbers of Pax9-deficient 
mice and controls (Table 5-3). Nine of the mice with normal epithelium had 
been sacrificed prior to completion of the scheduled 4-NQO treatment. 
However, mice in this group had a range of treatment durations (2 – 28 weeks) 
and 4-NQO concentrations (10, 20 and 50 μg/ml). 
Thirty-eight cases showed epithelial dysplasia. Epithelial dysplasia was 
detected in even numbers of Pax9-deficient mice and controls (Table 5-3). The 
scoring pathologists did not stratify these cases according to grade of epithelial 
dysplasia. However, a wide range of architectural and cytological features were 
observed in both Pax9-deficient mice and controls (Figure 5-2). The shortest 
time to induction of epithelial dysplasia was two weeks. This was in a Pax9-
deficient mouse that had been treated with 20μg/ml 4-NQO and was sacrificed 
prematurely having developed a toxic systemic response to 4-NQO. Epithelial 
dysplasia was also detected in another Pax9-deficient mouse after four weeks 
of treatment with 20 μg/ml 4-NQO. By contrast, control mice sacrificed at four 
weeks (20 μg/ml), six weeks (10 μg/ml), and eight weeks (50 μg/ml) showed 
normal epithelium with no evidence of epithelial dysplasia. 
Oral squamous cell carcinoma (OSCC) was detected in ten mice. The 
histological features and invasive patterns of these tumours were diverse 
(Figure 5-3). The majority arose in Pax9-deficient mice (Table 5-3). The shortest 
time to induction was 22 weeks in a Pax9-deficient mouse treated with 20 μg/ml 
4-NQO. Interestingly, the majority of mice that developed OSCC were treated 
with the lowest dose (10 μg/ml 4-NQO). The shortest time to induction with 10 
μg/ml 4-NQO was 24 weeks.  
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Table 5-3 Summary of the number of Pax9-deficient and control mice 
assigned to each diagnostic category following histopathological examination 
 
Diagnostic 
category  
Pax9-deficient 
mice  
Control Total 
Normal microanatomy 10 10 20 
Epithelial dysplasia 19 19 38 
Squamous cell 
carcinoma 
7 3 10 
Total 36 32 68 
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Figure 5-2 Epithelial dysplasia involving dorsal and ventral tongue mucosa of 
Pax9-deficient mice and controls 
A, B) Both Pax9-deficient mice and controls developed epithelial dysplasia on the dorsal surface 
of the tongue. C, D) Mice with both genotypes also developed epithelial dysplasia on the ventral 
surface of the tongue. A diverse spectrum of architectural and cytological abnormalities were 
observed at both subsites. Epithelial dysplasia was not assigned to a histological grade during 
this project. 
Images taken at x100 magnification.  
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Figure 5-3 Histopathological features of OSCC involving the tongues of Pax9-
deficient mice and controls 
 
A) and B) OSCC shows early invasion of the lamina propria in a control and Pax9-deficient 
mouse respectively. C)  In a control mouse, OSCC has infiltrated the musculature of the tongue, 
extending through nearly the full thickness towards the posterior aspect. D) In a Pax9-deficient 
mouse, although there is an intact surface OSCC infiltrates the musculature of the tongue with 
aggressive, non-cohesive, and sarcolemmal pattern of invasion (arrowhead). 
A), B), and D) taken at x100 magnification; C) taken at x50 magnification. 
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5.3.7 Chronic inflammatory changes and ulceration 
Chronic inflammatory ulceration was detected in four cases. Chronic 
inflammation without ulceration was detected in one further case. 
Ulceration/chronic inflammation was recorded as an incidental finding and the 
mice were categorised according to other ‘worst’ diagnosis according to 
changes elsewhere in the mucosa (Table 5-3). 
5.3.8 Macroscopic tumours arising at other mucosal subsites 
This study focused primarily on squamous cell carcinoma and epithelial 
dysplasia involving the tongue. However, there was a subset of 14 mice in 
which tumours developed at non-tongue oral subsites. The subsites and 
numbers of Pax9-deficient mice and controls affected are summarised in Table 
5-4. An example of one tumour that has been confirmed histologically as an 
OSCC is shown in Figure 5-4. 
5.3.9 Oesophageal squamous cell carcinoma 
The oesophagus of each mouse was examined at autopsy. The majority of 
cases showed no oesophageal abnormality. However, in two Pax9-deficient 
mice the oesophagus was distended by tumour. The tumour had a pale-grey cut 
surface. In these cases, the oesophagus was submitted for histological 
examination. Macroscopically normal oesophagus from one control and one 
Pax9-deficient mouse was also submitted for comparison. 
Histological examination confirmed that both tumours were squamous cell 
carcinoma (Figure 5-5). Interestingly, both mice had appeared systemically well 
prior to autopsy, showing no sign of weight loss. Both were treated with 10µg/ml 
4-NQO and were able to complete the planned duration of treatment (27 weeks 
and 28 weeks). One had a FVB background and one was a hybrid. The FVB 
mouse had also developed OSCC of the tongue. The hybrid mouse showed 
epithelial dysplasia on the tongue but no evidence of OSCC.  
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Table 5-4 Summary of tumours identified macroscopically at non-tongue 
mucosal subsites 
 
Subsite Pax9-deficient 
mice 
Controls Total 
Floor of mouth 3 2 5 
Buccal mucosa 1 1 2 
Lip 2 1 3 
Gingiva 2 1 3 
Oropharynx 1 0 1 
Total 9 5 14 
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Figure 5-4 Oral squamous cell carcinoma arising on the buccal mucosa of a 
control mouse 
This is a section through the anterior buccal mucosa. Squamous cell carcinoma extends from 
the mucosal surface through the full thickness of the lip to undermine the skin. The insert shows 
islands of atypical squamous cells that show keratin formation centrally.  
Main picture taken at x50 magnification, insert at x100 magnification.  
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Figure 5-5 Oesophageal squamous cell carcinoma in a Pax9-deficient mouse 
A) and C) The control mouse shows the normal micro-anatomy of the oesophagus. There is a 
thick wall of muscle and the mucosa has an undulating outline. The squamous epithelium 
shows orthokeratosis. B) In the Pax9 mutant, the normal micro-anatomy is distorted by 
squamous cell carcinoma. The oesophagus is distended with compression and invasion of the 
muscular wall. Carcinoma almost entirely occludes the lumen (arrowhead). D) In the mutant, the 
epithelium is replaced by sheets of malignant squamous cells. 
A) and B) taken at x50 magnification;. C) and D) taken at x200 magnification.  
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5.3.10 Aged Pax9-deficient and control mice not treated with 4-NQO 
Two aged mice that had not been treated with 4-NQO were sacrificed for 
morphological and immunohistochemical analysis. Both were females and had 
a Black 6 genetic background. Both were aged two years at the time of 
sacrifice. One was a Pax9-deficient mutant with complete knockout phenotype; 
the second was a control. 
The control mouse showed a normal phenotype with the normal complement of 
filiform papillae on the dorsal surface of the tongue (Figure 5-6A). The Pax9-
deficient mouse showed a smooth dorsal surface due to loss of filiform papillae. 
Microscopically, there were a few sparse, abortive filiform papillae (Figure 
5-6B). Keratinocytes in the control showed a nuclear pattern of Pax9 expression 
that was most intense in the prickle cell layer (Figure 5-6C). By contrast, 
keratinocytes in the Pax9-deficient mouse were negative (Figure 5-6D). This 
confirmed site specific Pax9 knock-out in the K14 Pax9flox/flox mouse. The ventral 
surfaces of the control and mutant showed common histological features, with 
an undulating rete profile and light keratosis (Figure 5-6 F, G). Keratinocytes in 
the control mouse showed nuclear expression of Pax9, but were negative in the 
Pax9-deficient mouse (Figure 5-6H, I). 
On the dorsal surface of the tongue, the Pax9-deficient mouse showed 
fissuring. In these areas, the squamous epithelium invaginated and pushed 
down into the lamina propria and musculature of the tongue (Figure 5-7A, B). 
There was some up-regulation of Sox2 in the Pax9-deficient mouse relative to 
the control (Figure 5-7C, D). The control mouse showed nuclear Ki67 
expression in the basal keratinocytes at the tips of rete processes (Figure 5-7E). 
There was slight up-regulation of Ki67 in the Pax9-deficient mouse, notably at 
the apex of the fissure (Figure 5-7F). p53 was negative in the control, but a few 
p53-positive cells were identified in the Pax9-deficient mouse [data not shown].  
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Figure 5-6 Immunohistochemical characterisation of the dorsal tongue 
epithelium of control and Pax9-deficient adult mice not treated with 4-NQO 
A) H&E shows a normal complement of filiform papillae (FF) on the dorsal surface of the control. 
B) FF are absent (arrow) in Pax9-deficient dorsal tongue epithelium and only remnants of the 
mesenchymal papilla can be observed. C) Pax9 is expressed in basal and parabasal layers and 
is strongest in differentiating suprabasal keratinocytes in controls. D) Pax9 is absent in the 
Pax9-deficient mouse. E) and F) the ventral epithelium of the Pax9 deficient mouse and the 
control show similar features. However, whereas there is nuclear Pax9 expression in the control 
G), Pax9 is negative in the mutant. 
Images taken at x100 magnification.  
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Figure 5-7 Comparison of SOX2 and Ki67 immunohistochemistry in the 
fissured tongue of an aged Pax9-deficient mouse and a control 
A) The control mouse shows filiform papillae (FF) on the dorsal tongue. B) In the Pax9-deficient 
mouse, filiform papillae are absent and there is a prominent fissure (arrowhead). C) Expression 
of the oral keratinocyte marker Sox2 is restricted to the basal and parabasal layers in the 
control. D) In the Pax9-deficient mouse, Sox2 expression varies, but is up-regulated in areas. E) 
Expression of the proliferation marker Ki67 is restricted to the basal layer in the control. F) 
There is up-regulation of Ki67 at the apex of the fissure in the Pax9-deficient mouse. 
Images taken at x100 magnification.  
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5.3.11 Selection of 4-NQO treated cases for immunohistochemical 
analysis 
Representative Pax9-deficient and control mice were selected for initial 
molecular analysis by immunohistochemistry. The majority of the mice that were 
selected showed epithelial dysplasia. Three control mice with morphologically 
normal epithelium were analysed as a comparator (Table 5-5). 
5.3.12 Initial molecular characterisation of mice treated with 4-NQO 
Expression of Ki-67, p53, and Sox2 were analysed by immunohistochemistry in 
tongue epithelium from Pax9-deficient mice and controls. Ki67 and p53 were 
analysed as both are up-regulated in dysplastic epithelium relative to normal 
epithelium in human OPMD. Ki67 is a marker of proliferation, and p53 a marker 
of cell damage (Kovesi and Szende, 2003; Varun et al., 2014). Our analysis of 
human tissue samples and the literature to date suggests that SOX2 is a 
marker of cancer stem cells and may have an oncogenic role in OSCC 
formation (Boumahdi et al., 2014). 
The expression of each of the three biomarkers in dysplastic epithelium was 
compared relative to normal epithelium in both Pax9-deficient mutants and 
control mice. On the ventral tongue, both p53 and Sox2 were significantly up-
regulated in dysplastic epithelium relative to the normal epithelium in both Pax9-
deficient mice and controls (Figure 5-8; Sox2 up-regulation shown in Figure 
5-9). Ki67 was also up-regulated in dysplastic epithelium relative normal 
epithelium. However, the difference was not significant in either Pax9-deficient 
mice or controls (Figure 5-8). The same trends were identified in the dorsal 
tongue [data not shown].  
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Table 5-5 Summary of the 4-NQO-treated cases selected for 
immunohistochemical analysis 
 
Mouse ID Sex Genotype 
Age 
(weeks) 
Strain 
4-
NQO 
(µg/m
l) 
Duration 
(weeks) 
Tongue Phenotype 
 
Normal epithelium 
 
1001 F Control 36 Hybrid 10 28 Normal 
1033 M Control 30 B6 10 22 Normal 
1034 M Control 30 B6 10 22 Normal 
 
Epithelial Dysplasia  
 
846 F Mutant 45 B6 50 14 Normal 
922 M Control 38 B6 50 15 Normal 
925 M Mutant 37 B6 50 14 Complete KO 
982 M Control 34 B6 20 23 Normal 
983 M Mutant 33 B6 20 22 Complete KO 
987 F Control 33 B6 20 22 Normal 
988 F Mutant 33 B6 20 23 Complete KO 
989 F Mutant 33 B6 20 23 Partial KO 
1030 M Mutant 29 B6 10 22 Complete KO 
1031 M Mutant 30 B6 10 22 Complete KO 
959 M Control 43 FVB 10 27 Normal 
960 M Mutant 43 FVB 10 27 Complete KO 
973 F Control 43 FVB 10 27 Normal 
974 F Mutant 43 FVB 10 27 Complete KO 
994 M Mutant 36 Hybrid 10 28 Complete KO 
995 F Control 36 Hybrid 10 28 Normal 
997 F Mutant 36 Hybrid 10 28 Complete KO 
998 M Mutant 36 Hybrid 10 28 Complete KO 
999 F Control 36 Hybrid 10 28 Normal 
1004 M Mutant 36 Hybrid 10 26 Partial KO 
 
(Mouse ID - reference identification for internal mouse and Home Office databases; Sex - F = 
female, M = male; Strain - genetic background of mice analysed (hybrid = BL6 x FVB crossed 
mice); Tongue phenotype - either complete or partial knockout or normal Pax9 expression as 
determined by presence or absence of filiform papillae on the dorsal tongue.  
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Figure 5-8 Bar chart comparing mean PPN Ki-67, p53, and Sox2 values of 
normal and dysplastic ventral epithelium of Pax9-deficient and control mice 
The proportion of p53-positive and Sox2-positive nuclei is significantly increased in ventral 
epithelial dysplasia relative to histologically normal epithelium. This trend was identified in both 
controls and mutants (p<0.01 for p53; p<0.05 for Sox2). Ki-67 expression was also up-regulated 
in epithelial dysplasia relative to the normal epithelium, but the differences were not statistically 
significant.  
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Figure 5-9 Sox2 protein expression in normal and dysplastic ventral 
epithelium of control and Pax9-deficient mice treated with 4-NQO 
The proportion of Sox2-positive cells is increased in epithelial dysplasia relative to the normal 
epithelium in both control mice (A and C) and in Pax9-deficient mutants (B and D). 
Images taken at x 200 magnification.  
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5.4 Discussion 
Mouse models of oral carcinogenesis are critical to the evaluation of biomarkers 
and chemotherapeutic targets (Herzig and Christofori, 2002). Chemical 
induction of oral carcinogenesis using 4-nitroquinolone-1-oxide (4-NQO) is a 
well-established technique. 4-NQO has been used in the evaluation of 
chemotherapeutic agents in wild-type mice (Czerninski et al., 2009). It has also 
been used in combined models using transgenic mice to determine the 
contribution of specific genetic alterations to oral squamous cell carcinoma 
(OSCC) formation (Zhang et al., 2006). This feasibility study is the first of its 
kind to induce Pax9-deficient mice using 4-NQO. It is therefore analogous to a 
phase I clinical trial in humans. Phase I trials are designed to identify the 
response to a particular treatment, the safe dose range, and the possible side 
effects of treatment (Cancer Research UK, 2013). This study has identified 
important trends in the susceptibility of Pax9-deficient mice to formation of 
epithelial dysplasia and OSCC in response to 4-NQO treatment. Moreover, this 
study has detected enhanced sensitivity to the systemic effects of 4-NQO in 
these Pax9-deficient mice. It therefore has important recommendations for the 
experimental design of future studies involving larger groups of mice (Cancer 
Research UK, 2013; Understanding Animal Research, 2014). 
5.4.1 Formation of epithelial dysplasia 
Epithelial dysplasia was detected in the majority of both control and Pax9-
deficient mice following 4-NQO induction. The prevalence of epithelial dysplasia 
across the group confirms the experimental reliability of the 4-NQO model 
(Vitale-Cross et al., 2009). It also confirms the inductive efficacy of the three 
dosages used in these experiments (i.e. 10, 20, and 50μg/ml). 
Pax9-deficient mice developed epithelial dysplasia after just two weeks 
following the start of 4-NQO treatment. By contrast, in control mice the shortest 
time from 4-NQO induction to development of epithelial dysplasia was 15 
weeks. Induction of epithelial dysplasia after just two weeks has been reported 
in rats (Nauta et al., 1996). However, the majority of studies using 4-NQO 
induction in mice report an eight week time-lag from the start of treatment to 
development of epithelial dysplasia (Tang et al., 2004; Vitale-Cross et al., 
2004b). 
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This finding provides some support for our hypothesis that Pax9-deficient mice 
are more susceptible to 4-NQO due to the loss of Pax9 tumour-suppressor 
function. However, this finding must be interpreted with caution. A relatively 
small number of mice were sacrificed after a brief duration of 4-NQO treatment. 
In order to confirm that epithelial dysplasia is induced more rapidly in Pax9-
deficient mice, a future experiment would need to schedule the sacrifice and 
autopsy of matched control and Pax9-deficient mice at short, predetermined 
intervals of treatment (e.g. weekly intervals for the first six weeks). Such 
experiments are likely to require considerably larger mouse populations. The 
incremental loss of mice from early in the experiment would otherwise reduce 
the number of cases exposed for a sufficient length of time to develop OSCC. In 
the current experiment, detection of epithelial dysplasia at two weeks was 
essentially an incidental finding, i.e. it was due to the unexpected loss of mice 
early in the experiment due to a toxic systemic response to 4-NQO rather than 
in accordance with the experimental design. 
5.4.2 Grading of epithelial dysplasia 
The scoring pathologists did not categorise cases according to a stratified grade 
of epithelial dysplasia. There is a risk that this approach has failed to identify 
important differences between and trends with Pax9-deficient mice and controls 
regarding the severity of epithelial dysplasia. It is conceivable that Pax9-
deficient mice develop high-grade epithelial dysplasia more frequently (and/or 
more rapidly) than controls. Such trends would not be detected using the 
current binary (i.e. ‘present’ or ‘absent’) classification. However, there is no 
agreed classification system for grading oral epithelial dysplasia in mice. Mouse 
epithelium is thinner than human epithelium. This confounds the direct 
transference of classification systems for human epithelial dysplasia. It is well 
documented that the grading of human oral epithelial dysplasia is subject to 
inter-observer and intra-observer variability (Kujan et al., 2007). It is our 
experience that grading epithelial dysplasia in control mice is challenging. This 
is due to difficulty in distinguishing between normal epithelial and subtle basal 
cell hyperplasia in the thinner mouse epithelium, and the keratinisation of the 
ventral epithelium as part of the normal microanatomy of the mouse tongue. 
Grading is further complicated in Pax9-deficient mice, in which the normal 
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squamous epithelium shows architectural abnormalities. In the context of an 
already abnormal epithelial architecture, it is conceivable that architectural 
changes specifically reflecting epithelial dysplasia may be either overlooked or 
identified erroneously. These issues reflect the difficulties inherent to the study 
of a genetically modified mouse strain with a unique phenotype. They also 
highlight the need for clear guidelines to be developed for the diagnosis and 
grading of epithelial dysplasia in mice. Such guidelines would support 
researchers using the 4-NQO model and potentially bring greater uniformity and 
reliability to the literature. 
There are also potential ethical implications if cases were stratified according to 
the grade of epithelial dysplasia. By using a binary ‘absent’ or ‘present’ 
approach, the methodology used in the present study is consistent with the 
principle of reducing the number of animals required in an experiment to a 
minimum (Understanding Animal Research, 2014). In order to support valid 
statistical comparisons, considerably larger numbers of mice would be required 
in an experiment that stratified epithelial dysplasia according to the World 
Health Organisation (WHO) or Squamous Intraepithelial Neoplasia (SIN) 
classifications (Barnes et al., 2005). 
5.4.3 Formation of oral squamous cell carcinoma 
4-NQO treatment induced OSCC formation in both control and Pax9-deficient 
mice. However, the majority of OSCC arose in Pax9-deficient mice. This 
provides some support for our hypothesis that Pax9 mutant mice are more 
susceptible to OSCC formation than controls due to the loss of the tumour-
suppressor function of Pax9. 
Across all diagnostic categories, the association between genotype and 
diagnosis was statistically significant. However, statistical comparison according 
to genotype within the group of mice that developed OSCC is compromised by 
the small number of cases (n = 10). Further serial sections will be examined as 
the analysis of the tongue tissue continues beyond this project. It is conceivable 
that further OSCC will be identified during this process. Larger numbers of 
OSCC cases would support further statistical analysis. However, our 
macroscopic analysis and initial histological assessment suggest that the 
number of OSCC is not likely to increase substantially as a result of further 
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sectioning. The present data therefore need to be verified by future experiments 
that use standardised conditions on greater numbers of mice. 
The shortest interval from the start of 4-NQO induction to OSCC formation was 
22 weeks. This is concordant with several previous 4-NQO studies in which 4-
NQO treatment has continued for up to 50 weeks (Ma et al., 1999; Ide et al., 
2001). However, it is longer than the eight-week induction interval reported by 
Hasina et al (2009). In that study, a much higher concentration of 4-NQO was 
used (100 μg/ml). Given the strong association with high dosage and toxic 
systemic effects of 4-NQO, this dose is not feasible to use in a population of 
Pax9-deficient mice. Our data show that the maximum dosage in the present 
study (50 μg/ml 4-NQO) resulted in a rapid toxic systemic effect. It is therefore 
likely that treatment of Pax9-deficient mice with 100 μg/ml 4-NQO would result 
in unnecessary suffering or even premature death. This would be in clear 
breach of the principle of ‘refining’ experiments to ensure that any suffering of 
the animals is kept to an absolute minimum (Understanding Animal Research, 
2014). In fact, it is interesting to note that the majority of mice that developed 
OSCC were actually treated with the lowest concentration (10 μg/ml 4-NQO). 
This confirms findings from previous studies that 10 μg/ml 4-NQO is a sufficient 
concentration to induce OSCC formation, albeit over a longer period (Ma et al., 
1999; Ide et al., 2001). 
It is interesting that the majority of mice that developed dysplastic nodules were 
also Pax9-deficient mice. These dysplastic nodules resemble papillary 
squamous cell carcinoma in humans. The precise criteria required in order to 
establish a diagnosis of papillary squamous cell carcinoma in humans is a 
subject of debate (Barnes et al., 2005). Similar lesions have been described 
previously in mice treated with 4-NQO (Czerninski et al., 2009). As with grading 
epithelial dysplasia, however, established criteria for making this diagnosis in 
mice are not available at present. It is conceivable that some of these dysplastic 
nodules may show invasion of the lamina propria on examination of deeper 
levels. It is also possible that had there been a greater interval between the 
cessation of 4-NQO treatment and sacrifice, some of these lesions may have 
developed into conventional squamous cell carcinoma. Future experiments may 
therefore benefit from an increased time interval from the end of 4-NQO 
treatment to sacrifice/autopsy. The experimental model could be further 
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enhanced by examining the oral cavity of mice under anaesthesia at intervals 
during 4-NQO treatment. Mice with nodular lesions could then be selected for a 
longer interval between cessation of 4-NQO treatment and sacrifice. 
5.4.4 Oesophageal squamous cell carcinoma 
The majority of epithelial dysplasias and invasive squamous cell carcinomas 
involved the oral cavity, specifically the tongue. However, two Pax9-deficient 
mice developed squamous cell carcinoma of the oesophagus. This is consistent 
with the site affinity of 4-NQO documented in the literature to date. This affinity 
reflects the high concentration of diaphorase, a reductase that activates 4-NQO, 
in the oesophagus as well as in the oral cavity (Imaida et al., 1989; Kanojia and 
Vaidya, 2006). It is interesting that these mice were otherwise well and did not 
show extreme weight loss, which might have been expected given the extent of 
oesophageal obstruction. Autopsy did not identify tumours elsewhere in the 
gastrointestinal tract. This is consistent with the negative autopsy findings 
beyond the oral cavity/oesophagus documented by Tang et al (2004). 
5.4.5 Non-specific inflammatory changes 
Only a small subset of mice showed non-specific inflammatory changes and/or 
non-specific ulceration as a result of 4-NQO treatment. This is in concordance 
with the literature regarding the method of action for 4-NQO, which is generally 
less irritant than chemical carcinogens such as DMBA (Eveson and MacDonald, 
1978). 
5.4.6 Systemic effects of 4-NQO induction 
Our data show that Pax9-deficient mutant mice are at greater risk of developing 
a systemic response (i.e. excessive salivation, extreme weight loss) to 4-NQO 
treatment relative to wild-type controls. 
The precise mechanism for this increased sensitivity is unclear. Excessive 
salivation was an early sign in all mice that subsequently deteriorated (i.e. 
developed extreme weight loss and a hunched position). However, it did not 
portend a poor prognosis in all cases. Excessive salivation may have had a 
range of effects, to which mice were variably susceptible: 
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 Excessive salivation may result in fluid loss and dehydration 
 Dehydrated mice may subsequently attempt to maintain homeostasis by 
drinking greater quantities of water: 
o In the context of this experiment, where 4-NQO is present in drinking 
water, this would in turn have increased their exposure to 4-NQO 
o This generates a cycle of deterioration: excessive salivation leads to 
increasing water consumption, thus increasing 4-NQO exposure and 
causing a further increase in salivation, and drinking 
o This cycle culminates in a relentless increase in the concentration of 
4-NQO and its metabolites in the bloodstream 
 Finally, it is possible that excessive salivation may have been accompanied 
by loss of appetite/impaired masticatory efficiency. This would contribute to 
weight loss independent of the other systemic effects of 4-NQO. The dental 
abnormalities detected in a minority of cases were mild and unlikely to have 
significantly compromised masticatory efficiency in isolation. 
The mice that deteriorated most rapidly had only one kidney. Impaired excretion 
of 4-NQO may have further contributed to an increase in systemic 4-NQO 
concentration. It was not possible to identify which Pax9-deficient mice had only 
one kidney prior to beginning 4-NQO treatment. The cause of hunching in these 
mice was unclear. It may have reflected either visceral or muscular pain from 
the abdominal region. Mice with one kidney may have developed kidney failure 
due to 4-NQO toxicity. The hunching may also have been related to kidney 
failure. All organs from these mice have been formalin fixed and stored. 
Histological analysis of vital organs, especially the kidney, may provide greater 
insight into the nature of the systemic impact of 4-NQO. Future experiments 
using Pax9-deficient mice must be designed in order to avoid suffering and loss 
from the experiment of this vulnerable subset of mice with only one kidney. One 
possibility would be to assess the presence of both kidneys prior to 
commencing treatment by imaging, such as CT scanning. 
5.4.7 Optimisation of a combined 4-NQO/Pax9 knockdown model 
Over the past 15 years, several workers have attempted to optimise an 
experimental protocol for the 4-NQO model, varying parameters such as the 
duration, site/mechanism of carcinogen application, overall duration of 
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treatment, and point of sacrifice (Vitale-Cross et al., 2009). Our data suggests 
that experiments involving Pax9-deficient mice should include the following 
design considerations: 
1) Genetic background: Our data showed that Pax9-deficient mice with a 
Black 6 genetic background are more susceptible to 4-NQO than 
mutants with a FVB or hybrid background. Although wild-type Black 6 
mice did not demonstrate a heightened sensitivity to 4-NQO, Pax9-
deficient mice with a Black 6 background are at greater risk of suffering. 
The Black 6 background strain should therefore be avoided in future 
combined 4NQO/Pax9 experiments. Other strains such as FVB and 
hybrids should be used where possible as they are more resilient to the 
systemic effects of 4-NQO 
2) 4-NQO concentration: Our data also show that a concentration of 10 
µg/ml 4-NQO was sufficient to induce formation of epithelial dysplasia 
and OSCC. Concentrations greater than 10 µg/ml are associated with 
increased risk of systemic effects. This suggests that there is little 
experimental benefit in using high dosages of 4-NQO. Loss of Pax9 
mutant mice due to the systemic effects of high 4-NQO concentration 
may compromise the overall efficiency of the experiment through attrition 
of the sample population 
3) Sex: Although the difference in response between males and females 
was not statistically significant, our data suggests that males are more 
resilient to 4-NQO than females. In a study of Pax9-deficient mice, males 
may therefore be better candidates for 4-NQO treatment 
4) Interval between cessation of 4-NQO treatment and sacrifice: Future 
experiments may therefore benefit from an increased time interval from 
the end of 4-NQO treatment to sacrifice/autopsy. This would allow 
dysplastic lesions to progress to OSCC while mice are free from the 
potentially toxic systemic effects of the 4-NQO treatment 
5) Oral inspection: In the present experiment, mice were sacrificed either at 
the end of the planned experimental period or due to toxic systemic 
effects of 4-NQO. The decision to sacrifice and analyse the tongue was 
not based upon the clinical appearances following exposure to 4-NQO. 
This could be modified by performing an oral examination of the mice at 
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intervals following the start of 4-NQO treatment. Mice could then be 
selected for analysis according to whether they had developed a 
potentially dysplastic lesion. Alternatively, mice with clinically identifiable 
lesions could continue 4-NQO treatment for a range of different time 
intervals in order to assess the development of specific types of lesion. 
Oral inspection would need to be performed under a brief general 
anaesthesia (GA). GA is performed at the FGU by a number of research 
groups. Although it would add to the complexity of the experiment, there 
are facilities and suitably trained staff to make this modification feasible 
6) Tissue biopsy: Oral inspection could be complemented and enhanced by 
performing a tissue biopsy while the mouse is under anaesthesia. This 
biopsy could take the form of either a brush biopsy or a small punch 
biopsy. The selection of cases would reduce the numbers of mice 
required for the overall experiment. 
5.4.8 Immunohistochemical profile of normal and dysplastic epithelium 
The increase in Ki-67 and p53 observed in the ventral tongue dysplasias 
compared to normal epithelium is consistent with published literature (Nylander 
et al., 2000; Scholzen and Gerdes, 2000; Kovesi and Szende, 2003; Varun et 
al., 2014). That the increase is present in both Pax9-deficient mice and controls 
suggests that Pax9 inactivation does not interfere with the molecular pathways 
of these key genes, as there is no change between the controls and Pax9 
mutants. Conservation of these pathways suggests that the combined Pax9 
mutant mouse chemical carcinogenesis induction model is a suitable model of 
OSCC formation in humans. In both Pax9-deficient and control mice, Sox2 
expression is increased in epithelial dysplasia compared to normal epithelium. 
This supports evidence from the literature that suggests Sox2 may have an 
oncogenic function in oral carcinogenesis (Freier et al., 2010; Qiao et al., 2013; 
Kokalj Vokač et al., 2014).  
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5.5 Conclusion 
This feasibility study has demonstrated that Pax9-deficient mice are more 
susceptible to OSCC formation than controls. This may be due to loss of the 
tumour-suppressor function of Pax9. However, Pax9-deficient mice are also 
more sensitive to the systemic effects of 4-NQO treatment. Based on these 
data, future experiments using a combined 4-NQO/Pax9 knockdown model 
should be performed using mice with a FVB or hybrid genetic background, as 
these are more resilient to the systemic effects of 4-NQO than mice with a Black 
6 genetic background. Pax9-deficient mice should be imaged prior to treatment 
in order to confirm the presence of two kidneys; only mice with two kidneys 
present should be treated with 4-NQO. A concentration of 10 µg/ml is adequate 
to induce OSCC and a range of precursor lesions within a 24-week period. 
Higher concentrations of 4-NQO have an increased risk of causing toxic 
systemic effects, without significantly reducing the length of the experiment or 
inducing either more or a wider spectrum of epithelial lesions. 28 weeks is a 
suitable length of 4-NQO treatment. A longer interval between cessation of 4-
NQO treatment and sacrifice would allow more time for established precursor 
lesions and OSCC to develop, and thus add value to the experiment. Oral 
inspection in conjunction with a biopsy of the lingual mucosa could be used to 
assess the response of the mucosa to the 4-NQO treatment and guide the 
selection of cases for either sacrifice or a further period of 4-NQO treatment. 
Oral inspection could be carried out at intervals e.g. once per month.
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Chapter 6. Generation of Stably-inducible Oral Squamous Cell 
Carcinoma Cell Lines 
6.1 Introduction 
Normal keratinocytes harvested from the oral cavity for primary cell culture 
generally senesce following three to four passages (Prime et al., 1990). Growth 
in vitro may require mesenchymal support, for example by co-culturing with 
mitomycin C-treated 3T3 fibroblasts (Rheinwald and Green, 1975). Malignant 
keratinocytes derived from oral squamous cell carcinoma (OSCC) exhibit 
diverse phenotypes and may show characteristics of either normal or malignant 
cells (Parkinson, 1989). In contrast to their behaviour in vivo, cells cultured from 
OSCC may show little or no growth in vitro. Lack of growth may be due to 
inappropriate cell culture conditions or insufficient numbers of cancer stem cells 
(Rheinwald and Beckett, 1981). OSCC-derived cells vary in their dependence 
on mesenchymal support. Mesenchymal support may actually compromise the 
growth of some OSCC-derived cells (Rupniak et al., 1985; Prime et al., 1990). 
Despite the challenges that the primary culture of malignant oral keratinocytes 
presents, several well characterised OSCC-derived cell lines have been 
established (Prime et al., 1990; Edington et al., 1995). These cell lines are 
valuable tools in the study of oral carcinogenesis. They have been 
characterised with regard to differentiation, behaviour in vitro (Sugiyama et al., 
1993; Prime et al., 1994a) and tumorigenicity following both subcutaneous and 
orthotopic transplantation in athymic mice (Prime et al., 1994b; Paterson et al., 
2002). Furthermore, the cells have been genetically modified to study the 
functional significance of key molecules in oral carcinogenesis (Paterson et al., 
2002). 
The findings reported in Chapters 4 and 5 suggest that PAX9 has a tumour-
suppressor effect and SOX2 has a tumour-promoting effect. This chapter 
outlines the screening of a panel of OSCC cell lines and selection of two lines 
for stable transfection with plasmid DNA targeting PAX9 and SOX2 expression.  
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6.2 Aims 
The aims of this chapter are: 
1. To summarise the identification and selection of a cell line with low 
endogenous PAX9 expression (for transfection with an inducible PAX9 
expression plasmid) and a cell line with high endogenous SOX2 
expression (for transfection with an inducible SOX2 ‘knock-down’ 
plasmid) 
2. To describe the generation of stably-inducible transfectants using 
lentivirus vectors 
3. To demonstrate proof of principle that the expression constructs are 
functional using an exemplar cell line.  
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6.3 Selection of suitable oral squamous cell lines for transfection 
Nine commercially-available OSCC-derived cell lines were screened by 
assessing PAX9 and SOX2 RNA and protein expression. An immortalised 
normal oral keratinocyte line, OKF6/hTERT, was used as a comparator. A long-
term aim is to test the transfected cell lines in an orthotopic mouse model of 
tumorigenesis (Prime et al., 2004). Consequently, the selection strategy 
combined assessment of relative PAX9 and SOX2 expression with 
consideration of the known tumourigenesis of the parent cell line. 
6.3.1 Semi-quantitative RT-PCR analysis comparing relative PAX9 and 
SOX2 RNA expression in each cell line 
RNA was extracted from each of the cell lines. Semi-quantitative RT-PCR 
analysis was then performed to compare the relative endogenous expression of 
PAX9 and SOX2 RNA in each cell line. Expression of PAX9 and SOX2 RNA 
was normalised relative to expression of the housekeeping gene β-actin (ACTB 
RNA). 
PAX9 RNA expression was low in three of the OSCC cell lines: H103, H314, 
and H357. Interestingly, PAX9 expression was also low in the normal 
keratinocyte OKF6/hTERT control relative to several OSCC-derived cell lines 
(Figure 6-1). Only one OSCC cell line, H400, had higher levels of SOX2 
expression than the OKF6/hTERT control (Figure 6-1). Interestingly, none of the 
OSCC-derived cell lines showed a combination of low PAX9 and high SOX2 
expression, the expression profile anticipated in light of our data from human 
and mouse tissue samples.  
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Figure 6-1 Semi quantitative RT-PCR analysis comparing endogenous PAX9 
and SOX2 RNA expression in a range of cell lines 
Row 1) PAX9 RNA expression was lowest in the H103, H314, and H376 cell lines (red arrows). 
Interestingly, PAX9 expression in the OKF6/hTERT control (lane 1) was low relative to several 
of the OSCC-derived cell lines. Row 2) SOX2 expression was highest in the OKF6/Htert control 
and H400 (red arrows). H400 was the only cell line with SOX2 RNA expression that was higher 
than the OKF6/Htert control after normalising against the ACTB housekeeper (shown in Row 3). 
There were similar band intensities for the ACTB housekeeper, indicating consistent quantities 
of total RNA in the samples.  
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H357 was not considered to be an ideal candidate for transfection with the 
PAX9 over-expression plasmid. Although it had low endogenous PAX9 
expression, it does not form tumours following orthotopic transplantation to 
athymic mice (Prime et al., 2004). By contrast, both H103 and H314 are 
tumorigenic in athymic mice (Prime et al., 2004). Although H103 does not form 
metastases following transplantation, both H103 and H314 were considered to 
be potentially suitable candidates for transfection with the PAX9 over-
expression plasmid. In order to confirm the results of the semi-quantitative RT-
PCR analysis, immunohistochemistry was performed on H103 and H314 to 
determine their relative endogenous expression of PAX9 protein. 
For transfection with the SOX2 knockdown plasmid, the results of the semi-
quantitative RT-PCR analysis suggested that H400 was most suitable due to its 
high endogenous expression of SOX2 RNA. H400 was also suitable in terms of 
its documented experimental behaviour. In vitro, it is the most invasive of the 
OSCC cell lines (Robinson et al., 2003). Moreover, it is also tumorigenic 
following orthotopic transplantation in athymic mice (Prime et al., 2004). 
6.3.2 Immunohistochemical analysis comparing PAX9 and SOX2 protein 
expression in H103, H314, H400, and OKF6/hTERT cell lines 
Expression of PAX9 and SOX2 protein was analysed by immunohistochemistry 
in each of the three candidate OSCC cell lines and in the OKF6/hTERT control. 
Immunohistochemistry was initially performed on cell pellets. However, 
repeated attempts were unsuccessful, resulting in either weakly stained or 
completely negative sections [data not shown]. Key variables in the manual 
immunohistochemical staining protocol were manipulated, including the 
conditions used for antigen retrieval and the length/temperature of incubation 
with primary/secondary antibodies. Unfortunately, staining was consistently 
weak, particularly for SOX2 protein. The reason for this was unclear. It is 
possible that PAX9 and SOX2 antigens were damaged during either 
trypsinisation or preparation of the cell pellets. 
As an alternative strategy, immunocytochemistry was performed on cells 
prepared using the Surepath™ technique. Cells were trypsinised and 
transferred in suspension to the Department of Cellular Pathology, where 
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Surepath™ preparations were performed by Biomedical Scientists. Stained 
slides were scanned using the Aperio CS2 Scanscope™ platform and 
underwent digital image analysis. 
Using the Surepath™ preparations, immunostaining for both PAX9 and SOX2 
was stronger than that of the corresponding cell pellets. It confirmed the relative 
expression of PAX9 and SOX2 RNA identified by semi-quantitative RT-PCR 
analysis. PAX9 protein expression was low in H103 and H314 relative to both 
OKF6/hTERT and H400. PAX9 expression was lowest in the H314 cell line 
(Figure 6-2A). SOX2 staining was weaker than PAX9 staining across all the cell 
lines. However, SOX2 expression was appreciably stronger in OKF6/hTERT 
and H400 relative to H103/H314. SOX2 expression was almost entirely absent 
from H314 cells (Figure 6-2B). 
Digital image analysis of the Surepath™ stained slides confirmed that PAX9 
expression was lower in the H314 cell line than in H103 (Table 6-1). By contrast 
to the results of semi-quantitative RT-PCR analysis, SOX2 expression was 
actually higher in OKF6/hTERT relative to H400. However, SOX2 expression in 
the H400 cell line was consistently higher than in either H103 or H314 (Table 
6-1). 
Table 6-1 Summary of digital image analysis of PAX9 and SOX2 protein 
expression by immunohistochemistry in OKF6/hTERT, H400, H103, and H314 cell 
lines 
 
Cell line PAX9  SOX2 
PPN 3+PN Rank* PPN 3+PN Rank** 
OKF6 99.1 37.2 4 50.0 1.06 1 
H400 89.0 35.5 3 18.1 0.371 2 
H103 83.2 1.12 2 4.54 0.0486 3 
H314 77.8 0.289 1 0.550 0.322 4 
*Ranked low to high (1 = lowest; 4 = highest) 
**Ranked high to low (1 = highest; 4 = lowest)   
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Figure 6-2 PAX9 and SOX2 protein expression by immunohistochemistry in 
OKF6/hTERT, H103, H314, and H400 cell lines 
A) PAX9 protein expression was low in both H103/H314 relative to the OKF6/hTERT control line 
and H400. PAX9 expression was lowest in the H314 cell line. B) Across all the cell lines, SOX2 
immunostaining was weak compared to PAX9 staining. However, SOX2 expression was 
appreciably higher in OKF6/hTERT and H400 than in either H103 or H314. SOX2 expression 
was almost entirely absent from the H314 cell line. 
Images taken at x100 magnification.  
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6.3.3 Immunohistochemical confirmation of squamous differentiation of 
the cultured cells 
The cell lines were cultured for several months while the RNA and protein 
assays were performed. The cell lines exhibited differences in cytomorphology. 
In particular, H314 showed a spindle-shaped morphology that was dissimilar to 
that of the OKF6/hTERT control. H400 and H103 were polygonal and more 
closely resembled normal keratinocytes. There was concern that H314 may 
have undergone epithelial-mesenchymal transition during in vitro culture. Loss 
of squamous differentiation would make it an unsuitable candidate for 
transfection with the PAX9 over-expression plasmid. Squamous differentiation 
was therefore verified by immunohistochemistry. Staining was performed on cell 
pellets using the automated Ventana platform in the Department of Cellular 
Pathology. Assays were performed for two markers of squamous differentiation, 
cytokeratin 5/6 (CK5/6) and p63. 
Interestingly, automated immunostaining of the cell pellets was more successful 
than the manual immunostaining for either PAX9 or SOX2. Each of the cell lines 
exhibited strong cytoplasmic expression of the squamous marker CK5/6. Each 
cell line also showed strong nuclear expression of p63 (Figure 6-3). This 
confirmed that despite its spindle-shaped morphology, H314 continued to 
exhibit squamous differentiation. 
6.3.4 Final selection of parent OSCC lines for transfection with PAX9 and 
SOX2 constructs 
It was decided to use H314 for transfection with the PAX9 over-expression 
plasmid, as it had lower endogenous PAX9 expression than H103. H314 was 
also preferable in that it forms metastases following orthotopic transplantation to 
athymic mice, whereas H103 does not (Prime et al., 2004). H400 is tumorigenic 
in athymic mice, and both assays confirmed that it has high endogenous 
expression of SOX2 relative to other OSCC cell lines. H400 was therefore 
selected for transfection with the SOX2 knockdown plasmid. The characteristics 
of the selected cell lines are summarised in Table 6-2.  
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Figure 6-3 Immunohistochemical confirmation of squamous differentiation in 
OKF6/hTERT, H103, H314, and H400 cell lines 
Each of the four cell lines showed strong cytoplasmic expression of CK5/6 and strong nuclear 
expression of p63. The intensity of staining in the H314 line is similar to that in the other OSCC-
derived lines (H103 and H400) and the OKF6/hTERT control. This indicates that H314 retains 
squamous differentiation despite its spindle-shaped growth pattern in vitro. 
Images taken at x100 magnification. 
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Table 6-2 Summary of the selected cell lines and their PAX9/SOX2 expression profiles, donor characteristics, and behaviour following 
orthotopic transplantation into athymic mice 
 
Cell 
line 
Experimental 
aim 
Inducible 
construct 
design 
mRNA Protein Donor characteristics Orthotopic transplantation 
PAX9 SOX2 PAX9 SOX2 Site Lymph node 
metastasis 
Distant 
metastasis 
Tumour 
formation 
Response to 
TGF-β 
Metastasis 
H314 PAX9 tumour 
suppressor 
function 
PAX9 over-
expression 
↓ ↓ ↓ ↓ FOM + - +++ Refractory +++ 
H400 SOX2 
oncogenic 
function 
SOX2 
knockdown 
↑ ↑ ↑ ↑ AP - - ++ Marked 
inhibition 
- 
(FOM – floor of mouth; AP – anterior palate) 
N.B. Both lines were derived from pStage II moderately differentiated squamous cell carcinoma. 
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6.4 Generation of tetracycline-inducible plasmid constructs 
Generation of the PAX9 over-expression cell line was initially planned using the 
T-REx™ system (Invitrogen, Life Technologies, Paisley, UK). The T-REx™ 
system is a tetracycline-regulated mammalian expression system in which the 
chosen cell line is serially transfected with two separate plasmids. The first is 
the regulator plasmid, pcDNA6/TR©, which generates high levels of 
tetracycline-repressor (TetR) protein under the control of a cytomegalovirus 
(CMV) promoter sequence. The second plasmid, pcDNA™4/TO/lacz, contains 
the gene of interest located downstream to a ‘Tetracycline-on’ (TetO) sequence. 
In the absence of tetracycline, the pcDNA6/TR© regulator produces TetR 
molecules which subsequently form a homodimer. The homodimer binds to the 
TetO sequence in the main pcDNA™4/TO/lacz plasmid, blocking transcription 
of the gene of interest. When added, tetracycline binds to the TetR molecules 
and induces a conformational change, forcing cleavage of the homodimer and 
dissociation from the pcDNA™4/TO/lacz plasmid. The gene of interest is 
therefore de-repressed and subsequently transcribed. 
The experimental pcDNA™4/TO/lacz plasmid was constructed in three stages 
(Figure 6-4). In the first stage, human PAX9 cDNA was ligated into the Zero 
Blunt® pCR vector (Invitrogen, Life Technologies, Paisley, UK) alongside a 
Kozak sequence. The plasmid product was expanded through transformation 
into TOP10 chemically competent E. coli (Invitrogen Life Technologies, Paisley, 
UK). In the next stage, the final cassette was constructed by ligating the PAX9-
kozak sequence with internal ribosomal entry site (IRES) and enhanced green 
fluorescent protein (EGFP) sequences in the second vector. The cassette was 
verified by analytical restriction digests and then inserted into the T-REx™ 
pcDNA™4/TO/lacz plasmid in the third stage (Figure 6-4). 
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Figure 6-4 Generation of the T-REx™ tetracycline-inducible PAX9 pcDNA™4/TO/lacz plasmid 
The PAX9/Kozak sequence was expanded and purified, then inserted alongside an IRES-EGFP sequence in the second vector to construct the final cassette. After 
being verified by analytical restriction digests, the cassette was then inserted into the pcDNA™4/TO/lacz plasmid. 
(IRES – internal ribosome entry site; EGFP – enhanced green fluorescence protein; CMV – strong human cytomegalovirus; bGH-pA - reverse primer sequence. The 
red line at the start of the PAX9 sequence indicates the position of the Kozak sequence. Kanamycin and ampicillin antibiotics were used to select successfully 
transformed clones.) 
187 
 
6.5 Plasmid transfection of selected cell lines 
The cell line transfections were out sourced to Dundee Cell Products Ltd (DCP). 
In the T-Rex™ system, the first of the serial transfections introduces the 
regulatory tetracycline-repressor plasmid, DNA vector pcDNA6/TR©, into the 
chosen cell line. In order to increase the transfection efficiency, DCP scientists 
first linearized the pcDNA6/TR© vector using the SapI restriction enzyme. 
Further analytical digests were performed to verify that the correct vector was 
being used for the transfections. Approximately 150-200 µg of plasmid vector 
pcDNA6/TR© DNA was used for each transfection. DCP scientists used two 
transfection methods: Lipofectamine® 2000 Transfection Reagent (Life 
Technologies, Paisley, UK) (Felgner and Ringold, 1989) and calcium phosphate 
(Chen and Okayama, 1987). 
6.5.1 Low transfection efficiency of H314 and H400 cell lines 
A control plasmid was used to determine the transfection efficiency of both the 
H314 and H400 cell lines. DCP routinely use a commercially-available control 
plasmid to determine the transfection efficiency of a range of different 
mammalian cell lines. The control plasmid includes a green fluorescent protein 
sequence (Vivid Colors™, Life Technologies, Paisley, UK) that enables 
transfected cells to be detected by immunofluorescence. 
Immunofluorescence following transfection with the control plasmid showed low 
transfection efficiency for both H314 (~1-2%) and H400 (~10-20%). DCP 
reported that a large number of cells were used for the transfections in order to 
increase the probability of transfecting some of the cells. 
6.5.2 Blasticidin selection of transfected clones 
Following transfection with the regulatory pcDNA6/TR© plasmid, the cell lines 
were grown in the antibiotic blasticidin to select the transfected clones. Prior to 
selection, DCP performed triplicate kill curve analysis of the H314 and H400 cell 
lines to determine their blasticidin tolerance. The manufacturer’s recommended 
range of concentrations for use in mammalian cell lines is 1 – 10 μg/ml 
(InvivoGen, Toulouse, France). Scientists at DCP initially established the kill 
curve at a higher range of between 2 and 60 μg/ml.a 
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Subsequent to their kill curve analysis, DCP used blasticidin at a concentration 
of 10 μg/ml for selection. However, selection with 10 μg/ml blasticidin following 
the first attempt at the transfections was cytotoxic. Following later attempts at 
the transfections, a lower concentration of 5 μg/ml blasticidin was used. 
However, selection at this lower concentration was also cytotoxic. The absence 
of blasticidin-resistant clones, combined with low transfection efficiency of the 
control plasmid, suggested that the transfections had failed to introduce the 
regulator pcDNA6/TR© plasmid into either of the chosen cell lines, 
consequently, it was decided to terminate the transfection experiments. 
6.6 Lentivirus transfection of selected cell lines 
Lentivirus transfections are known to have higher transfection efficiency than 
liposome-based delivery systems (Ambrosini et al., 1999; Wiznerowicz and 
Trono, 2003). Lentivirus transfections were carried out in a level 3 containment 
tissue culture facility in the School of Medial Sciences, Newcastle University, in 
collaboration with the Dermatology Research group. The original experimental 
design was modified in order to maximise the long-term value of this 
collaboration. It was decided to transfect both parent cell lines (H314, H400) 
with both the PAX9/SOX2 knockdown particles and PAX9/SOX2 over-
expression particles. 
Generation of the PAX9 and SOX2 knockdown cell lines involved a single stage 
transfection with pTRIPZ™ lentivirus particles (Thermo Scientific, Life 
Technologies, UK). The pTRIPZ™ particles have a ‘tetracycline-on’ (TetO) 
design. Custom made pTRIPZ™ lentivirus particles were generated by Thermo 
Scientific. The custom made particles contained PAX9 and SOX2 short hair-pin 
inhibitory RNA (shRNAi) sequences downstream to a TetO sequence. In the 
pTRIPZ™ system, addition of tetracycline to transfected cells induces 
transcription of shRNAi to the gene of interest. The shRNAi subsequently 
inhibits transcription of the gene of interest, resulting in knockdown of 
endogenous protein expression. The pTRIPZ™ particles include a puromycin 
resistance cassette to facilitate selection and a red fluorescence protein (RFP) 
cassette to help visualise the transfected clones. 
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Generation of the PAX9 and SOX2 over-expression cell lines involved serial 
transfections with two lentivirus particles. In the first stage, the cell lines were 
transfected with ready-made Tetracycline-repressor lentiviral particles (Amsbio, 
AMS Biotechnology, UK). The lentiviral particles included a blasticidin-RFP 
fusion gene vector that facilitates selection and visualisation of transfected 
clones. The transfected clones subsequently produce tetracycline-repressor 
(TetR) protein. In the second stage, these TetR protein producing clones are 
transfected with custom-made lentiviral particles which contain a 
tetracycline/cytomegalovirus (Tet/CMV) sequence upstream of a PAX9/SOX2 
sequence (PAX9 lentiviral particles - Amsbio, AMS Biotechnology, UK; SOX2 
and non-targeting control particles – addgene, Cambridge, MA, USA). In the 
absence of tetracycline, transcription of PAX9/SOX2 is inhibited by binding of 
the TetR protein to the Tet/CMV sequence. Addition of tetracycline induces a 
conformational change in the TetR protein, which then dissociates from the 
Tet/CMV sequence. The Tet/CMV sequence subsequently promotes 
transcription of the target gene. The custom-made particles also contain a 
puromycin resistance cassette to facilitate selection following the second 
transfection. 
The experimental outline for the lentivirus transfections is summarised in the 
appendix. The cell lines were transfected with non-targeting controls in both the 
knockdown and over-expression experiments. 
6.6.1 Tolerance of parent H314 and H400 to puromycin and blasticidin 
The parent H314 and H400 cell lines were thawed down in the Dermatology 
Research tissue culture facility. When sufficiently expanded, the cells were 
seeded into 24-well plates at a density of 18,000 cells/well. In order to 
determine the tolerance of the parent lines to puromycin and blasticidin, cells 
were treated with variable concentrations of each antibiotic (puromycin 0 – 4 
µg/ml; blasticidin 0 – 10 µg/ml). The cells were treated in two groups: one was 
treated with antibiotic at seeding, the other was treated 24 hours after seeding. 
Antibiotic culture medium was replenished at intervals of 48 and 72 hours. 
Puromycin was required for selection of transfected cells in both knockdown 
and over-expression experiments. H314 was more sensitive to puromycin than 
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H400, with a more rapid cytotoxic response at high concentrations. However, at 
4 day following puromycin treatment, both H314 and H400 cell lines showed a 
cytotoxic response at concentrations at/above 0.5 µg/ml puromycin (H400 
shown in Figure 6-5). This concentration was therefore used for selection 
following transfections. 
Both the H314 and H400 cell lines showed similar tolerance to blasticidin, with a 
cytotoxic response at concentrations above 5 µg/ml [data not shown]. It was 
therefore decided to use 5 µg/ml blasticidin to select transfected clones 
following stage one of the over-expression experiment. This was the 
concentration that had been used by DCP following transfection with 
pcDNA6/TR© plasmid. 
Both antibiotics showed a similar cytotoxic effect at day four, irrespective of 
whether treatment started at seeding or at 24 hours after seeding. 
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Figure 6-5 H400 cells at day four following puromycin treatment at seeding 
At day four, untreated cells and those treated with the two lowest concentrations of puromycin 
(0.05 µg/ml and 0.1 µg/ml) were confluent. Cell growth was reduced at a concentration of 0.25 
µg/ml puromycin; however, there were a few viable cells at this concentration. Puromycin was 
cytotoxic at concentrations of 0.5 µg/ml and above. 
Images taken at x100 magnification.  
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6.6.2 PAX9 and SOX2 knockdown transfections 
H314 and H400 parent cell lines were transfected with PAX9, SOX2, and non-
targeting control pTRIPZ™ lentivirus particles according to the standard 
protocol used in the Dermatology Research tissue culture facility (Chapter 2, 
section 2.9). The transfected cells were seeded into T175 flasks and treated 
with 0.5 µg/ml puromycin. Unfortunately, the cells did not survive following the 
first attempt. There were a number of possible reasons for this: 1) the cells may 
have been trypsinised too soon following transfection; 2) the seeding density 
may have been too low; 3) puromycin selection may have been started too 
early. 
The transfections were repeated under the same conditions. However, following 
transfection the conditions were adjusted in order to give the cells more time to 
recover and increase their probability of surviving puromycin selection. 
Specifically, the cells were 1) incubated for 24 hours in the six-well transfection 
plates prior to being trypsinised; 2) seeded into smaller T25 flasks after 
passaging; and 3) puromycin selection was started 24 hours following seeding. 
The second attempt at transfecting both parent cell lines was successful. At day 
two following the start of puromycin selection, examination under an inverse 
light microscope showed a mixed population of cells that included adherent, 
viable cells and detached, non-viable cells. After one week of puromycin 
selection, the cells were expanded in normal culture medium. At the next 
passage, the transfected cells were seeded into six-well plates at a density of 
1x105 cells per well. At 24 hours, the culture media was replaced and the cells 
treated with doxycycline at six different concentrations (ranging from 0 to 1 
µg/ml). When the majority of wells were confluent (H400 – day four; H314 – day 
six), they were examined using an inverse fluorescence microscope. 
Transfected cells treated with diluent alone were negative. By contrast, each of 
the transfected lines treated with doxycycline at a concentration of 25 ng/ml or 
more showed a red fluorescent signal (H400 SOX2 TRIPZ ™ shown in Figure 
6-6). Cells treated with the highest doxycycline concentration (1 µg/ml) showed 
the most intense signal, but were generally less confluent than cells treated at 
concentrations at/below 500 ng/ml. This suggests that high doxycycline 
concentrations may have a mild cytotoxic effect.  
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Figure 6-6 Immunofluorescence of H400 SOX2 pTRIPZ™ cells after four days 
of induction with doxycycline 
H400 SOX2 pTRIPZ™ cells showed a positive RFP signal at day four following administration of 
doxycycline. Cells treated with the highest concentration (1 µg/ml, top left panel) showed the 
most intense signal, but were less confluent than cells treated at/below a concentration of 500 
ng/ml doxycycline. Cells that were not treated with doxycycline failed to show a red fluorescent 
signal (lower right). The light microscopy image (inset) confirms that this untreated group were 
confluent at the time of imaging. 
Images taken at x100 magnification.  
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6.6.3 PAX9 and SOX2 over-expression transfections 
Amsbio were unable to offer guidelines as to the quantity of the TetR lentiviral 
solution (LVP017-Bsd-RFP) required for the first stage transfection of our 
chosen cell lines. The solution contained a high concentration of lentiviral 
particles (1x 107 IFU/mL). As there had been a high transfection efficiency using 
the pTRIPZ™ system, it was decided to treat each well with a small amount (5 
µl) of the lentiviral particles during the first attempt. H314 and H400 cells were 
seeded into four wells of a six-well plate (100,000 cells per well) for transfection 
with TetR lentiviral particles. The transfection was performed under standard 
conditions as described in Chapter 2, section 2.9. 
Following the transfection, the cells were grown in culture containing 5 µg/ml 
blasticidin to select the transfected cells and induce the RFP cassette. 
However, at day four examination on the immunofluorescence microscope was 
negative [data not shown]. The cells were viable and seemed to be resistant to 
blasticidin. Selection was continued and the cells incubated under standard 
conditions. However, further examination at days six and ten also failed to show 
a positive red fluorescent signal [data not shown]. The negative results were 
interpreted to mean that the transfections had failed due to treatment with an 
insufficient quantity of the lentivirus solution. 
The transfections were repeated using a larger quantity of the TetR lentiviral 
solution. H314 and H400 cells were seeded into two wells of a 24-well plate (1.8 
x 104 cells/well). When suitably confluent, the cells were treated with 40 µl of the 
lentivirus solution. The transfection was otherwise performed according to the 
standard protocol. However, following several days of blasticidin selection the 
cells were again viable in the absence of a positive fluorescence signal. 
Amsbio were contacted for further advice. They reported that the RFP 
sequence was detectable on their microscopes using a modified DS Red filter at 
an excitation of 545 nm and emission of 620 nm. A TRITC filter had been used 
to detect the positive fluorescence signal from the pTRIPZ™ lines. It was 
therefore possible that a positive signal was being missed due to a different 
filter being used. 
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Unfortunately, a DS red filter was not available for use on our inverse 
microscope. The transfected cells were grown as monolayers in chamber 
slides. After three days, the cell monolayers were fixed and mounted with cover 
slips. The slides were then viewed using a DS Red filter in a Nikon confocal 
light microscope system. This detected a weak red signal in each of the 
transfected lines, including the clones originally treated with just 5 µl of the TetR 
lentivirus solution [data not shown]. 
The transfected H314TetR and H400TetR clones subsequently underwent the 
second stage in which they were transfected with lentivirus particles encoding 
PAX9, SOX2, and non-targeting sequences. Following the second transfection, 
cells were selected in puromycin at a concentration of 0.5 µg/ml. After day two 
of puromycin selection, there were mixed populations of cells including 
adherent, viable cells and detached, non-viable cells. Following one week of 
puromycin selection, the cells were expanded, frozen down and archived under 
liquid nitrogen.  
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6.7 Characterisation of H400 SOX2 pTRIPZ cell line 
Full characterisation of the transfected cell lines was outside the remit of the 
thesis; however, proof of principle that the expression constructs were 
functional was explored using one exemplar cell line. This section outlines the 
initial characterisation of H400 SOX2 pTRIPZ™ cell line. 
6.7.1 Semi-quantitative reverse transcription PCR 
The H400 SOX2 pTRIPZ™ line was seeded into a six-well plates and treated 
with doxycycline at the concentrations summarised in section 6.6.1. When 
confluent, RNA was extracted from the cells using Trizol. The RNA was then 
reverse transcribed (Chapter 2, section 2.10.3) and cDNA samples used for 
semi-quantitative PCR analysis. For each sample, two PCRs were performed: 
one using primers that amplified SOX2 and a second using primers that 
amplified the housekeeper β-actin (ACTB RNA). 
The samples were run on a 2% agarose gel. Each showed bands at the 
expected lengths (SOX2 - 191 base pairs; ACTB – 550 base pairs). For SOX2, 
there was an inverse relationship between band intensity and doxycycline 
concentration. The band intensity increased as the doxycycline concentration 
decreased. The untreated H400 SOX2 pTRIPZ™ sample showed the highest 
band intensity, which was similar to that of the non-transfected parent line 
(Figure 6-7A). There was some variation in the intensity of the ACTB band, but 
this did not show a specific correlation with doxycycline concentration (Figure 
6-7B). However, variable ACTB band intensity suggests the samples may have 
contained different quantities of total RNA. 
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Figure 6-7 Gel Doc™ image showing RT-PCR product of H400 SOX2 pTRIPZ™ 
lines treated with doxycycline and two non-transfected parent lines 
A) SOX2 assay. Lanes 1 – 6 show an inverse relationship between SOX2 band intensity and 
doxycycline concentration. The band intensity is lowest in the sample treated with 1 µg/ml 
doxycycline (lane 1, arrowed) and increases as the concentration of doxycycline decreases. 
Band intensity is highest in the untreated sample (lane 6, arrowed), which is similar to that of the 
native H400 cell line samples (lanes 7, 8).B) ACTB assay. The samples show some variation in 
the ACTB band intensity, suggesting they contain variable quantities of total RNA.  
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6.7.2 Quantitative PCR 
Following semi-quantitative RT-PCR analysis, the cDNA samples were 
amplified by real-time quantitative PCR (qPCR) to provide a more accurate 
assessment of SOX2 knock down in the H400 SOX2 pTRIPZ™ cell line. A 96-
well plate was set up with triplicate repeats for each sample. The plate was run 
on an Applied Biosystems® 7500 Real-Time PCR machine (Life Technologies, 
Paisley, UK). Cycle threshold values were used to calculate mean fold values 
as described in Chapter 2 (section 2.10.5). Samples were then ranked 
according to their mean fold value (Table 6-3). 
The non-transfected H400 parent cell lines had the highest ranking, followed by 
the non-treated H400 SOX2 pTRIPZ™ sample. Overall, the mean fold values 
showed the same trend that had been identified by semi-quantitative RNA 
analysis, i.e. there was an inverse relationship between the mean fold value and 
doxycycline concentration. However, several of the mean fold values did not fit 
this relationship in a continuous pattern. Samples 2 and 5 (treated with 500 and 
25 ng/ml doxycycline) had the same mean fold value, as did samples 3 and 4 
(treated with 100 and 50 ng/ml). These outliers may have been caused by 
variation in the quantity of ACTB RNA. 
Table 6-3 Ranked qPCR mean fold values for H400 SOX2 TRIPZ™ samples 
and two non-transfected H400 parent cell lines 
 
Sample number* Mean fold value Rank** 
1 0.07 6 
2 0.17 4 
3 0.11 5 
4 0.11 5 
5 0.17 4 
6 0.22 3 
7 1.00 2 
8 1.02 1 
*As per lane key in Figure 7; ** Ranked high =1; low = 8  
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6.7.3 SOX2 protein quantification by Western blot 
The transfected lines were seeded into six-well plates and treated with 
doxycycline at the same concentrations as those used for RNA preparation. 
Protein was extracted from the transfected lines using RIPA buffer (Sigma 
Aldrich, UK; Chapter 2, section 2.10.6). Western blotting was performed on 
each of the samples using antibodies to both SOX2 and GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase). 
Analysis of band intensity confirms the inverse relationship between SOX2 band 
intensity (expected band width – 35 kDa) and doxycycline concentration. Band 
intensity is weakest for the sample treated with the highest concentration of 
doxycycline (1 µg/ml) and increases as the concentration of doxycycline 
decreases. Untreated H400 SOX2 pTRIPZ™ had the highest band intensity, 
similar to that of the non-transfected parent lines (Figure 6-8A). The Western 
blot for GAPDH (expected band length of 37 kDa) shows a similar band 
intensity for each sample (Figure 6-8B). This indicates that there were similar 
quantities of total protein in each of the samples. Overall, comparison of relative 
SOX2 protein expression by Western blot confirmed the trends identified by 
comparison of SOX2 RNA. Together, the results indicates that doxycycline 
administration induces knockdown of SOX2 expression in H400 SOX2 
pTRIPZ™.  
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Figure 6-8 Western blot showing SOX2 and GAPDH protein levels in H400 
SOX2 pTRIPZ™ cells treated with doxycycline and non-transfected parent lines 
A) SOX2 assay. At the expected band length of 35 kDa, there was an inverse relationship 
between band intensity and doxycycline concentration. Band intensity is lowest in the sample 
treated with 1 µg/ml doxycycline (lane 1, arrowed) and increases as the concentration of 
doxycycline reduces. Intensity is highest in the untreated sample (lane 6, arrowed), which 
shows a similar band intensity to that of the parent H400 cells (lanes 7, 8).There are non-
specific bands at ~45 and 55 kDa, which show the opposite relationship to doxycycline 
concentration. 
B) GAPDH assay. The Western blot shows similar GAPDH band intensity (expected band 
length 37 kDa) for each sample, indicating that they contained similar quantities of total protein.  
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6.8 Discussion around the limitations of the work carried out to date and 
suggestions for future work 
6.8.1 Endogenous expression of PAX9 and SOX2 in parent OSCC lines  
Identification of suitable OSCC cell lines for transfection relied on two assays, 1) 
semi-quantitative analysis of reverse transcription PCR (RT-PCR) data to 
compare relative RNA expression, and 2) manual immunohistochemistry to 
compare relative protein expression. These techniques were used as they were 
already established in our laboratory and had been optimised on a range of 
other samples (e.g. the protocol for manual PAX9 immunohistochemistry had 
been performed successfully on both human and mouse tissue).  
Quantitative real-time PCR (qPCR) analysis of RNA and Western blot analysis 
of protein levels may have provided more accurate data and helped to 
distinguish more reliably between the endogenous expression of PAX9/SOX2 in 
each cell line. However, protocols for these techniques were not developed at 
that stage in the experiment. To do so may have delayed starting the 
transfections. The protocols used in the initial characterisation of the pTRIPZ™ 
cell lines still require modification (see next points). When these protocols are 
optimised, qPCR and Western blots may be performed on each of the 
candidate OSCC cell lines in order to verify our selection of H314/H400. 
6.8.2 Failure of PAX9 and SOX2 immunohistochemistry on cell pellets 
It remains unclear why PAX9 and SOX2 immunohistochemical staining was 
unsuccessful using cell pellets. This finding is particularly unusual given that the 
cell pellets stained positively for AE1/AE3, CK5/6, and p63 using the automated 
Ventana platform. It may be that the PAX9/SOX2 antigens are more sensitive 
than cytokeratin/p63 either to trypsinisation or specific steps in the preparation 
of cell pellets.  
Since the initial screening of the cell lines, SOX2 immunohistochemistry has 
been optimised on the automated Ventana platform. In future, it will therefore be 
possible to perform SOX2 immunohistochemistry on cell pellets using the 
Ventana platform. Similarly, a new PAX9 antibody that may be suitable for use 
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on the Ventana platform has been now identified. Further work could also be 
carried out to optimise the preparation of the cell pellets. 
6.8.3 Cytoplasmic immunostaining using Surepath™ preparations 
Stronger immunostaining was achieved using Surepath™ preparations 
compared to the cell pellets. However, the expected nuclear signal was 
accompanied by non-specific cytoplasmic staining. This was particularly 
noticeable for PAX9. It may have contributed to the high PAX9 PPN and 3+PN 
values generated by digital image analysis. This non-specific staining may 
reflect cellular disruption caused during trypsinisation or preparation of the 
Surepath™ slides. 
The protocol for preparing the Surepath™ slides has already been optimised for 
use on human cells. It is used regularly in the Department of Cellular Pathology 
for diagnostic immunocytochemistry. It is therefore unlikely that the existing 
protocol can be further optimised to reduce the cytoplasmic staining. If improved 
immunostaining of cell pellets can be achieved by using the Ventana platform, it 
may not be necessary to continue using Surepath™ in future. If Surepath™ 
slides are used again, the immunostaining protocol could be adjusted by 
reducing the antigen and/or DAB incubation times. 
6.8.4 Housekeeper controls for RT-PCT, qPCR, and Western blotting 
During initial characterisation of the H400 pTRIPZ™ line, the housekeeper β-
actin (ACTB RNA) was used as a control for RT-PCR/qPCR whereas GAPDH 
was used for Western blotting. ACTB was chosen as the control for RT-PCR 
and qPCR as the ACTB RT-PCR protocol had already been optimised in our 
laboratory. It had also been used during the screening of candidate OSCC cell 
lines. However, there is anecdotal evidence that ACTB is sensitive to 
doxycycline [Martina Elias, personal communication]. Sensitivity to doxycycline 
may account for the contrast between the consistent ACTB band intensity 
detected while screening native OSCC lines, and the variable band intensity 
detected while characterising doxycycline-treated H400 SOX2 pTRIPZ™ cells. 
It may also account for the aberrant mean fold values detected by qPCR. 
Together, the RT-PCR and qPCR results suggests that doxycycline impacts 
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ACTB transcription and is therefore an unsuitable control for induction 
experiments. 
Western blot analysis showed consistent GAPDH protein band intensity. This 
suggests that the samples had even quantities of total protein and that GAPDH 
is more resistant to doxycycline than ACTB. Further work is required to optimise 
a protocol for RT-PCR and qPCR using GAPDH primers. However, GAPDH 
may be a more suitable housekeeping control in future experiments. 
6.8.5 Quantity and quality of RNA/protein samples 
There has been some difficulty in extracting RNA from the cell lines prior to RT-
PCR and qPCR. The RNA yield from the H314 cell lines has been particularly 
low. The current RNA extraction technique TRIzol® Reagent (Life 
Technologies, Paisley, UK). TRIzol® is used to lyse and extract RNA from 
tissue samples. It may be too strong to extract RNA from cultured cells. An 
alternative reagent designed specifically for extracting RNA from cultured cells, 
such as Reliaprep™ RNA Cell Miniprep System (Promega, UK), may yield 
greater quantities of RNA. Cells could also be grown in larger wells and left until 
they had achieved 100% confluence prior to extracting RNA. 
6.8.6 PAX9 antibody for Western blotting 
SOX2 Western blotting has successfully used the same antibody used for 
manual immunohistochemistry. By contrast, PAX9 Western blotting has been 
unsuccessful to date. The PAX9 antibody used for manual PAX9 
immunostaining is a monoclonal rat antibody produced from hybridoma cell 
lines (Abcam, Cambridge, UK). As it is a cell supernatant, the antibody’s precise 
concentration is unknown. This makes it difficult to calculate appropriate 
dilutions for use in Western blotting. In immunohistochemistry, is effective at a 
1:40 concentration. However, similarly high concentrations have not worked in 
the Western blot. An alternative rabbit monoclonal PAX9 antibody has been 
now identified (D9F1N, Cell Signalling Technology®, US). Further work is 
required to optimise the protocol for this antibody before PAX9 knockdown can 
be verified in either the H314 PAX9 pTRIPZ™ or H400 PAX9 pTRIPZ™ cell 
lines.  
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6.8.7 Polyclonal population of transfected cells 
The transfected cell lines currently comprise a polyclonal population of cells in 
which lentiviral DNA has integrated at different sites in the host genome. 
Depending on the experimental model, it may be preferable to work with a 
polyclonal population as problems arising from specific genome integration sites 
are avoided. However, induction/knockdown of gene expression in a polyclonal 
population can be inefficient. There may also be ‘leaky’ non-specific expression 
in the absence of the inducing agent [Prof. Josef Heidenreich, personal 
communication]. 
As the initial characterisation is incomplete, it is too early to say whether either 
of these potential problems will have a significant impact on our cell lines. 
However, it may prove necessary to work with defined clones in the future. 
Individual clones could be selected by seeding the cells in petri dishes at low 
density. After being selected in a blasticidin/doxycycline culture, cloning rings 
can then be applied around colonies with strongly-positive fluorescent signals. 
When colonies are confluent within the cloning ring, they can then be 
trypsinised and transferred to a 24-well plate for further expansion. It has been 
recommended that a minimum of three clones should be characterised and 
used for functional assays. Using an isolated clone may yield aberrant results 
that reflect the impact of the integration site as opposed to the impact of 
modifying expression of the gene of interest [Prof. Josef Heidenreich, personal 
communication]. 
6.8.8 Functional assays 
Once the polyclonal cell lines have been characterised it will be possible to 
begin functional assays. We plan to analyse basic cellular parameters of the 
transfected cells and compare these with native, non-transfected control lines. 
These parameters include determination of cellular viability, using the MTT 
assay, and cellular proliferation and apoptosis, using fluorescence-activated cell 
sorting (FACS) analysis. In the longer term, the genetic pathways regulating the 
molecular changes identified in the inducible PAX9 and SOX2 OSCC cell lines 
could be delineated by DNA microarray analysis. This would generate genome 
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wide expression profiles, which can be analysed by bioinformatics. Significant 
changes in gene expression can be further validated by qPCR. 
6.9 Conclusion 
This study identified cell lines with low endogenous PAX9 expression (for 
transfection with an inducible PAX9 over-expression plasmid) and high 
endogenous SOX2 expression (for transfection with an inducible SOX2 ‘knock-
down’ plasmid). H314 was selected for inducible PAX9 expression and H400 
was selected for SOX2 knockdown. Poor transfection efficiency using plasmid 
DNA lead to the adoption of an alternative transfection strategy using lentivirus 
vectors. The experimental plan was further modified so that both cell lines were 
transfected with PAX9 over-expression and SOX2 knockdown constructs. 
Using an exemplar cell line, H400 SOX2 pTRIPZ, we have demonstrated proof 
of principle that the expression constructs are functional. Knockdown of SOX2 
expression using doxycycline induction has been confirmed by RNA and protein 
assays. However, the initial characterisation was limited by the use of sub-
optimal housekeeper genes to act as controls, and technical difficulties which 
compromised the quantity and quality of RNA that was extracted from some cell 
lines. The transfected cell lines are currently polyclonal, which potentially limits 
their utility for functional assays and future in vivo experiments. Further work is 
therefore required to optimise the analysis of the transfected cells lines and to 
establish a range of characterised clones for each cell line. 
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Chapter 7. Discussion 
7.1 Introduction 
Oral squamous cell carcinoma (OSCC) is a major global healthcare problem 
(Jemal et al., 2011). The incidence of OSCC in the UK is increasing, a trend 
which is likely to continue as the population ages (Cancer Research UK, 2010). 
OSCC has devastating consequences for many patients diagnosed with the 
disease. Cure is often precluded either by late presentation (McGurk et al., 
2005) or formation of second primary tumours (Day and Blot, 1992; Tsou et al., 
2007). The current treatment modalities for OSCC - surgical resection and 
radiotherapy – are associated with complications and functional impairments 
that may result in psychological problems and even non-cancer-related mortality 
(Zwahlen et al., 2008; Shah and Gil, 2009; Campos et al., 2014; Szczesniak et 
al., 2014). 
Outcomes for patients with OSCC may be improved if the disease is identified 
in its precursor stages, termed oral potentially malignant disorders (OPMD) (van 
der Waal, 2009; Goodson and Thomson, 2010). However, histological 
assessment of OPMD is subjective and does not reliably predict which cases 
will progress to OSCC (Lodi et al., 2006; Kujan et al., 2007). Several candidate 
biomarkers have emerged in recent decades but, as yet, none are validated as 
reliable biomarkers for use in routine diagnostic practice (Nylander et al., 2000; 
Kovesi and Szende, 2003; Varun et al., 2014). 
This study sought to address the continuing need for biomarkers that stratify 
OPMD according to their risk of malignant transformation and thus facilitate 
early detection and management of OSCC (Mishra, 2012). This discussion 
highlights the key findings of this study regarding the classification of epithelial 
dysplasia, and the potential diagnostic utility/functional significance of each 
biomarker evaluated: EGFR, SOX2, and PAX9.  
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7.2 Key findings 
7.2.1 The binary classification of epithelial dysplasia is more predictive of 
clinical course than the SIN classification 
Our data show that the binary classification of epithelial dysplasia is more 
predictive of clinical outcome than the Squamous Intra-epithelial Neoplasia 
(SIN) classification. High-grade epithelial dysplasia correlated with malignant 
transformation in OPMD, whereas SIN 3 did not. The absence of a correlation 
with SIN 3 is likely to reflect the subset of cases that underwent malignant 
transformation but were classified with SIN 2 on morphological assessment. 
There is evidence that removal of the intermediate SIN 2 category, equivalent to 
moderate epithelial dysplasia in the World Health Organisation (WHO) 
classification, reduces inter-observer variation and enhance the predictive value 
of the assigned dysplasia grade (Barnes et al., 2005; Kujan et al., 2006 ). Our 
data support this contention, but must be interpreted with some caution. The 
correlation between high-grade epithelial dysplasia and malignant 
transformation was relatively weak compared with two of the biomarkers studied 
(see sections 7.2.2 and 7.2.9). Used in isolation, high-grade epithelial dysplasia 
had relatively low sensitivity and specificity for detecting cases destined to 
undergo malignant transformation. This supports the view that there are 
fundamental limitations to the predictive value of a morphological diagnosis, 
irrespective of the accuracy and reliability of the classification system upon 
which it is based (Kujan et al., 2007; Dost et al., 2014). 
Our analysis of the mouse model of oral carcinogenesis did not classify cases 
according to a grade of epithelial dysplasia. Rather, cases were categorised 
simply according to whether epithelial dysplasia was present or absent. This 
methodology may have failed to detect subtle differences between Pax9-
deficient mice and controls. For example, it is possible that Pax9-deficient mice 
developed high-grade epithelial dysplasia more frequently/rapidly than controls, 
a trend that our methodology would not have detected. However, there is no 
agreed classification system for grading oral epithelial dysplasia in mice. 
Morphological differences between the oral squamous epithelium of mice and 
humans confounds the direct transference of the human classification system to 
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mice, mainly due to the relatively thin epithelium in the mouse. Initial attempts 
by the scoring pathologists to assign grades of epithelial dysplasia in control 
mice were challenging and not reproducible. In Pax9-deficient mice, dysplasia 
grading was further complicated as the architecture of normal (i.e. non-
dysplastic) squamous epithelium is already altered. For these mice, it is 
conceivable that architectural changes indicative of epithelial dysplasia may be 
either overlooked or identified erroneously. On balance, the risk that our 
methodology resulted in ‘lost’ data was outweighed by the enhanced reliability 
and reproducibility of our simple classification system. Moreover, the approach 
was in keeping with the principle of reducing the number of mice required for 
the experiment to a minimum (Understanding Animal Research, 2014). Many 
more mice would have been required to support valid statistical comparison of 
epithelial dysplasia stratified according to the WHO/SIN classification (Barnes et 
al., 2005). 
7.2.2 EGFR gene copy number abnormalities detect cases of OPMD 
destined to undergo malignant transformation 
OPMD with abnormal EGFR gene copy number were at greater risk of 
malignant transformation than cases with normal EGFR gene copy number. 
Although abnormal EGFR gene copy number used in isolation had relatively low 
sensitivity for identifying cases destined to undergo malignant transformation, its 
specificity was relatively high. The high specificity of abnormal EGFR gene copy 
number indicates that EGFR in situ hybridisation (ISH) may be a useful as part 
of a broader panel of biomarkers. Our algorithms show that when abnormal 
EGFR gene copy number and high-grade epithelial dysplasia were combined 
they were more reliably predictive than either used in isolation. 
Our findings are in concordance with two recent studies which suggested that 
abnormal EGFR gene copy number is an early feature of OPMD destined to 
undergo malignant transformation and may precede gross EGFR genomic gain 
(Benchekroun et al., 2010; Poh et al., 2012). Evidence from both studies 
supported the inclusion of cases with trisomy and low polysomy alongside those 
with EGFR genomic gain as currently defined in the interpretation of EGFR ISH 
signals in non-small cell carcinoma of the lung (Nicholson et al., 2001; Hirsch et 
al., 2003). It remains unclear whether it is appropriate to apply criteria validated 
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for the interpretation of EGFR ISH signals in lung cancer to OSCC and OPMD. 
However, our data show that including cases with trisomy and low polysomy 
provide valuable prognostic information in the context of OPMD. Further work is 
required to establish agreed criteria for the interpretation of EGFR ISH signals 
in cancers and pre-cancerous lesions outside the lungs (section 7.3). 
7.2.3 EGFR genomic gain is present in a quarter of early-stage OSCC but 
does not correlate with clinical outcome 
EGFR genomic gain was detected in a quarter of early-stage OSCC in this 
study. This is higher than the rate reported in a comparable study of early-stage 
OSCC of the tongue (Rössle et al., 2013). The discrepancy may reflect 
methodological differences between the studies, specifically the use of tissue-
microarrays (TMA) rather than whole sections, which risks failure to detect 
EGFR genomic gain in heterogeneous cases (Rössle et al., 2013). Our rate is 
actually towards the lower end of the range reported in previous studies of 
mixed-stage and late-stage OSCC (Freier et al., 2003; Chung et al., 2006; 
Agulnik et al., 2007; Temam et al., 2007; Pectasides et al., 2011; Ryott et al., 
2009). This suggests that EGFR genomic gain is a relatively late event in oral 
carcinogenesis. However, the majority of OPMD with abnormal EGFR gene 
copy in the present study progressed to OSCC, and most of the corresponding 
OSCC biopsies showed a higher EGFR gene copy number category relative to 
the index OPMD. This suggests that the progressive accumulation of EGFR 
gene copy number aberrations is functionally significant in the transition from 
epithelial dysplasia to OSCC. Given the heterogeneity of EGFR gene copy 
number signals, it is conceivable that the low rate identified in early-stage 
OSCC in this study reflects a sampling error. Alternatively, it may also represent 
the selection of different clones as oncogenic genetic changes accumulate 
within the tumour. 
Our analysis did not identify a correlation between EGFR genomic gain and 
clinical outcome in early-stage OSCC. By contrast, a previous study reported 
dramatically reduced five-year survival rates in patients with EGFR genomic 
gain compared to patients with a normal EGFR signal (Temam et al., 2007). 
Although the previous study used quantitative real-time PCR to detect EGFR 
genomic gain, its conclusions have been have been supported by other studies 
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that have assayed for EGFR genomic gain by ISH (Freier et al., 2003; Chung et 
al., 2006). However, each of these studies has examined OSCC at a wide 
range of clinical stages. The absence of a correlation between EGFR genomic 
gain and clinical outcome in the present study may therefore reflect its narrower 
inclusion criteria and focus on early-stage OSCC. Rӧssle et al (2013), in a study 
that was also confined to early-stage OSCC, failed to detect a correlation 
between EGFR gene copy number and clinical outcome. 
7.2.4 EGFR protein over-expression is prevalent in OPMD and early-stage 
OSCC, limiting its clinical utility 
This study confirms that EGFR protein is over-expressed in the majority of 
OPMD and early-stage OSCC (Grandis and Tweardy, 1993a; Ries et al., 2013). 
Our results also show a positive correlation between EGFR protein expression 
and grade of epithelial dysplasia in OPMD. However, we were unable to 
replicate the significant correlation between EGFR over-expression and risk of 
malignant transformation that has been reported in two previous studies 
(Nankivell et al., 2013; Ries et al., 2013). Both earlier studies benefitted from 
whole section rather than TMA analysis. However, they relied upon subjective 
semi-quantitative assessment of EGFR protein expression rather than digital 
image analysis. Different thresholds may also have been used to define EGFR 
over-expression (Nankivell et al., 2013; Ries et al., 2013). On balance, the 
prevalence of EGFR over-expression in OPMD identified in the current study 
makes a positive correlation with clinical parameters unlikely. 
EGFR over-expression was more prevalent in early-stage OSCC than in 
OPMD. The biological significance of this is uncertain. It supports the contention 
that EGFR is more likely to be functionally significant in the later stages of oral 
carcinogenesis (Ryott et al., 2009). However, the literature to date consistently 
draws attention to the complexity of the EGFR pathway. Increased EGFR 
expression may be a bystander change, reflecting, but not driving, oral 
carcinogenesis. This would account for the lack of correlation with disease-
specific clinical outcomes in either OPMD or early stage OSCC. On balance, 
our findings support the view that EGFR protein has limited clinical utility as a 
biomarker for stratifying patient management (Forastiere, 2007; Gusterson and 
Hunter, 2009; Rosin and Califano, 2010). 
211 
 
7.2.5 SOX2 protein expression is heterogeneous in OPMD but does not 
correlate with clinical outcome 
SOX2 protein has a heterogeneous expression profile in OPMD, but is down-
regulated in the majority of cases. No correlation was identified between SOX2 
protein expression and clinical outcome in OPMD. 
To date, the profile of SOX2 expression in OPMD has been described in an 
isolated study (Qiao et al., 2013). SOX2-positivity was reported in 90% of 
OPMD. Co-expression of SOX2 and Oct4 - a feature not detected in the normal 
epithelium – was also identified in the majority of OPMD. Similar trends were 
detected in an animal model. However, the study was limited by several factors. 
These include small sample size, semi-quantitative scoring of stained sections, 
and categorisation of cases as either SOX2-positive or SOX2-negative, without 
indicating the intensity of staining. Moreover, the level of SOX2 expression in 
normal human epithelium was not reported as a control, precluding comparison 
of the relative SOX2 expression of OPMD (Qiao et al., 2013). It is therefore 
difficult to compare our data with the results of the previous study meaningfully. 
Further work is required to confirm the findings of our study. However, our 
analysis suggests that SOX2 has limited potential value as a prognostic 
biomarker in OPMD. 
7.2.6 SOX2 protein expression is up-regulated in early-stage OSCC 
SOX2 protein had a heterogeneous expression profile in early-stage OSCC. 
However, in the majority of cases there was a significantly increased proportion 
of strongly SOX2-positive nuclei relative to the normal epithelium. 
Up-regulation of SOX2 has been documented previously in squamous cell 
carcinoma (SCC) of the lung, oesophagus, cervix, and penis (Hussenet et al., 
2010; Lu et al., 2010; Maier et al., 2011). Increased SOX2 expression in OSCC 
has been reported in several studies by immunohistochemistry (IHC) (Freier et 
al., 2010; Huang et al., 2014), proteomic analysis (Misuno et al., 2013) and in 
situ hybridisation (ISH) (Freier et al., 2010; Kokalj Vokač et al., 2014). 
Interestingly, Freier et al (2010) reported that SOX2 was over-expressed in only 
a small subset of cases. The study used a TMA-based approach to tissue 
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analysis; the heterogeneous pattern of SOX2 expression that we observed 
suggests that such data may be unreliable due to sampling limitations. Our data 
show that the proportion of strongly SOX2-positive cells was increased in 
OSCC relative to the normal epithelium in over half of cases, suggesting a ‘gain 
of function’ or an oncogenic effect in at least a proportion of oral cancers. Freier 
et al (2010) reported that SOX2 gene copy number amplification was present in 
more than half of cases. This suggests SOX2 genomic gain may be a more 
homogeneous feature in OSCC and not subject to the limitations of TMA 
analysis and classification.  The proportion of OSCC with SOX2 gene 
amplification is consistent with our SOX2 protein expression assessed by IHC. 
Our analysis shows that OSCC with adverse outcomes had significantly lower 
expression of SOX2 relative to cases with no adverse outcome. This is in 
contrast to three previous studies that show high SOX2 expression correlates 
with poor clinical outcome, particularly an increased risk of metastasis to 
cervical lymph nodes (Du et al., 2011; Michifuri et al., 2012; Huang et al., 2014). 
There are several possible explanations for this discrepancy: inclusion of late-
stage OSCC in previous studies; use of manual staining methods rather than 
the automated platform used in the present study; use of different SOX2 
antibodies, including polyclonal antibodies (Michifuri et al., 2012; Huang et al., 
2014); finally, the use of semi-quantitative scoring as opposed to digital image 
analysis. As an isolated finding, however, the correlation between low SOX2 
expression and adverse outcomes in OSCC detected in our study should be 
interpreted with caution. 
Michifuri et al (2012) also highlighted the heterogeneous profile of SOX2 
expression and proceeded to categorise cases according to whether SOX2 was 
expressed peripherally or diffusely throughout the tumour. Our study includes 
cases consistent with both patterns. However, this binary classification system 
does not account for several cases in our study in which SOX2 expression was 
generally down-regulated/lost or showed a variable staining that was not 
consistent with either pattern. The authors of the previous study reported a 
correlation between the pattern of SOX2 staining and specific clinical outcomes. 
It is not possible to comment on a potential correlation between staining pattern 
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and clinical outcome in our cases due to the small number with uniform patterns 
and the generalised heterogeneity of SOX2 staining identified.  
7.2.7 SOX2 may be significant in the maintenance and functioning of 
cancer stem cells 
In humans, SOX2 expression was significantly increased in OSCC relative to 
OPMD. In both Pax9-deficient and control mice, Sox2 expression was 
increased in epithelial dysplasia compared to normal epithelium. These findings 
are concordant with the literature suggesting SOX2/Sox2 has an oncogenic 
function in oral carcinogenesis (Freier et al., 2010; Qiao et al., 2013; Kokalj 
Vokač et al., 2014). However, this hypothesis was not borne out by analysis of 
SOX2 expression in the subset of human OPMD that underwent malignant 
transformation and their subsequent OSCC. Analysis of these groups of cases 
further highlighted the heterogeneity of SOX2 expression at each stage of oral 
carcinogenesis, and the limits of its potential diagnostic utility. 
Although the heterogeneous expression profile of SOX2 limits its potential as a 
biomarker, it remains plausible that SOX2 is functionally significant in oral 
carcinogenesis. Its heterogeneous expression has several explanations. It may 
be hypothesised that SOX2 has multiple stage-dependent roles in oral 
carcinogenesis, with a spectrum of oncogenic and tumour-suppressor functions. 
Alternatively, subsets of OPMD/OSCC may be variably dependent on the 
oncogenic function of SOX2, and thus show variable expression of SOX2 
protein. 
Interestingly, previous in vitro studies show that SOX2, along with OCT4, is up-
regulated in oral cancer stem cells (CSC) (Lim et al., 2011; Bourguignon et al., 
2012; Misuno et al., 2013). SOX2 contributes to stem cell functioning in normal 
oral squamous epithelium (Okubo et al., 2009). We noted that SOX2 expression 
was often strongest in foci of tumour cells with a basaloid cytomorphology; it is 
conceivable that these foci contain CSC. Further work is required to delineate 
the contribution of SOX2 to the maintenance, survival, and proliferation of CSC. 
CSC are responsible for resistance to therapy, local recurrence, and metastatic 
spread in head and neck squamous cell carcinoma, and therefore represent 
important therapeutic targets (Routray and Mohanty, 2014). The hypothesis that 
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SOX2 is a marker of CSC suggests it may therefore be an important 
chemotherapeutic target in OPMD/OSCC. The stably-inducible cell lines 
generated in this project will be useful in testing this hypotheses. 
7.2.8 PAX9 has a potential tumour-suppressor function in oral 
carcinogenesis 
This study demonstrated reduced PAX9 expression in OPMD relative to normal 
epithelium. PAX9 protein expression in OSCC was reduced relative to both 
normal epithelium and OPMD. This profile of progressively down-regulated 
PAX9 expression is consistent with the role of Pax9 in the differentiation of 
mouse oral squamous epithelium (Jonker et al., 2004) and evidence from a 
study of oesophageal SCC that suggests PAX9 acts as a tumour-suppressor 
gene (Gerber et al., 2002). 
The study by Gerber et al (2002) demonstrated that PAX9 expression was 
either lost or significantly reduced in the majority of oesophageal SCC and 
dysplastic epithelial lesions. There was an inverse relationship between PAX9 
expression and clinical course: a decrease in the proportion of PAX9-positive 
cells correlated with increasingly malignant behaviour. This correlation was also 
identified in the current study: OSCC with adverse outcomes had significantly 
lower PAX9 expression compared to cases with no adverse outcome.  
Pax9-deficient mice developed epithelial dysplasia more rapidly than controls. 
One Pax9-deficient mutant mouse developed epithelial dysplasia after just two 
weeks of chemical induction. This is less than the eight-week minimum period 
reported in previous studies (Tang et al., 2004; Vitale-Cross et al., 2004b). The 
finding that Pax9-deficient mice are more susceptible to 4-NQO supports the 
hypothesis that Pax9 has a tumour-suppressor function in oral carcinogenesis. 
However, it must be interpreted with caution. Only a small number of mice were 
sacrificed following less than eight weeks of 4-NQO treatment. The detection of 
epithelial dysplasia at two weeks was essentially an incidental finding due to the 
toxic systemic response to 4-NQO in Pax9-deficient mice (see 7.2.10). 
Pax9-deficient mice were more likely to develop OSCC following chemical 
induction than controls. This further supports the hypothesis that Pax9 has a 
tumour-suppressor function. However, statistical comparison is limited by the 
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small number of cases that developed OSCC. Further serial sections will be 
examined as the analysis continues in future projects. More cases of OSCC 
may be identified during this process, supporting statistical analysis. There is 
also scope to verify our findings in future experiments using standardised 
conditions on greater numbers of mice (section 7.3). 
Pax9-deficient mice also had higher rates of dysplastic nodules than controls. 
Dysplastic nodules bear a resemblance to human papillary squamous cell 
carcinoma. However, they lacked the definitive evidence of invasion required to 
group them with the OSCC cases. The precise criteria required in order to 
establish a diagnosis of papillary squamous cell carcinoma in humans is a 
subject of debate (Barnes et al., 2005). Lesions similar to papillary squamous 
cell carcinoma have been described in previous 4-NQO studies (Czerninski et 
al., 2009). However, criteria for making the diagnosis in mice have yet to be 
established. Some of these dysplastic nodules may show invasion of the lamina 
propria on examination of further serial sections. It is also conceivable that had 
there been a greater interval between the cessation of 4-NQO treatment and 
sacrifice, some of these lesions may have progressed to conventional OSCC 
(section 7.3). 
Two Pax9-deficient mice developed oesophageal SCC. This is consistent with 
the site affinity of 4-NQO documented in the literature (Kanojia and Vaidya, 
2006). The number of cases is too small to support statistical analysis. 
However, the finding is consistent with the previous study of human 
oesophageal SCC and lends further weight to the hypothesis that Pax9 has a 
tumour-suppressor function (Gerber et al., 2002). Interestingly, these mice were 
otherwise well and did not show weight loss, which might have been expected 
given the extent of oesophageal obstruction. Consistent with the negative 
autopsy findings documented by Tang et al (2004) there was no evidence of 
tumour formation elsewhere in the gastrointestinal tract. The site specificity 
identified in the present study support the suitability of the 4-NQO model of oral 
carcinogenesis for use in future experiments.  
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7.2.9 PAX9 is over-expressed in transforming OPMD and their 
subsequent OSCC 
Paradoxically, PAX9 was increased in OPMD that underwent malignant 
transformation and high levels were also maintained in the resultant OSCC. 
This contrasts with the evidence outlined in Section 7.2.8, which supports the 
hypothesis that PAX9 has a tumour-suppressor function. There are two possible 
interpretations for this finding. 
Firstly, it may be hypothesised that PAX9 has an oncogenic function and is 
transiently up-regulated in OPMD prior to/shortly after transformation to OSCC. 
Over-expression of PAX9 was more reliably predictive of malignant 
transformation than high-grade epithelial dysplasia. This suggests PAX9 over-
expression is an important event during the transition from epithelial dysplasia 
to invasive OSCC. It is conceivable that PAX9 is dynamically expressed during 
oral carcinogenesis: down-regulation and loss of its tumour-suppressor function 
may be critical to the development of early dysplastic lesions; up-regulation and 
gain of its oncogenic function may be vital to established lesions as they 
progress towards invasion. The oncogenic function of PAX9 may be redundant 
in established OSCC due to acquisition of further genetic changes following 
invasion. This would account for the down-regulation of PAX9 expression that 
we have documented in early-stage OSCC. 
The view that PAX9 has potential oncogenic functions is supported by previous 
in vitro studies (Kendall et al., 2007; Lee et al., 2008; Harris et al., 2011). 
However, the hypothesis that PAX9 is dynamically expressed in oral 
carcinogenesis must be considered cautiously. The present study of human 
tissue is observational and has a cross-sectional rather than longitudinal design. 
This precludes accurate temporal description of PAX9 expression in individual 
cases. Comparison of PAX9 expression in selected cases is also confounded 
by variable time intervals between biopsies, and the variable numbers of 
biopsies performed for each lesion. Previous OPMD biopsies do not exist for 
the majority of early-stage OSCC cases in our study. The latter showed 
significantly lower PAX9 expression relative to the group of OSCC that 
transformed from OPMD. It is open to conjecture whether these early-stage 
OSCC were preceded by OPMD with low or high levels of PAX9 expression. 
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An alternative hypothesis is that PAX9 is over-expressed in a subset of OPMD 
and OSCC, but that over-expression is not uniformly critical to oral 
carcinogenesis. Interestingly, ‘normal’ (i.e. relatively high) levels of PAX9 
expression were reported in a subset of oesophageal SCC and dysplasias by 
Gerber et al (2002). It is possible that these oesophageal lesions with high 
PAX9 expression were biopsied at a time when they were undergoing malignant 
transformation, which would support the previous hypothesis. However, it also 
suggests that OPMD and OSCC may be separated into two groups according to 
whether their PAX9 expression profile is low or high relative to normal 
epithelium; it is thus conceivable that the majority of early stage OSCC in this 
study were preceded by OPMD with low PAX9 expression. 
In conclusion, our data show similar trends in PAX9 expression to those 
documented in oesophageal SCC and squamous epithelial dysplasia. They 
support the hypothesis that PAX9 has a tumour-suppressor function. However, 
there is also compelling evidence to suggest that PAX9 has an oncogenic 
function. These functions may be stage-dependent or, alternatively, either 
function may predominate in individual cases. The cell lines generated in this 
project may help to determine the precise contribution of PAX9 to oral 
carcinogenesis. Importantly, however, our data indicate that PAX9 may be a 
useful biomarker that detects OPMD at high risk of progressing to OSCC. 
7.2.10 Pax9-deficient mice are more susceptible to the toxic systemic 
effects of 4-NQO treatment 
Our data show that Pax9-deficient mice have enhanced sensitivity to the toxic 
systemic effects of 4-NQO than controls. These included extreme weight loss 
and excessive salivation. 
Several mice with excessive salivation deteriorated rapidly. It is possible that 
fluid loss and dehydration were gradually compounded by further intake of 4-
NQO as the mice drank more in an attempt to quench thirst, culminating in a 
cycle of progressive decline. This would have caused a relentless increase in 
the concentration of 4-NQO and its metabolites in the bloodstream. Excessive 
salivation may also have been accompanied by loss of appetite and impaired 
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masticatory efficiency. This would further contribute to weight loss and 
exacerbate the toxic systemic effects of 4-NQO as body mass declined. 
The precise mechanism for the enhanced sensitivity of the Pax9-deficient mice 
is unclear. Toxic systemic effects of 4-NQO have not been documented 
previously. The Pax9-deficient mice that deteriorated most rapidly had only one 
kidney. Impaired excretion of 4-NQO may have further contributed to an 
increased 4-NQO concentration in the bloodstream. The present study was not 
designed to identify which Pax9-deficient mice had only one kidney prior to 
beginning 4-NQO treatment. The cause of hunching in these mice was unclear. 
It may have reflected either visceral or muscular pain from the abdominal 
region. Mice with one kidney may have developed kidney failure due to 4-NQO 
toxicity; the hunching may also have been related to kidney failure. 
Our data confirm the time interval from start of 4-NQO induction to OSCC 
formation reported in several previous studies (Ma et al., 1999; Ide et al., 2001). 
Although it was longer than the interval reported in a study which used a higher 
concentration of 4-NQO (Hasina et al., 2009), our decision to use lower 
concentrations of 4-NQO was justifiable given the greater sensitivity of Pax9-
deficient mice to the toxic systemic effects of 4-NQO. Treating Pax9-deficient 
mice with 100 μg/ml 4-NQO would have resulted in the unnecessary suffering or 
even death of many mice, in breach of the principle of refining experiments to 
ensure that suffering is kept to an absolute minimum (Understanding Animal 
Research, 2014). Importantly, the majority of the mice that developed OSCC 
were actually treated with the lowest concentration of 4-NQO (10 μg/ml). This 
confirms findings from previous studies that 10 μg/ml 4-NQO is sufficient to 
induce OSCC formation, albeit over a longer period (Ma et al., 1999; Ide et al., 
2001).  
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7.2.11 Future combined 4-NQO and Pax9 knockdown models of oral 
carcinogenesis may be optimised to reduce suffering and improve 
experimental efficiency 
The methodology used in this study drew on key studies in the literature in 
which workers sought to optimise the 4-NQO protocol by varying parameters 
such as the treatment duration and mechanism of application (Vitale-Cross et 
al., 2009). However, our data show that 4-NQO induction in Pax9-deficient mice 
requires specific considerations and modifications.  
Pax9-deficient mice with a Black 6 genetic background were more susceptible 
to the toxic systemic effects of 4-NQO than mice with a FVB or hybrid 
background. The Black 6 genetic background should therefore be avoided in 
future experiments and other, more resilient, strains such as FVB/hybrids 
should be used. For the same reason, male Pax9-deficient mice should be used 
rather than females. Pax9-deficient mice should be imaged to determine the 
number of kidneys present prior to the start of chemical induction. Only those 
with two kidneys present should be treated with 4-NQO. 
A concentration of 10 µg/ml is sufficient to induce OSCC and a range of 
precursor lesions within a 24-week period. Higher concentrations of 4-NQO 
have an increased risk of causing toxic systemic effects, without significantly 
reducing the length of the experiment or inducing either more or a wider 
spectrum of epithelial lesions. There is therefore little experimental benefit in 
using high dosages of 4-NQO. Loss of Pax9-deficient mice due to the systemic 
effects of a high 4-NQO concentration may compromise the overall efficiency of 
the experiment through attrition of the sample population.  
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7.3 Future work 
Since the start of this project, additional cases of OPMD that have transformed 
to OSCC have been diagnosed in the Department of Cellular Pathology. It has 
not been possible to add all of these to the group of OPMD analysed in this 
study. In future, however, the assays carried out in this study could be 
performed on these additional cases. There have also been further cases of 
OPMD that have not, according to our database, subsequently transformed to 
OSCC. There is therefore potential to liaise with clinical colleagues to continue 
with long-term follow-up of these cases, work that was started by Diajil et al 
(2013). Alternatively, our initial findings could be validated by testing a set of 
samples collected and characterised at another unit. This would increase the 
numbers in each outcome group, underpinning further statistical analysis. 
Longitudinal analysis of biomarker expression in specific lesions would facilitate 
testing of the hypothesis that certain biomarkers, including PAX9, are 
dynamically expressed during oral carcinogenesis. 
The clinicians served by the Department of Cellular Pathology are familiar with 
the WHO classification of epithelial dysplasia. It is also the practice of several 
Pathology Consultants to include the corresponding SIN grade in the 
histopathology report. This causes little conceptual ambiguity as the two 
classification are closely related. The main difference is the SIN 3 grade, which 
combines severe epithelial dysplasia and carcinoma in-situ. Our finding that the 
binary classification has greater predictive value suggests that clinicians may 
benefit from inclusion of a binary grade on the histopathology report. This is 
potentially a major change to clinical practice. It risks causing confusing 
clinicians and possibly patients. With this in mind, any such change to practice 
would need to be piloted cautiously following careful consultation with end users 
and stakeholders. The change would also need to be audited in order to 
determine its impact on clinical decisions. 
Our work highlights the need for clear guidelines for the interpretation and 
grading of epithelial dysplasia in mice. Such guidelines would support 
researchers using the 4-NQO model of chemical induction and bring greater 
uniformity and reliability to the literature. Agreed guidelines would also support 
studies of chemically-induced oral carcinogenesis in genetically modified mice. 
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Ideally, however, there is also a need to develop specific criteria for grading 
epithelial dysplasia in each group of genetically-modified mice in which the 
phenotype is characterised by disturbed epithelial morphology. 
Further work is required to develop standardised criteria for the interpretation of 
EGFR gene copy number signals in OPMD and OSCC. Our data support the 
use of a broader ‘abnormal’ EGFR gene copy number category rather than the 
current criteria used to define EGFR genomic gain in OPMD. It remains unclear 
whether it may also be appropriate to use a broader definition in OSCC. EGFR 
gene copy number may help to predict the response of head and neck cancers 
to EGFR-targeted agents. For example, high EGFR gene copy number has 
been shown to predict which patients have an increased likelihood of response 
to erlotinib therapy (Agulnik et al., 2007). The present study was not designed to 
investigate response to EGFR-targeted agents. Whether the sub-groups of 
cases with abnormal EGFR gene copy number or EGFR genomic gain have 
differential responses to EGFR-targeted agents or other therapies remains to be 
tested. 
Future experiments in which Pax9-deficient mice are treated with 4-NQO need 
to consider a modified protocol as outlined in section 7.2.11. The experiment 
may also benefit from an increased time interval from the end of 4-NQO 
treatment to sacrifice/autopsy. This would allow dysplastic lesions to progress to 
OSCC while mice are free from the potentially toxic systemic effects of 4-NQO 
treatment. Mice could also be subject to an intra-oral examination under general 
anaesthesia at specific intervals. This would inform decisions around when to 
sacrifice mice in order to examine analyse lesions. The surveillance could be 
further enhanced by performing oral brush biopsy or a small punch biopsy.  
All organs from the mice sacrificed in this experiment have been formalin fixed 
and archived. Histological analysis of vital organs, especially the kidneys, may 
provide greater insight into the nature of the toxic systemic effects of 4-NQO. 
This work could be carried out in collaboration with either veterinary 
pathologists or specialist histopathologists in the Department of Cellular 
Pathology.  
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The stably-inducible cell lines generated during this project need to be fully 
characterised. The cell lines are currently polyclonal. Specific clones will 
therefore need to be selected and characterised. These defined clones will then 
be used for functional assays. We plan to analyse basic cellular parameters of 
the transfected cells and compare these with native, non-transfected control 
lines. These parameters include determination of cellular viability, using the 
MTT assay, and cellular proliferation and apoptosis, using fluorescence-
activated cell sorting (FACS) analysis. In the longer term, the genetic pathways 
regulating the molecular changes identified in the inducible PAX9 and SOX2 
OSCC cell lines could be delineated by DNA microarray analysis. This would 
generate genome wide expression profiles, which can be analysed by 
bioinformatics. Significant changes in gene expression can be further validated 
by qPCR.  
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7.4 Conclusion 
EGFR protein is over-expressed in OPMD and early-stage OSCC, but does not 
correlate with clinical outcome in either group. By contrast, EGFR gene copy 
number abnormalities are associated with malignant transformation in OPMD. 
SOX2 has a heterogeneous expression profile in both OPMD and OSCC. This 
limits its potential clinical utility as a biomarker. However, the pattern of 
expression supports the hypothesis that SOX2 is a marker of oral cancer stem 
cells. SOX2 may therefore be highly significant in oral carcinogenesis and 
should be considered as a candidate chemotherapeutic target. 
PAX9 is down-regulated in OPMD and early-stage OSCC. Pax9-deficient mice 
are more likely than controls to develop OPMD and OSCC following chemical 
induced. These findings support the hypothesis that PAX9 has a tumour-
suppressor function. Paradoxically, PAX9 is over-expressed in the subset of 
OPMD that underwent malignant transformation. This suggests PAX9 may be 
dynamically expressed and play diverse roles during oral carcinogenesis, 
including an oncogenic function. 
Pax9-deficient mice are more susceptible to the systemic effects of 4-NQO 
treatment. This finding has informed important modifications to the protocol for 
future experiments that involve 4-NQO induction in Pax9-deficient mice. 
The cell lines developed during this project are potentially valuable tools that will 
facilitate further assessment of the role of PAX9, SOX2, and their downstream 
targets in oral carcinogenesis.  
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Appendix 
 
Emergency procedures for dealing with a 4-NQO spillage 
 
4-NQO 
phase 
Action 
Powder 
 
Remove all sources of ignition 
Dampen solid material with acetone 
Wearing gloves, soak up using paper towels 
Place damp towels in a clinical waste bag 
Wash all contaminated surfaces with acetone 
Wash again with soap and water 
Seal all contaminated towels gloves, etc, in a clinical waste bag 
Stock and 
experimental 
solutions 
 
Remove all sources of ignition 
Wipe the conatminated area with paper towels 
Wash all contaminated surfaces with acetone 
Wash again with soap and water 
Seal all contaminated towels gloves, etc, in a clinical waste bag 
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First aid measures for dealing with human exposure to 4-NQO 
 
Site of 
contact 
First Aid 
Eyes 
 
Check for contact lenses and remove if present 
Flush eyes with normal saline (or water if saline is unavailable) for 
between 20 and 30 minutes 
Skin 
 
Immediately flood the affected area with water for at least 15 
minutes 
Remove contaminated clothing. Isolate in a sealed clinical waste 
bag. 
Gently wash with soap and water 
Inhalation 
 
Leave the contaminated area 
Take deep breaths of fresh air 
Monitor for symptoms such as wheezing, coughing, shortness of 
breath, or a burning sensation in the oral cavity or throat 
Ingestion 
 
Do not attempt to induce vomiting 
Drink 1-2 glasses of water to dilute the 4-NQO 
Following administration of first aid seek urgent medical advice 
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Experimental outline for the knockdown lentivirus transfections 
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Experimental outline for the over-expression lentivirus transfections 
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Summary of reagents not otherwise specified in the text 
 
Reagent/ Buffer Source Information 
100bp DNA ladder Promega 
100bp DNA marker for agarose gel 
electrophoresis 
Go-Taq Polymerase and 
Buffer (15mM McCl2) 
Promega - 
10x dNTP Promega dATP, dTTP, dGTP and dCTP mix 
Antibody Diluent Dako-Envision Kit 
Used to dilute antibodies to desired 
dilutions 
Peroxidase blocking solution Dako-Envision Kit Blocking reagent for IHC 
HRP-labelled polymer Dako-Envision Kit Conjugated with secondary antibodies 
DAB substrate buffer Dako-Envision Kit 
1 drop DAB chromagen stain into 1ml 
DAB substrate buffer 
DAB chromagen stain Dako-Envision Kit 
Trizol reagant Invitrogen Used for RNA extraction 
Random Primer (500ng/ml) Promega Used for reverse transcription 
Citric acid buffer Sigma Aldrich 
4.2g Sigma Aldrich citric acid powder in 
2l of distilled H20, corrected to pH 6.0 
using 5M NaOH 
10 x TBS buffer Sigma Aldrich 
87.60g Nacl, 24.24g Trizma base, 
900ml H20, adjusted to pH 7.4 with HCl 
1M EDTA antigen retrieval 
buffer 
Sigma Aldrich 
0.372g Sigma Aldrich EDTA powder, 1l 
distilled H2O, corrected to pH 8.0 using 
5NM NaOH 
Scotts’ bluing solution Sigma Aldrich 
2.0g sodium bicarbonate, 20.0g 
magnesium sulphate, 1000ml dH2O 
 
